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Abstract 
The conventional biochemical diagnosis of disease using isolated blood biomarkers must be 
revisited by clinicians, replacing it with a multi-biomarker, personalised profile of human 
health. A label-free nanoparticle array technology, Liscar, has been developed. It is capable of 
performing rapid, multi-biomarker assays from complex biological samples which, if employed 
to assay the Complement cascade of the innate immune system, has the potential for a novel 
systemic profile of patient health. 
An assay for IgG has been developed on the Liscar platform with a detection limit of 380 ± 
100 ng/mL IgG in model sera. Furthermore, addition of a chaotropic agent to the complex 
sample is shown to improve the accuracy of the IgG assay. Competitive binding between 
nonspecific interfering proteins and specific target analytes (IgG) at the sensor surface is 
studied, and a quantitative mathematical model is developed to analyse the data, yielding 
evidence for the active displacement of albumin by IgG-antigen binding. 
With a sensitive, accurate multi-biomarker detection platform, a systemic profile of patient 
health may be possible by examination of the Complement cascade. The Complement system 
can be activated by a variety of immunological challenges, causing large numbers of activation 
biomarkers to be produced quickly. Assays for three activation markers, C3d, TCC and Bb are 
developed, with detection limits of 0.864 ACS Units, 2.32 ng/ml and 54.7 ng/ml respectively. 
Complement activation was tested in a prospective cohort study of 45 patients undergoing 
major abdominal surgery. Patient recovery was monitored from admission to ~60 hours 
postoperatively by Complement activation and consumption using C3d, TCC, Bb, C3 and C4 as 
biomarkers. A response profile was obtained for the entire cohort for C3 and C4 assays by 
normalising with respect to individual analyte levels on admission, against which individual 
responses are compared. 22% of patients in the study suffered postoperative complications, 
and 73% showed Complement activation by increased levels of C3d, as expected from the 
initial trauma of surgery. Expansion of the trial is needed to establish clinical significance and 
utility, especially in relation to the presymptomatic diagnosis of disease. 
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Chapter 1 
Introduction 
Conventional biochemical diagnosis of infection requires the detection of an infecting 
pathogen. An alternative approach could monitor the host’s immune response to such a 
challenge, although its presence in the body may not necessarily lead to symptoms of illness. 
Most often the host’s immune system mounts a response, either by the innate or adaptive 
immune systems without the need for medical intervention. Undoubtedly, however, the 
efficacy of each person’s response has a different threshold regarding the level of infection 
required to trigger immunological activation, and the rate of response is a personalised 
measure of systemic health which could be profiled. Using a panel of biomarkers, such an 
approach would require a rapid diagnosis of disease, possibly at the point-of-care, coupled 
with an assessment of the state of a patient’s immune system. The results could be combined 
to determine whether an intervention is necessary, and from the data the clinician could 
administer a more targeted treatment, based on the type of infection and immune response. 
Only with this enhanced differential diagnosis of infection can the significant challenges facing 
medical science regarding the use and abuse of antibiotics, for example, be addressed. This is 
applicable not just for herd immunity or strata of patients, but perhaps even for individual 
patients – truly personalised medicine. There is a vast body of literature regarding the 
unnecessary intervention with antibiotics with an emphasis on the concern that bacteria are 
becoming resistant [1; 2]. This places a responsibility on the medical community to develop 
differential diagnosis methods, coupled with an assessment of the immunological state of the 
patient so that more targeted treatments can be given only when needed.  
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What is needed is a companion diagnostic to determine the state of a patient’s immune 
system so that treatments may be prescribed to specifically accompany the body’s defence 
mechanism. Companion diagnostics have been defined by the US. Food and Drugs 
Administration (FDA) as devices that provide essential information for the safe and effective 
use of a corresponding therapeutic product [3]. Ideally a companion diagnostic should be 
available for every disease state to support clinicians in their treatment of patients. 
Unfortunately, the development of these so-called companion diagnostics is difficult to 
achieve, and requires the co-operation of governments, funding bodies, pharmaceutical 
companies, universities and hospitals. It also requires an extended and expensive process that 
is subject to significant delays. A comparison with the Pharma R&D drug discovery timeline is 
presented by Pickl et al [4], reproduced in Figure 1.1, and displays the complexity of this 
process against the comparatively well-established progression for drug development. The 
research into companion diagnostics must be clinician led, with all other auxiliary parties 
working to facilitate the end point desired by the clinician for a successful clinical trial. If 
diagnostic tests are to be developed, coupled with immunological assessment, the approach 
has to be co-ordinated so that all bodies involved are working in harmony. 
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Figure 1.1. Comparison between companion diagnostic development aligned to the Pharma R&D new drug development process. Reproduced with  permission 
from Pickl et al [4]. 
Phase I
Sensitivity and 
specificity
Registration
Phase IIa
Proof of 
concept
New 
Target 
Proposal
Lead 
Identification
Target 
Validation
Lead 
Optimisation
BH 
Enabling
Preclinical 
safety
Phase I
Early 
clinical 
safety
Phase III
Key 
registration 
trials
Phase IIb
Early 
clinical 
efficacy
Registration
Development ~ 8 years
Research ~ 7 years
Project 
initiation
Filing decision 
for first 
indication
Full 
development 
decision
Entry into 
lifecycle 
management
Entry into 
humans
Clinical 
candidate 
selection
Pharma R&D process 
and decision points
From Biomarkers to ‘Companion Diagnostics’
• Technologies
• Timelines
•Quality Requirements
• Regulatory Requirements
Align studies with:
Biomarker 
Discovery
Phase III
Clinical benefit and 
economics
Phase II
PPV and NPV
Clinical Phase ~ 3 yearsPreclinical assay development ~ 2 years
BM Dx candidate 
identified
Clinical impact 
of Dx
Clinical utility 
of Dx
Clinical 
validation of Dx
BM assay on clinical platform
Nonclinical test performance
Replication
Confirm markers and assay reproducibility
Analytical Development
Translation of assay onto a clinical platform
CoDx development 
process and milestones
 
28 
However the situation is not particularly straight forward; as a cautionary tale, the acceptance 
and clinical utility of the prostate cancer diagnostic, Prostate Specific Antigen (PSA) has been 
well documented and disputed [5]. It is therefore a good example of the difficulties 
encountered in the adoption of a companion diagnostic test, and will be considered here. In 
1986, the United States Food and Drug Administration (FDA) approved PSA to monitor patients 
treated for prostate cancer, and in 1994 it became a diagnostic marker in its own right. 
However the threshold for PSA as a diagnostic of prostate cancer of ≥ 4 ng/ml in blood is 
heavily criticised, both for being too low and too high [5]. There is concern that this threshold 
has led to many diagnoses of prostate cancer in patients where their cancer may never have 
affected their lives had they not gone for the PSA test. It is sometimes argued that this ‘low’ 
threshold of PSA for diagnosis increases the test’s sensitivity at the expense of its specificity, 
however, it has also been shown that prostate cancer is not that rare in patients with PSA 
levels <4ng/ml. Clinically, the ‘positive’ results from the test initiated a process whereby 
doctors make a decision based on a range of qualitative factors, whilst considering the level of 
PSA.  
A large European study found prostate cancer in 21-25% of patients with PSA levels between 
2-2.99ng/ml, and in 33% of patients with PSA in the range 3-3.99ng/ml [6]. Appropriately, 
recent thinking has concluded that a single cut-off for PSA is inappropriate, and that the 
number should be considered along with a range of other factors including race, age and 
hereditary presence of the disease, as done by the Prostate Cancer Prevention Trial (PCPT) 
calculator which can be found online [7]. A validation of the PCPT calculator was performed by 
Parekh et al, who found that the PCPT calculator produced an area under its receiver operating 
characteristic (ROC) curve of 65.5%, and even greater for African-American men at 80.0% [8]. 
However, given that this study compared a PSA-only analysis which gave an area under the 
ROC curve of 64%, the average result for the PCPT calculator is not significantly better, unless 
the patient is an African-American man. This gives some idea about the different, stratified 
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diagnosis approach that is becoming more commonplace, and is pointing the way to 
personalised medicine in the future.  
Personalised medicine attempts to make a patient-specific diagnosis and treatment regimen 
taking into account all comorbidities, phenotype and genotype, prescribing patients with the 
right drug at the right time at the right dose: the next frontier in patient care. It is largely 
dominated by diagnosing and treating disease on the basis of genetic variations that have been 
found to contribute to human illness. Extending the genotype to the phenotype of a patient’s 
systemic health, we postulate that the relationship between infecting disease and host 
immunity can also act as a personal marker for disease, and therefore treatments prescribed 
from such a diagnosis can also be tailored for the individual. Companion diagnostic tests can 
be developed to aid the clinician, either from a laboratory test or at the point-of-care. The 
logistics of performing the diagnostic test is dependent on a number of factors such as the 
nature of the sample being tested, the state of the patient and assay equipment mobility. 
Therefore it is important to involve the clinician on the development of such tests, so as to 
direct the development of the test to maximise clinical utility.  
It is also possible that a panel of assays could be used as a single diagnostic test, such as 
interconnected proteins that form part of a biological system. An example of such a 
‘multivariate index assay’ is OVA1, an FDA-approved panel assay consisting of 5 biomarkers 
and an algorithm [9] to help evaluate ovarian masses for the likelihood of cancer 
preoperatively. Development of such tests are likely to produce ‘diagnostic values’ from an 
algorithm based on a variety of data from each contributing assay and demographics, rather 
than absolute protein values. It is important that any complex analysis steps are removed, so 
that the factors contributing to the ‘diagnostic value’ can be entered and calculated by a 
computer, much like the online PSA calculator described above. It would therefore be 
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desirable to have a technology that would allow the screening of multiple biomarkers at the 
point-of-care, in order for clinicians to have such information readily available.  
In light of these considerations, this thesis will focus on developing detection methods and 
high-throughput screening of blood biomarkers using optical techniques, namely Surface 
Plasmon Resonance (SPR), Optical Scattering (OS) and Electrochemiluminescence (ECL) to 
establish the feasibility of immune system profiling by measuring plasma proteins to observe 
the response of the Complement (C) cascade to the surgical trauma of major surgery. Thus, 
this thesis will ultimately investigate a well defined challenge to the immune system; the 
surgical insult and trauma following major abdominal surgery, and the recovery of the patient 
postoperatively. 
Here, four key factors relating to biomarker detection from real samples are considered with a 
view to employing the biomarker for patient-health monitoring. The study performed in this 
thesis deals with the issue in two parts, first focusing on the general issues presented by real 
sample complexity for biomarker detection and analysis of label-free protein-protein binding 
studies from real biological samples. The second part of the thesis aims to develop 
immunologic biomarkers and implement those markers in a clinical trial to monitor patient 
recovery postoperatively. Specific focus will be on the kinetics of antibody-antigen 
interactions, the effect of nonspecific binding (NSB) on these interactions and ways to reduce 
the effects, and the Complement system, specifically its utility for monitoring the 
immunological state of the patient. 
This Chapter will introduce each of the topics mentioned above, and elaborate on any 
techniques employed in the study, such as SPR, OS, and ECL. The C System will also be 
introduced, as it becomes the focus for the second part of the thesis for biomarker 
development and implementation. Finally, the assessment of a biomarker for diagnosis will be 
a discussed. 
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1.1 Biomarker Detection Techniques 
Philipp Angenendt, from the German Cancer Research Center, has written that “the wide 
variety of different applications in which protein microarrays are employed … underlines the 
urgent need for technologies that are capable of high-throughput analysis of proteins and 
antibodies” [10]. Clearly there is also a very high commercial interest in such technologies. It is 
for these reasons that a great range of techniques have been employed to reach this common 
goal, including ELISA (enzyme-linked immunosorbent assay), immunoturbidimetric assays and 
ECL assays. Label-free SPR platforms have been commercialised and have been employed very 
successfully in detecting antibodies and antigens in simple buffer samples [11; 12]. Attempts 
have also been made to screen analytes from complex samples like whole serum [13], but with 
less success due to the problems posed by dealing with real biological samples.  
1.1.1 Label-Free Biosensors 
Surface Plasmon Resonance 
The leaders in the field of label-free sensor technologies [14; 15; 16] are those based on 
continuous surface or particle plasmons. SPR is an optical phenomenon that permits the 
measurement of biomolecular interactions. SPR is observed when an incident beam of p-
polarised light of a given wavelength strikes a thin metal surface at a given angle (the SPR 
angle) through a prism as shown by the Kretschmann configuration, Figure 1.2.  
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Figure 1.2. The Kretschmann configuration (A) of SPR, with the origin of the signal illustrated 
schematically (A) and (B). 
The SPR angle is greater than the critical angle, but instead of complete total internal 
reflection, some of the energy is lost to the metal-dielectric interface exciting the surface 
plasmon, thereby causing a drop in reflectivity of the incident beam, with minimum reflectivity 
at the SPR angle (θspr). The local conditions at the metal-dielectric interface (for example RI) 
determine the SPR angle, and therefore any change in these properties will cause the angle to 
shift, Δθspr, Figure 1.2. 
Surface plasmons are waves that propagate along the interface between a conducting metal 
and a dielectric material. The plasmon resonance wave propagates parallel to the metal-
dielectric interface [17; 18], the intensity of its associated optical electric field decaying 
exponentially with increasing distance from the metal surface [19]. The distance at which the 
intensity of the plasmon field decays to 1/e of its value at the interface is called the 
penetration depth. This plasmon field allows for the investigation of properties (crucially 
refractive index) of the medium up to approximately 200-300 nm [17; 20] away from the 
surface.  
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This property can be utilised in different ways by SPR sensors. The angle of incidence can be 
fixed in order to measure the change in resonant wavelength associated with ΔRI of the 
medium above the metal surface. Conversely, with fixed wavelength of the incoming light, a 
detector can monitor the SPR angle as the minimum in reflected light intensity profile, as done 
by SensiQ (Nomadics) and Biacore (Biacore AB) instruments. According to the equation: 
  ( )             
Equation 1.1 
the constants c1 and c2 relate the SPR angle at a given wavelength λ to the change in 
refractive index n at the surface and the change in thickness d of the surface layer [18]. The 
mass of biomolecules landing on the surface changes the local refractive index (RI) within the 
plasmon field from water (RI = 1.33 [21]) to protein (RI = 1.36-1.55 [22]), signifying that SPR 
sensor is a mass sensing device. This change alters the SPR angle, which is detected and 
generates the signal. In order for the sensor to be considered a biosensor, the surface must 
first be functionalised with a surface ligand, against which specific interactions with 
biomolecules can be observed. 
The applications of conventional SPR are numerous and wide reaching. It is an excellent tool 
for evaluating macromolecules, equilibrium measurements, protein-protein kinetic analysis, 
and interrogation of mutant proteins. Studying small analytes can be problematic due to their 
small contribution to layer thickness on the sensor surface. The majority of existing platforms 
also have limitations for high throughput assays, as they provide only dual channel analysis, 
allowing for the interrogation of single protein-protein interactions only. However, more 
recent instruments such as the Biacore Flexchip does have label-free high throughput 
screening capabilities [23] [11], which further strengthens its viability as a biosensor.  
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Optical Scattering using Gold Nanoparticles 
Optical scattering can also be used for the detection of biomolecules by the same principle of 
sensing ΔRI, generally employing nanoparticles in an array format. Such nanoparticle based 
biosensors are being developed to provide label-free, high throughput screening of 
biomarkers, using kinetic parameters as in conventional SPR to quantify target analytes in a 
given sample [24]. Noble metal nanoparticles exhibit a strong optical extinction in the visible 
region of the electromagnetic spectrum, which occurs when the incident photon frequency is 
in resonance with a localised surface plasmon mode in the conduction band of the 
nanoparticles. There is both a scatter and absorption element to the optical extinction 
displayed by the nanoparticles, however when the particles have a diameter >25 nm the 
scattering part dominates [24], allowing a photo camera to detect it. The size, shape and 
composition of the nanoparticles determine their optical properties, and therefore these can 
be altered and optimised by various nanoparticle production techniques. These optical 
properties can change in response to localised, biochemical binding events within the plasmon 
field of the particle, which normally penetrates ~20nm. This can be compared with a 
penetration depth of ~200-300 nm in conventional, continuous surface SPR [17; 20]. 
The implications of the difference in penetration depth between the two techniques are very 
important in terms of nonspecific binding. As the interaction of interest (protein-protein 
binding) happens on the continuous gold or nanoparticle surface, it is unnecessary, and even 
disadvantageous to have a sensor that probes well beyond the space in which this interaction 
takes place. In ‘clean’ experiments, where the sample contains one analyte only, this is not a 
problem, but for complex biological fluids or multi-analyte samples it can pose real difficulties. 
The greater sensing range of the continuous surface setup means that it is susceptible to large 
amounts of background noise caused by nonspecific constituents in a complex sample. The 
signal obtained is therefore largely dominated by nonspecific proteins entering the plasmon 
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field, whether binding to the surface or not, and therefore affects the interaction of interest. 
As the nanoparticle plasmon propagation distance is over ten times less than with continuous 
surface plasmons, it is far less susceptible to this passing, nonspecific protein noise, and 
therefore the signal obtained is more attributable to the specific interaction studied. 
1.1.2 Chemically Labelled Biosensors 
Enzyme Linked Immunosorbent Assay (ELISA) 
The general ELISA principle was invented by Engvall and Perlmann [25] as an alternative to 
immunofluorescence and radioimmunoassay. They linked antibodies with enzymes, rather 
than fluorescent markers or isotopes. The principle was that a chromogenic of fluorogenic 
substrate could be degraded by the enzyme, yielding an amplification factor by way of colour 
change which enabled sensitive and accurate detection of the enzyme, and therefore also the 
antibody it is linked to. 
There are several variations to the general ELISA technique, three of which will be detailed 
here. Firstly, the competitive ELISA test for a target antigen. Two tests are run in tandem, one 
where a known sample of the antigen plus unknown antigen sample is labelled with an enzyme 
and allowed to bind to antibody immobilised in the solid phase. The addition of substrate 
allows a comparison between the two tests, the offset in signal being attributed to the 
unknown antigen sample. 
Secondly, the indirect method involves the passive absorption of antigen onto the solid phase, 
followed by the incubation of test sera containing the antibody to allow antibody-antigen 
binding. Washing then removes any unreacted serum components, after which an antiglobulin 
enzyme conjugate is added and incubated, allowing the antiglobulin to bind to the antibody-
antigen complex. Finally, after washing, the enzyme substrate is added and produces a colour 
change which measures the amount of fixed conjugate, which is proportional to the amount of 
antibody in the test sample. 
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Finally, there is also the double antibody ‘sandwich’ technique. The solid phase is coated with 
antibody, which is then reacted with the test sample and binds any of its respective antigen 
present in the sample. After washing to remove excess sample constituents, an enzyme 
labelled antibody is added (called the reporter antibody), also specific to the target antigen. 
After further washing, the substrate is added producing a colour change proportional to the 
amount of reporter antibody present, and therefore the amount of antigen. 
Electrochemiluminescence Assays 
Electrochemiluminescence (ECL) involves the emission of light by a species that has taken part 
in an electron transfer reaction at an electrode surface [26]. When a voltage is applied to an 
electrode where an ECL luminophore such as Ru(bpy)3
2+ (bpy = 2,2’-bipyridine) is present, light 
is emitted and collected on a very sensitive CCD camera which produces an ECL assay with very 
low detection limits for a target analyte (≤10-13M) [27]. Therefore, ECL is a technique whereby 
radiative energy is produced from electrical energy by means of light emitting reactive 
intermediates from stable precursors at the surface of an electrode once a voltage is applied. 
In the excited state formed by the ECL reaction, an electron moves from the metal based dπ 
orbitals to ligand-based π* orbitals, known as a metal-to-ligand charge-transfer (MLCT) 
transition [26]. After excitation, the electron undergoes intersystem crossing to the lowest 
state of the complex, from where fluorescence emission occurs [26]. The fluorescence 
intensity is then proportional to the ECL luminophore concentration, from which a calibration 
curve can be constructed for the quantification of analyte concentrations in samples. 
ECL has been employed extensively in immunoassays and DNA analyses by using an ECL-active 
species as a label on biomolecules [27; 28; 29]. The high sensitivity of the assay and the use of 
CCD cameras allows ECL assays to be employed in the multi-well plate format with specific 
assays localised to each well. The technique’s high sensitivity and selectivity has suited it well 
to commercial application, where various systems have been developed to detect a range of 
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important analytes. The Meso Scale Discovey (MSD) platform is one commercial 
implementation [30; 31]. MSD sell commercial assays for cytokines exploiting the unique 
sensitivity (~10 pM) and this platform is used extensively in biomarker detection in the 
research laboratory [32; 33]. It is not qualified for clinical practice, but its sensitivity and 
multiplex assay capabilities make it an attractive tool for use in high throughput sample testing 
[34; 35] 
Practically, ELISA and ECL techniques are very similar, as the only difference of note is the label 
on the reporter antibody. Therefore conventional sandwich assays can also be performed by 
ECL, whereby an immobilised capture antibody fixes the target antigen, after which the 
labelled reporter antibody can bind to the analyte, generating the signal when a voltage is 
applied across the solid phase. 
1.1.3 Other Labelled Detection Techniques 
Immunoturbidimetric Assays 
Immunoturbidimetric assays rely on the reduction of scattered light owing to aggregation of 
latex particles in suspension [36; 37]. The latex particles are functionalised with antibody, and 
in the presence of antigen aggregation is caused by the formation of antibody-antigen immune 
complexes. This aggregation increases the optical opacity of the suspension and reduces the 
amount of light that can travel through the suspension, and therefore the greater the 
concentration of antigen in a sample, the greater the aggregation. It is a simple technique that 
has been automated for high throughput screening of biomarkers, and has found application in 
clinical chemistry laboratories for CRP, C3, and C4 [38], used later in this thesis. 
1.2 Handling Complex Biological Samples 
Although many clinical assays have been developed to screen for biomarkers from biological 
samples, they have largely been limited to Immunoturbidimetric and ELISA. Nonspecific 
interference on the sensor by background proteins present in the sample is the single biggest 
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challenge to overcome if many of the detection platforms available, especially SPR, are to be 
employed successfully in a clinical setting.  
Investigators in the field have devised a variety of solutions to the problems posed by 
nonspecific binding, focussing their efforts on adjusting both the detection platform sensor 
surface and the samples. Special surface chemistries have been developed for SPR platforms, 
and the addition of products to samples, such as the surfactant Tween 20, has become 
commonplace for SPR, OS, ECL and ELISA. In this section we explore some of the techniques 
used to screen biomarkers in biological samples, and then investigate some of the auxiliary 
techniques developed that deal with real biological sample complexity.  
1.2.1 Surface Chemistry Development 
The current gold standard for SPR sensor surfaces is the widely used1 Biacore CM5 chip, which 
employs a carboxymethylated dextran surface on which ligands can be covalently immobilised 
by EDC/NHS2 coupling chemistry. Carboxylic groups on the dextran surface react (first with 
EDC, then NHS) to form a semi stable NHS-ester, which can react with free amine groups on 
incoming proteins, forming an amide bond which covalently binds the protein to the surface. 
The CM5 chip allows for greater surface loading due to the three dimensional structure of the 
dextran layer. Proteins can diffuse through and into the layer, allowing for a greater density of 
molecules to be absorbed onto the surface. Finally, the CM5 chip also offers resistance to 
nonspecific binding due to its hydrophilicity. This combination of properties has made it the 
most widely used sensing chip for SPR studies worldwide. 
Therefore efforts to reduce the effect of nonspecific binding have focussed on creating 
relatively inert hydrophilic sensor surfaces [39] that create a suitable environment for 
biomolecular reactions, similar to that of the CM5 chip. 
                                                          
1
 The current author estimates that there have been over 500 papers reporting work with the Biacore 
CM5 chip published in the first 6 months of 2012 alone. 
2
 EDC = 1-ethyl-3-(3-dimethylpropyl)-carboiimide, NHS = N-hydroxysuccinimide 
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1.2.2 Sample Preparation Protocols 
Ideally a diagnostic assay should be performed with minimum sample preparation, however 
the effect of nonspecific binding has forced many investigators to develop pre-treatment 
methods for biological samples so as to reduce the effect of nonspecific binding on the assay. 
Most simply, some studies have diluted the samples [40; 41] in order to reduce the 
concentration of nonspecific constituents in the sample. Obviously, this also reduces the 
concentration of the analyte present in the sample, and therefore it is an unsuitable method 
for use with analytes that are already low in concentration, such as the cytokines [42]. 
Some researchers have also shown that nonspecific binding could be reduced by heating the 
sample (serum) at 56ºC for 30 minutes [43]. Although this method is successful for reducing 
some of the effect of nonspecific binding (referred to as the ‘Ingredients Effect’ [43]), it is not a 
practically plausible solution in a clinical environment, and has obvious denaturation 
implications for the target analyte. The addition of some other ingredient to the sample that 
limits nonspecific binding would be preferred, as the time consumed by such a step would be 
negligible compared to a 30-minute heating step. 
One such proposed ingredient is the chaotropic anion, thiocyanate (SCN-). It has been reported 
that a final concentration in the sample of 100 mM thiocyante can eradicate any signal caused 
by nonspecific albumin interference [7]. It was demonstrated by the same principal 
investigator that thiocynate can also disrupt the interactions between living cells and 
macromolecules [44]. Thiocynate, a relatively large anion, has a very large entropy of 
hydration [45], and is therefore thought to modulate the structure of water surrounding 
macromolecules, and therefore disrupts the nonpolar effects that underpin protein-protein 
interactions. This allows the protein-specific interactions of antibodies and antigens to 
dominate over the general, nonspecific interactions between proteins. 
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1.2.3 Kinetic Analysis of Label-free, Protein-Protein Binding Studies 
To obtain biologically meaningful data from label-free binding studies, the data must be 
analysed to extract kinetic rate constants, thereby allowing the determination of an unknown 
concentration of an analyte in a sample, or protein-protein binding interaction energies. This is 
needed for SPR to become clinically useful, so as to specifically determine the concentration of 
a biomarker in a given sample, and not just to determine whether it is present or not. The 
current standard for data analysis of kinetic binding studies using SPR is the 1:1 interaction 
model [46; 47], whereby a finite number of binding sites on the surface become occupied 
singly by individual analyte molecules without interaction between species on the surface. This 
model is acceptable for simple binding studies of protein pairs where there are no other 
species present, but the presence of high concentrations of nonspecific background proteins in 
real biological samples requires this model to be altered, as it no longer becomes an accurate 
description of the processes taking place.  
The 1:1 adsorption model is the simplest adsorption isotherm, and is based on three 
assumptions. Firstly, the adsorption cannot exceed a monolayer. Secondly, the binding surface 
is uniform and all sites on it are equivalent. Finally, the occupation of neighbouring sites does 
not affect a given molecule’s ability to adsorb to a particular site. The nonspecific proteins will 
undoubtedly have some effect on the specific binding interaction, and therefore the use of this 
model for complex sample analysis is unsuitable. 
It is clear that if SPR is to become a successful biomarker detection platform from real 
biological samples, a different analytical approach is needed to take account of sample 
complexity, along with surface chemistry and sample handling developments. 
1.3 Detecting Biomarkers in Clinical Samples: Monitoring Biological Systems  
The primary function of biomarkers is to assist in the diagnosis of disease – to evaluate organ 
damage or dysfunction, or to monitor the state of progression of a disease and the 
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effectiveness of prescribed treatments. Biomarkers have been defined as ‘molecules that 
indicate an alteration in physiology from normal’ [48], and thus they can be used as 
companion diagnostics for certain physiological alterations. Trull et al. [49] have written that: 
“a diagnostic test is one element of a process which begins with a clinical question; the 
ideal test is one which provides an unequivocal answer to the question and enables a 
decision to be made on what action must be taken next.” 
Unfortunately no perfect biomarker exists; one which can provide an undisputed answer about 
a particular disease or immunological state, as evidenced by the prostate cancer biomarker, 
PSA, above. All biomarkers assays have a limited diagnostic performance, which should be 
taken into account by the clinician, who will use the test results as supporting evidence only as 
part of his ongoing investigation. The majority of biomarkers are single proteins, their 
abundance or deficiency signalling for a particular disease state or organ dysfunction. For 
example, there is a wealth of biomarkers available for the determination of kidney dysfunction 
and renal disease (creatinine, urea, urate, cystatin C), however they can all be influenced by a 
variety of factors including muscle mass, diet and tubular secretion. Could it be possible to 
treat an entire biological system as a biomarker instead of using single proteins, and in doing 
so negate much of the variability throughout a population for a single protein biomarker? 
Additionally, would such an approach also enable the biomarker development process to 
require a smaller number of patients in clinical trials? The premise is that, compared with 
individual protein biomarkers that can fluctuate immensely from patient to patient, the 
constituents of a biological system are interrelated, so although individual concentrations may 
differ, these relationships may remain more constant for a particular state of a biological 
system. 
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In terms on infection and immunity, several such biological systems exist; the activation of T-
cells by cytokines, the acute phase response, blood clotting, and the C system, which will be 
the immunological system interrogated in this study. 
1.3.1 The Complement System 
The C system is a defence mechanism that is part of the innate mammalian immune system. It 
is comprised of over 30 plasma and cell surface proteins that form part of a ‘cascade system’, 
whereby the components activate one another in series [50]. The cascade can be activated by 
three effector pathways by antibody-antigen immune complexes, microbial cell surfaces and 
lectins. The primary aim of the C system is to cause cell lysis by formation of the membrane 
attack complex (MAC) [50], however it also has the secondary functions of inflammation [51] 
and opsonisation for phagocytosis [51]. Thus determination of C activation may imply a host 
response to an immunological challenge, such as a bacterial infection. The C cascade will be 
explored in more detail below, along with an introduction to its regulators. 
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Figure 1.3. The C cascade, showing the three upper cascade pathways leading to the terminal pathway 
and ultimately MAC formation.  
The Complement Cascade 
The entire C cascade consists of three initiating pathways that lead to a fourth, lytic or terminal 
pathway. It is an enzymatic cascade based on positive feedback, and therefore once triggered 
it can be activated rapidly, quickly producing very large quantities of C activation products [52].  
The Classical pathway, so-called because it was the first pathway discovered, is primarily 
triggered by antibody complexes formed from the interaction between antibodies and their 
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respective antigens [52]. The antibody-antigen complex creates a binding site for C1, a 
macromolecular component comprised of two C1r molecules, two C1s molecules, and one 
molecule of C1q, on which the binding site for the interaction with the antibody-antigen 
complex is found [53; 54]. The binding of C1q to the antibody-antigen complex causes a 
conformational change in C1r which then activates C1s [55; 56]. 
Before continuing, it should be noted here that the nomenclature for C components is 
determined by their order of discovery, and therefore the numerical sequence assigned to 
proteins does not follow the order of interactions. Also, in line with recent rationalisation of 
the nomenclature in the literature [57] regarding the C2 fragments, C2a and C2b, this 
investigation refers to the larger, protease fragment as C2b, and the smaller, nonproteolytic 
fragment as C2a by analogy with C3, C4 and C5 fragments.  
Returning to the Classical pathway, the activated C1s cleaves C4 into C4a and C4b, the latter 
then binding to C2 before it is also cleaved by C1s into C2a and C2b. These reactions produce 
the Classical pathway C3 convertase, C4bC2b. This convertase can cleave C3 into C3a and C3b, 
the latter fragment initiating the amplification loop (discussed below), producing yet more 
C3b. The increased density of surface-deposited C3b gradually leads to a second convertase, 
C4dC2bC3b, which is the Classical pathway C5 convertase and initiates the Lytic pathway by 
cleaving C5 into C5b, the first molecule in the sequence to MAC formation, and C5a, a 
powerful anaphylatoxin [57; 58]. 
The Lectin pathway, an antibody-independent activation runs adjacent to the first part of the 
Classical pathway. This pathway is initiated by the Mannose Binding Lectin (MBL) which binds 
to mannose or N-acetyl glucosamine on the surface of micro-organisms. This binding event 
activates MBL-associated serine proteases (MASP), which in turn cleave C4 and C2 into their 
respective fragments. Following these cleavages the pathway continues as in the Classical 
pathway. 
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The third C activation pathway, the Alternative pathway, is another antibody-independent 
pathway that is activated by the presence of foreign surfaces. The Alternative pathway may be 
considered as two sub-pathways; the ‘tick over’ process and the amplification loop. It is 
commonly triggered by substances on microbial cell walls, especially molecules with repeating 
units, for example lipopolysaccharide or techoic acid, found in the cell walls of gram negative 
and gram positive bacteria respectively [59; 60]. The Alternative pathway is on constant 
standby, in a low-level activation state, said to ‘tick over’ slowly at cell surfaces. This ‘tick over’ 
process involves the spontaneous hydrolysis of a small fraction of C3 molecules into C3H2O. The 
factor B (fB) protease then binds to C3H2O [57] (which has many of the properties of C3b), and 
the bound fB is cleaved enzymatically by Factor D (fD), generating an initial, soluble C3 
convertase C3H2OBb (here called the ‘tick over’ C3 convertase, as it is generated during ‘tick-
over’ activation and not during the amplification loop) that can activate C by cleaving C3 into 
C3a and C3b.  
It is this that allows for the enormous amplification potential of the alternative pathway, as 
upon cleavage of C3 a short-lived thioester moiety in C3b becomes exposed which can 
covalently attach to amine and carbohydrate groups on a foreign surface. The amplification 
continues uninterrupted on foreign cells, and is regulated on host cells, so as to not self harm. 
If foreign cells are not present, the C3b will be hydrolysed and the ‘tick over’ process will 
continue. However, if C3b does come into contact with an attacking micro-organism, the 
Alternative pathway can be amplified by the binding of C3b to fB, which is once again 
enzymatically cleaved by fD, yielding the Alternative pathway C3 convertase C3bBb. This 
convertase can be further stabilised by Properdin (C3bBbP) to prolong its activity. As in the 
Classical pathway, further deposition and gradual binding of C3b to this C3 convertase 
produces the C5 convertase C3bBbC3b, which can cleave C5 into C5a and C5b, initiating the 
Lytic pathway.  
 
46 
The Lytic, or terminal C pathway is the final part of the C cascade, and culminates in the 
production of the Terminal Complement Complex (TCC), also known as C5b-9n or MAC. In 
terms of host defence, TCC is assembled at the surface of the target cell after C5b associates 
with C6 and C7, the intermediate complex inserting itself into the cell wall. Once inserted 
further association with C8 and several molecules of C9 forms a lytic pore, through which cell 
lysis can occur. The nomenclature for the soluble form of TCC is SC5b-9 [61], which is formed 
when the formation of TCC is intercepted by S Protein binding to the C5b-7 [62] complex 
before it is inserted. The assembly of soluble TCC continues, however the lytic functionality of 
the protein is lost. 
Regulation of Complement 
Effective regulation of C is imperative to avoid the C system attacking the host’s own cells. 
Several proteases in the Classical and Lectin pathways are regulated by C1 esterase inhibitor 
(C1-INH), as well as two additional Lectin pathway modulators namely sMAP and MAP-1, both 
nonproteolytic splice products of the MASP2 and MASP1/3 genes respectively. These 
regulators seem to compete with MASPs for binding to MBL and ficolins. In-solution activation 
of the Alternative pathway is regulated by Factor H (fH) [57], which acts mainly on C3 by 
competitively removing Bb from C3bBb, or by acting as a cofactor to Factor I (fI) [57] in the 
degradation of C3b. A similar regulator, C4-binding protein (C4BP) is found in the Classical 
pathway, which has analogous effects on the Classical pathway convertases. Crucially fH and 
C4BP also contribute to self recognition by engaging in host-specific surface patterns such as 
sialic acid or glycosaminoglycans. 
In self defence, most human cells also present C convertase regulators that act as cofactors for 
fI, such as CR1 and membrane cofactor protein (MCP or CD46), or as decay accelerators, such 
as CR1 or decay-accelerating factor (DAF, or CD55). The anaphylatoxins C3a and C5a are also 
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regulated by carboxypeptidase-N, which quickly converts both molecules into their respective 
desarginated forms. 
Complement System Utility 
The multiple activation pathways and cascade kinetics suggest that the C system may be used 
to detect indirectly an immune system challenge by monitoring its level of activity. During ‘tick 
over’, concentrations of C activation fragments will be low compared with when it is activated. 
Therefore, detection of high concentrations of these markers will indicate a C response, and if 
pathway specific activation could be determined, it might lead to the differential diagnosis of 
disease based on what is known about the specific triggers of each pathway. If C fragments 
could be detected in blood or urine samples, it could provide useful biochemical information 
to a clinician for assessment of a patient’s immunological state, which may lead to better 
disease diagnosis and patient care. 
1.4 Assessing Biomarkers for Diagnosis 
In order to use a complex mechanism such as the C system as a diagnostic biomarker, 
whatever metric calculated to determine a particular diagnosis (as with OVA1 above) will still 
need to pass the same rigorous statistical tests to determine its validity as a good biomarker. In 
light of this, consideration should be given to the question of what makes a good diagnostic 
biomarker, and how it becomes a statistically acceptable companion diagnostic. 
C-Reactive Protein (CRP) is an extensively assayed biomarker in hospital laboratory blood tests, 
and is a marker for the acute phase response. CRP is indicative of inflammation and is triggered 
by cytokines, part of the innate mammalian immune system. It is a pentraxin protein with a 
variety of well known functions [63] – it binds to the C polysaccharide of some streptococcal 
cell walls, promotes phagocytosis and is believed to activate C through the Classical pathway. 
As a result of this it has been described by some as a ‘primitive antibody molecule’ [64]. CRP is 
a useful biomarker in that it varies over three orders of magnitude in concentration during 
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activation, returning to its initial value when the acute phase response ends. Its concentration 
can range from an average of 0.8mg/L to >500 mg/L [63] during a severe acute phase 
response, for example inflammation after severe tissue damage as a result of surgery [65; 66]. 
This means that it is easy to distinguish CRP levels between healthy individuals and individuals 
undergoing an acute phase response to an immunological challenge. General elevated levels of 
CRP are also seen in individuals with rheumatoid arthritis [67] and SLE [68]. 
CRP is therefore a general marker for the acute phase response, but elevated systemic levels 
are also seen for certain permanent conditions. Attention should be given here to the 
mechanism of the acute phase response, and its helpfulness in providing such diagnostic 
markers. The acute phase response is a systemic, nonspecific physiological and biochemical 
response ‘to most forms of tissue damage, infection, inflammation and malignant neoplasia.’ 
[63]. The initial trigger of the acute phase response may be localised, but the cytokines that 
originate at the site of pathology triggers further protein synthesis and the wider acute phase 
response. After a single stimulus, such as a surgical insult, CRP is synthesised rapidly, and 
reaches a peak after approximately 48 hours, after which it is cleared with a half-life of ~19 
hours for both healthy and diseased individuals [63]. The use of CRP for subsequent patient 
monitoring following the single stimulus event is problematic, as a prolonged synthesis process 
produces elevated CRP levels long after the event that caused it happened. Therefore any 
further stimulating event, such as a bacterial infection, would be masked by the initial CRP 
production for a significant period of time. 
However it is not only CRP that poses problems for diagnosis. Often single biomarkers are not 
enough for a clinician to make a confident, evidence-based diagnosis. This is the case with 
Prostate Specific Antigen (PSA), introduced above. PSA acts as an indicator of tumour growth, 
specifically prostate cancer [5], however it can also suggest benign conditions such as 
prostatitis [69] (inflammation of the prostate gland) or benign prostatic hyperplasia (BPH) [70]. 
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PSA is produced in the prostate gland, and is normally present at low levels in healthy men. 
Elevated levels of the protein cannot distinguish between cancer and benign conditions, 
however the level of PSA concentration in the blood is considered by the clinician when 
ordering further examination. The lower limit for cancer diagnosis based on PSA level was 
altered after a study in 2004 by Thompson et al [71]. Previously PSA levels below 4ng/mL were 
considered normal, however in this study prostate cancer was diagnosed in 15.2% of men with 
a PSA level below 4ng/mL. Furthermore, in 15% of these men, (2.3% overall) had high grade 
cancers.  
By contrast, another routinely used biomarker is Troponin I for the diagnosis of acute 
myocardial infarction [72], as well as a range of other cardiac-related diseases such as chronic 
ischemic heart disease [73] and unstable angina [74]. A helpful contrast can be drawn with 
Troponin T which is also used to help diagnose acute myocardial infarction [72]. It has a 94% 
sensitivity towards myocardial infarction, however it has a lower specificity relating to this 
disease than Troponin I. This illustrates two key requirements for a good biomarker; sensitivity 
and specificity, and in the case of PSA, sensible cut-offs for these requirements. By contrast, 
total PSA has 60% specificity and 70% sensitivity for the diagnosis of prostate cancer [75]. 
Sensitivity and Specificity 
The sensitivity of a given biomarker in relation to its predictive value is defined as the 
proportion of true positives correctly identified as such whereas the specificity of a biomarker 
is defined as the proportion of true negatives it correctly predicted as such [76; 77]. The 
number for sensitivity of a given biomarker is obtained by dividing the number of true 
positives by the number of true positives plus the number of false negatives. In the case of 
disease diagnosis, this therefore translates as the probability of a positive result given that the 
patient is in fact ill. It is not the quality of the assay for the biomarker, but rather the immune 
response that will dictate whether this parameter renders an assay useful or not. If, for a given 
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target analyte, the immune response to a particular compromise drastically changes the level 
of the analyte (as is the case with CRP), then the biomarker has a better chance of being 
sufficiently sensitive, as distribution of CRP concentrations between healthy and inflamed 
patients will vary greatly. If, on the other hand, the levels of an analyte are barely different 
between healthy and diseased individuals, it is unlikely that the marker will ever succeed as a 
clinical biomarker for disease, as it will not be able to discriminate between healthy and 
diseased. The number for specificity can be obtained by dividing the number of true negatives 
by the number of true negatives plus false positives. 
Specificity and sensitivity can also be used to describe the quality of an assay, where specificity 
relates to the ability of the assay to isolate and detect one particular analyte, and the 
sensitivity of the assay is its detection limit – usually the level of background signal plus two 
standard deviations. 
The Perfect Biomarker 
In conclusion, a good biomarker for disease should display good sensitivity and specificity. It 
will be disease discriminating, achieved by exhibiting a large rise or fall in concentration 
between healthy and diseased states. This will enable lower false positive and false negative 
diagnosis rates to be achieved, which will give the clinician confidence in the assay. Ideally the 
marker should also respond rapidly to the host’s immunological state, and therefore be an 
intimate marker of a patient’s condition at a given time. 
1.5 Aims and Objectives 
This thesis aims to employ the C system as a companion diagnostic for postoperative, hospital 
acquired infection, and as a metric with which to measure postoperative patient recovery. This 
requires developing a set of assays that collectively produce a snapshot of the C system at a 
given time, thereby using the C system as a biomarker to measure the host’s immunological 
response. The hypothesis is tested in a clinical trial, correlating C activation and consumption 
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with infection and patient recovery. Initially, some challenges are addressed regarding the 
general handling and screening of real biological samples, namely nonspecific binding, and the 
analysis of data generated from complex samples. This part of the investigation is largely 
performed using the in-house optical scattering instrument, Liscar, which generates binding 
curves of interactions between macromolecules, label-free. The second part of the 
investigation employs the Meso Scale Discovery (MSD) ECL platform in order to develop assays 
for various components of the C system in order to monitor C activation. These assays are 
utilised in a clinical trial to monitor perioperative C activation in all patients in order to assess 
the efficacy of the C system as an indicator of systemic health 
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Chapter 2 
Assay Development in Complex Media: 
Chaotropes and Biophotonic  Nanoparticle  
Array Sensors 
2.1 Introduction 
From the perspectives of the hospital patient, the medical professional and the healthcare 
investor, there is an obvious need for a fast, multiple-biomarker biosensor that is capable of 
disease diagnosis from whole blood or serum at the point-of-care. Such a device will enable 
physicians to provide significantly better care to the hospital patients by ‘personalising’ each 
course of treatment based on the feedback that such a diagnostic instrument would provide.  
As mentioned previously, single biomarker studies and tests have been performed on Prostate 
Specific Antigen (PSA) to diagnose prostate cancer, for example [12], and have yielded 
consequent advantages for the diagnosis of the respective diseases. In order to achieve 
success with such studies, one must overcome the significant challenge of detecting low 
concentrations of the target biomarker against large protein background concentrations [42]. 
For example human serum albumin has a concentration range of 35 – 50 mg ml-1 [78] 
throughout a population of healthy and diseased patients. Albumin, a negative acute phase 
reactant [79], is currently being investigated as a potential biomarker for disease progression 
and mortality in conjunction with other serum proteins [80; 81; 82]. There is also the 
remainder of the blood proteome to consider, and the final goal must be to detect, selectively, 
individual target biomarkers against background proteins that might be as much as ten orders 
or magnitude more concentrated, as is the case between the cytokines and albumin [42]. 
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Figure 2.1. Reference intervals for 70 protein analytes in human plasma. Reproduced with permission from Anderson et al [42]. Abundance is plotted on a log 
scale spanning 12 orders of magnitude. Where only an upper limit is quoted, the lower end of the interval line shows an arrowhead. 
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This is clearly illustrated by Figure 2.1, which shows the classical plasma proteins at a far 
greater concentration than the interleukins, and the nonspecific interference from the former 
will have to be overcome before a successful assay can be developed for the latter. 
Furthermore, an ideal diagnostic test should be performed label free at the point of care, 
ideally on whole blood or on a sample with minimal pre-test preparation.  
A number of SPR platforms have been used to conduct label-free biomarker detection studies, 
however these studies have generally been limited to only one or two biomarkers per assay 
[40; 41; 83; 84]. The majority of the investigations have been performed using dual-channel, 
continuous surface SPR platforms. Some multi-analyte, array format SPR technologies have 
been developed to detect multiple biomarkers simultaneously [11; 85], including a 
nanoparticle array and a light scattering based immunoassay [20; 24; 86], described in section 
2.2.1. However, all SPR studies of complex fluids suffer from extreme nonspecific binding to 
the gold sensor surface owing to the intrinsic affinity that proteins have for gold. 
This has presented a potent problem for all SPR investigators hoping to develop assays in 
complex fluids, and attempts have been made to alter the chemistry of the surface [87; 88], so 
as to deter nonspecific proteins whilst still allowing the target analyte to gain access to the 
surface target. If the surface chemistry is able to effectively deter nonspecific protein 
interactions, the investigator would be relieved of much of the background signal associated 
with nonspecific proteins. Also, considering the schematic in Figure 2.2, a biosensor that is only 
sensitive to changes close to the surface, as far as the binding reaction between antibody and 
antigen, would be relieved of much of the background noise associated with nonspecific 
proteins.  
Therefore, regarding the problem presented by nonspecific binding, the nanoparticles have an 
advantage over continuous surfaces in that the sensing plasmon field is more localised on 
nanoparticles than on continuous surfaces [20]. This enables much of the “biological noise” 
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generated by nonspecific proteins to go unnoticed by the sensor, while still being capable of 
generating a signal from binding reactions close to the surface. The smaller sensing depth of 
the localised plasmons means that these sensors are less sensitive than continuous surface SPR 
sensors, however nonspecific background signal is precisely the feature we want to eliminate 
from our signal, which shows the advantage of using such particle-based sensors to detect 
antibodies in complex media such as delipidized serum [86]. 
 
Figure 2.2. Schematic showing specific vs nonspecific binding on an SPR assay platform. 
In this chapter, we address the problem of nonspecific binding and patient-to-patient albumin 
concentration variation that would affect directly the performance of a point of care sensor. 
We have performed a series of measurements on antibody-antigen reactions in model HSA-
containing artificial serum solutions, using both continuous surface SPR and a nanoparticle-
based plasmon sensor. The complexity of the detection serum is increased systematically; 
starting with the target analyte, IgG present in Phosphate Buffered Saline (PBS) solution, and 
then systematically increasing the concentration of the nonspecific binding species, Human 
Serum Albumin (HSA) to resemble physiological levels. We also examine the effect of the 
chaotrope KSCN on the antibody-antigen reaction, with and without HSA present. 
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2.1.1 Nonspecific binding 
The high concentrations of nonspecific proteins and the significant variation over the normal 
range (35 – 50 mg ml-1 [78] for albumin) in patients causes problems for plasmon based 
immunokinetic assays, ELISA and immunoturbidimetric assays. The plasmon sensors are 
sensitive to two effects with increasing concentration of nonspecific binding protein as well as 
the concentration variation of the target analyte. Firstly, all plasmon-based sensors are 
essentially refractive index sensors, so changes in the total protein load in a patient’s blood 
including any other changes will change the bulk refractive index. Secondly, nonspecific 
binding to the gold or modified gold sensor surface will compete with the target signal 
detection event. The bulk refractive index changes causes an immediate initial baseline offset 
and additional temporal changes are associated with nonspecific binding of proteins to the 
sensor surface. Crucially, there is a kinetic advantage in competition between specific and 
nonspecific binding: the antibody-antigen reactions generally have a very slow dissociation 
rate, characterised by the constant kd, as well as a fast association rate with constant ka, so 
that the antibody-antigen complex is more stable. Whereas the nonspecific proteins have a 
similar association rate but a much faster dissociation rate as the nonspecific protein-protein 
interaction it does not form a stable complex. An affinity constant KD, can be calculated for 
each protein-protein interaction based on the ratio between the dissociation and association 
rates, kd/ka. The nonspecific binding association rate constant is typically 10
4 M-1s-1 which may 
be compared with the antibody association rate constant of 106 M-1s-1. For the dissociation 
rate constants, 10-2 s-1 compared with 10-4 s-1 respectively [86]. 
2.1.2 The Vroman Effect 
Another phenomenon that requires consideration is that of the Vroman Effect [89; 90; 91; 92]. 
In the case where proteins have similar nonspecific association rates, a phenomenon called the 
Vroman effect takes place, whereby lighter proteins are displaced by heavier ones [93; 94; 95; 
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96]. In an experiment where IgG is the target analyte, this is not of great concern, as IgG has a 
large molecular weight (~150kDa), which is more than twice the weight of albumin at ~67kDa.  
Therefore the kinetic factors, surface chemistry design and displacement properties of these 
proteins affect the overall sensitivity and accuracy of the assay. 
2.1.3 Surface Control Proteins  
In order to distinguish the specific antibody-antigen reaction from other nonspecific 
interactions taking place, control ‘channels’ are put in place where the specific epitope for the 
antibody being studied is absent. This allows the experimenter to distinguish between the 
nonspecific signal observed in the control channel and the specific signal that generates an 
offset in the antibody-specific channel. The concept of ‘blocking’ is also introduced, whereby 
another nonspecific protein is allowed to bind to the surface after the initial antigen 
immobilisation. This allows the surface to become completely covered in protein, and prevents 
any of the analyte sticking to the gold instead of the surface target, thereby providing a false 
signal. The target and control channels are therefore as similar as possible, save for the 
epitope specificity on the target protein for the analyte. A simple subtraction of the 
nonspecific channel signal from the specific channel signal will provide the data generated by 
the antibody-antigen reaction. 
2.1.4 Reducing Nonspecific Binding 
Several studies have been performed with the aim of lowering or eliminating the effect of 
nonspecific protein interactions, especially that of albumin. Efforts have included the addition 
of novel reagents [97], blocking agents [98] and tailored surface chemistries [99]. Other studies 
have also been performed on the addition of chaotropes and kosmotropes to the analyte 
medium, which is discussed further in section 2.1.6. 
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2.1.5 Protein Separation 
Protein separation techniques include solubility methods, first performed successfully by 
Mörner in 1894 [100], who separated four components of lens protein using the differential 
solubility technique. Ultracentrifuge methods have also been employed successfully, relying on 
the principle that large molecules sediment in an ultracentrifugal field at a rate which is 
dependent on a number of factors, described by Svedberg [101] as  
  
   
 (    )
 
Equation 2.1 
where M equals molecular weight, R universal gas constant, T absolute temperature, s 
sedimentation velocity, D is the diffusion coefficient, v is the partial specific volume of the 
material in question, and ρ the density of the solution. 
Electrophoresis is another quantitative and effective method for the separation of proteins. 
This technique became especially useful when performed on some support material, in 
addition to the demonstration of fractions when dyes were used, with the protein still 
remaining on the support, such as agar or starch. A development of this technique, 
immunoeletrophoresis, modified standard agar electrophoresis by identifying the protein 
fractions by the precipitin reaction which was made with antiserum placed in a trough cut 
placed in the agar parallel to the path of the electric current. Another technique for protein 
separation that has proved particularly successful is that of column separation, however it was 
only after the development of two cellulose-based ion exchangers that it became possible 
[102; 103]. ‘Gel filtration’ is another technique to spawn from column separation, whereby 
isolation of protein is achieved by the differential rate of diffusion in a dextran gel [104]. 
Unfortunately none of these techniques can be directly employed in an SPR-type experiment. 
What is needed instead is a method that restricts nonspecific interaction with the surfaces, 
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meanwhile allowing for the affinity between antibodies and antigens, so that these reactions 
can take place without interference from other proteins. This would be harder to achieve on a 
continuous surface SPR platform due to the greater sensing depth. Conversely, it could be 
particularly advantageous to particle sensors, and therefore the techniques mentioned in 
section 2.1.4 warrant further consideration, as they are the only realistic options available for 
on-sensor protein separation. A prepared surface that would favour specific binding only is the 
most desired solution, however addition of reagents to the analyte solution would also be a 
sensible, practical solution. For example urea and guanidine have been found to reversibly 
disrupt the tertiary structure of proteins, thereby reducing nonspecific binding, yet the 
mechanism for this is still unclear [105]. 
2.1.6 Protein Separation – Choatropes 
Chaotropes are small molecules, such as the anion CNS-, that exhibit stronger interactions with 
water than water with itself [106]. They are thought to surround proteins with a highly 
charged layer, altering the surface involved in protein-protein interactions [107; 108] by 
destabilising the salt bridges in protein-protein interactions via their effect of hydrogen 
bonding [109; 110]. There are many techniques available for separating plasma proteins for 
characterisation, including chromatography [111; 112; 113] and membrane separation 
techniques which can be used on biosensors [114]. Ionic and non-ionic surfactants have also 
been used to separate proteins, although not without complications: the proteins may become 
denatured, and surfactant micelles may form, therefore analysis below and above the critical 
micelle concentration and Krafft temperature needs to be considered [115]. Chaotrope 
molecules are also used in conjunction with surfactants to facilitate the separation of proteins 
in 2D gels [116]. Some success has come from employing chaotropes to separate proteins in 
solution when performing ELISA assays, where the question of specific and nonspecific binding 
competition was addressed [7]. 
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2.1.7 Aims and Objectives 
In this chapter we aim to determine the effect of nonspecific binding on continuous and 
nanoparticle based plasmon sensors, and also aim to mitigate its effect. This is achieved by 
doing a series of competitive binding experiments whereby a large protein background is 
introduced to a solution containing the analyte for a particular surface target. An 
antibody/antigen pair that is known to perform well in clean, buffer only experiments (aBSA-
BSA) was selected for the specific binding reaction, and an abundant blood protein (HSA) was 
chosen as the nonspecific protein. The chaotrope KSCN is then added to the solution in large 
concentration, and its effect on the specific and nonspecific binding reactions studied. 
2.2 Method 
Given the advantages for analyte detection in complex fluids outlined in section 2.1.1, we have 
developed a nanoparticle based, light scattering array reader (Liscar) platform in order to 
perform multi-analyte detection studies. Nanoparticle seeds are printed in an array format on 
glass substrates and grown to larger 130nm truncated polyhedral structures to create bright 
light scattering centres. The arrays are illuminated in a total-internal-reflection configuration 
and the scattered light is monitored by a photo-camera in real time. The variation of scattered 
light in time for each functionalised array spot leads to an immune-kinetic assay whereby the 
kinetic response of a control assay is used to determine the concentration of the target 
analyte. In principle, the array setup allows for the concentrations of many different analytes 
to be determined simultaneously, however for current development and optimisation of the 
platform we have concentrated on understanding the assay characteristics for up to 8 species 
in a 96-spot array. The technical aim is to develop a point-of-care device for which no sample 
preparation is required, hence the emphasis on the challenge posed by nonspecific binding. 
Several proprietary buffers are used commercially within the blood sample collection 
containers, including chaotropes, and we are investigating their effect on the immuno-kinetic 
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assay. However, the primary cause of variation in blood samples is the effect of patient serum 
concentrations.  
2.2.1 Experimental 
The label-free binding studies were performed on two platforms: the commercially available 
continuous surface SensiQ Discovery SPR instrument from ICX Nomadics and the biophotonic 
particle plasmon Liscar instrument, developed in-house. The Liscar design has been discussed 
elsewhere [20; 86], however the current configuration employs an LED light source (Thorlabs, 
660nm, 100mW) instead of the laser used previously. A schematic of the Liscar, including the 
fluidics system is shown in Figure 2.3a. A biophotonic sensor slide is prepared via a two-step 
process – firstly the fabrication of a gold nanoparticle array followed by functionalization with 
a target ligand. 
Gold nanoparticle array fabrication 
The gold nanoparticle array is manufactured by the chemical growth of small, ca.3 nm, gold 
nanoparticles that are spotted onto glass substrates in a 12×8 array format. Firstly a seed 
particle colloid by borohydride reduction of AuIII following the synthesis of Jana et al [117] to 
produce spherical seed gold particles with ca. 3 nm diameter. The seed solution is printed onto 
uncoated 25 mm × 25 mm glass slides in a 12 × 8 rectangular array using an inkjet printer 
(Arrayjet Aj100). The slides are  left to dry for 2 hours at room temperature. The seed arrays 
then undergo a particle growth procedure to produce an array comprised of much larger 
individual nanoparticles. The grown nanoparticles take the shape of truncated polyhedra, and 
are approximately 130 nm in size [86]. The slides are completely immersed for 30 minutes in 
developing solutions containing: (i) 0.1 M CTAB, 2  × 10-4 HAuCl4, and 4 × 10
-4 M ascorbic acid 
and 2 × 10-6 M AgNO3. The slides are then washed extensively in 18 MΩ deionised water to 
remove CTAB from the nanoparticle sureface. The slides are dried with nitrogen and stored at -
4°C. 
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Protein Functionalisation 
The nanoparticle arrays are then functionalized with the surface target proteins according to 
the array key in Figure 2.3(b). The slides are reinserted into the inkjet printer and 1 mg/mL 
protein solutions (in PBS) are printed precisely over the gold nanoparticle array according to a 
pre-determined functionalisation key, elaborated on in Section 2.2.3. 
Protein binding  measurements 
 The biophotonic sensor slide is installed into the Liscar and is equipped with a flow cell to 
enable kinetic protein-protein interaction assays to be recorded in real time by recording 
scattered light from the nanoparticles using a photo camera – incident light is scattered by the 
gold nanoparticles, and this scattering changes as proteins enter the plasmon field surrounding 
the nanoparticles. It is this change in scattered light that generates the signal. Therefore an 
individual kinetic trace can be recorded for each array spot, and in the case of this experiment, 
24 array spot traces are averaged together per target surface protein. 
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Figure 2.3. (a) Schematic of the Liscar instrument. (b) Protein functionalization array key. 
Initially, a stable baseline is obtained for 5-10 min using a standard PBS running buffer, after 
which an antibody-containing analyte is injected over the protein functionalised surface for 15 
min at a flow rate of 25µl min-1 (SensiQ) or 100 µl min-1 (Liscar) to ensure concentration limited 
kinetics [20]. The absolute response from the Liscar was calibrated for each set of 24 spots 
functionalised with the same protein, Figure 2.3b, by measuring the response to the buffer 
change from PBS to double concentrated PBS, corresponding to a change in bulk refractive 
index (RI) of 1.510-3 refractive index units (RIU); all data presented in the subsequent figures 
are presented as the change in RI, RI. Similar calibrations were performed for both channels 
of the SensiQ SPR instrument where the sensitivity is typically 2 × 10-6 RIU. 
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2.2.2 Chemicals 
N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS), 16-mercaptohexadecanoic acid (MHDA), potassium thiocyanate (99%), bovine serum 
albumin (BSA) (98%), human fibrinogen (FBR) (60%, with 40% buffer salts; the protein content 
is >80% clottable FBR), human serum albumin (HSA) (>96%), and transferrin (98%) were 
obtained from Sigma-Aldrich; sheep polyclonal antibodies to BSA (aBSA, 23mg/ml, IgG 
fraction) were supplied by AbD Serotec UK; all solutions where prepared in 18 MΩ deionised 
water and protein solutions were prepared in standard phosphate buffered saline (PBS, 137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.5 mM, KH2PO4, pH 7.3) unless otherwise stated. 
2.2.3 Sensor Surface Preparation 
SensiQ SPR Surface 
Proteins were immobilised on the two sensor channels of the SensiQ chip by peptide coupling 
between sensor surface carboxyl groups and free amine groups of the proteins. The two-
channel gold surface of the SensiQ sensor chip surface for the SensiQ instrument has a 50 nm 
thick continuous gold surface which was first cleaned with 10 mM HCl solution followed by 
incubation in 10 mM 16-MHDA in ethanol for 15 hours, which forms a carboxyl-functionalised 
self assembled monolayer (SAM) on the sensor surface. The SAM carboxyl groups were 
activated with 0.05/0.25 M NHS/EDC aqueous solution, forming amine-reactive succinimide 
ester groups. Immediately after the activation step, 1 mg ml-1 solutions of BSA and transferrin 
in 10 mM sodium acetate buffer, pH4.9, were injected into channels one and two respectively 
at a flow rate of 5 μl min-1 for 45 minutes. Following the protein immobilization step, both 
surfaces were capped with 1 M ethanolamine, and after a 10 mM HCl wash the running buffer 
was then changed to PBS. 
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Liscar Particle Surface 
The array format sensors were functionalized with proteins by spotting 1 mg ml-1 HSA, BSA, 
fibrinogen, and transferrin solutions in PBS directly over the nanoparticle containing array 
spots, according to the key on Figure 2.3(b). After 2 hour incubation the slides were washed 
with PBS and stored dry at 4oC. 
2.2.4 aBSA-BSA Binding Experiments 
In order to simulate physiological conditions, and to compare those conditions to a ‘clean’ SPR 
experiment where only PBS is used as a buffer, a series of experiments were performed 
whereby the analyte, BSA, was detected both in the presence of high concentrations of HSA 
and in clean PBS buffer. 
2.3 Results 
Several series of experiments were performed to establish the interference effects of the HSA 
concentration on the immuno-kinetic assay accuracy for aBSA concentration measurements in 
model sera. The effect of added chaotrope was also investigated in an attempt to recover the 
accuracy of the assay; the experimental series are summarised in Table 2.1 
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Table 2.1. Summary of experiment series performed for on the Liscar and SensiQ platforms 
Series [aBSA] [HSA] [KSCN] Liscar SensiQ Figure 
A varied 
10-50 nM 
- - + - Figure 
2.9 
B fixed 
30 or 50 nM 
varied 
100-450 nM 
- + + Figure 
2.4, 
Figure 
2.6 
C varied 
10-50 nM 
fixed 
450 nM 
- + - Figure 
2.7, 
Figure 
2.9 
D varied 
10-50 nM 
- fixed 
150 mM 
+ - Figure 
2.8, 
Figure 
2.9 
E fixed 
30 or 50 nM 
varied 
100-450 nM 
fixed 
150 mM 
+ + Figure 
2.6 
F varied 
10-50 nM 
fixed 
450 nM 
fixed 
150 mM  
+ - Figure 
2.9 
 
The aBSA-BSA binding kinetics were measured in pure PBS buffer acting as the control series. 
Further analyte solutions of 30 nM (SensiQ) and 50 nM (Liscar) aBSA with varying 
concentrations of HSA, were prepared in PBS and injected over the sensing surfaces of the 
SensiQ and Liscar platforms. Each injection lasted for 15 minutes and was followed by a 5 
minute, 10 mM HCl regeneration step. Repeat injections were performed for each series to 
establish reproducibility. The order of injection of the analyte solutions of different HSA 
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concentration was randomised so as not to perform the experiment in a systematic manner. 
The aBSA immuno-kinetic assay was repeated with a fixed physiological concentration of HSA 
(450 µM). These experiments were performed in three series, A – C,: 
A: The aBSA-BSA assay in PBS. This is the reference series with varying aBSA 
concentration from 10 to 50 nM, Figure 2.4 and Figure 2.9(b) 
B: The aBSA-BSA assay with varying concentrations of HSA 0 – 450 µM, with fixed aBSA 
concentration, 30 nM (SensiQ) or 50 nM (Liscar), Figure 2.4 and Figure 2.6. 
C: The aBSA assay was performed with fixed HSA concentration (450 µM), and varying 
concentrations, 10-50 nM, of aBSA. Figure 2.9 and Figure 2.8. 
The effect of nonspecific binding was investigated by repeating experimental series A-C with 
fixed concentration of the chaotrope, KSCN, at 150 mM [7], series D-F: 
D: The aBSA-BSA assay in PBS with 150 mM of chaotrope, analogous to Series A, Figure 
2.8 and Figure 2.9. 
E: The aBSA-BSA assay with varying concentrations of HSA 0 – 450 µM, with 150 mM 
KSCN, analogous to Series B, Figure 2.6.  
F: The aBSA assay was performed with fixed HSA concentration (450 µM), and varying 
concentrations, 10-50 nM, of aBSA.with 150 mM KSCN, analogous to Series C, Figure 
2.10 and Figure 2.9 
The series A-F were performed on the Liscar platform with B and E repeated on the SensiQ. 
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Table 2.1 summarizes the conditions of each experiment and the figures presenting the 
corresponding data.  
2.4 Discussion 
The principal objective of this investigation is to interrogate the effect of varying 
concentrations of HSA that reflect physiological conditions on an immunokinetic assay for 
aBSA. Further to this we investigate the effect of the Chaotrope, KSCN on the aBSA assay in the 
presence of HSA. The maximum used HSA concentration of 450 M roughly corresponds to the 
lower limit of clinical albumin concentration range expected clinically, 30 – 50 gL-1 [78]. 
Potential applications of the Liscar technology for the high throughput measurement of blood 
protein concentrations requires an understanding of the effect by the background blood 
proteome, as seen in Figure 2.4. It may be the case that HSA should be assayed simultaneously 
with the target analyte assays in order to accurately determine the concentration of the target 
analyte in whole blood or serum – aBSA in the present case. The arrays used in this experiment 
employed a 24-spot averaged fibrinogen control ‘channel’, Figure 2.3(b), to act as a nonspecific 
binding channel that is also sensitive to variations in light intensity and wavelength, both of 
which cause variations in the scattered light that generates our signal, and therefore add noise 
to the experiment. In addition, the normalisation of the averaged signal from the target spots 
against the fibrinogen control channel removes the effect of the large bulk RI change. ΔRI due 
to varying [HSA] in PBS is determined using the fibrinogen control and the absolute RI shift 
calculated for each of the model serum solutions, plotted in Figure 2.5. Although the data 
appear to present a complex, non-linear variation with concentration, a simple linear relation, 
r2 = 0.94, satisfactorily describes a first measure (within experimental error) of the bulk 
composition of the patient’s serum. 
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Figure 2.4. aBSA-BSA assay with varying concentrations of HSA; (a) 0 M, (b) 100 µM, (c) 200 µM, (d) 
300 µM, (e) 450 µM 
The response detected from the sensor surface reflects the complex kinetics from an 
amalgamation of processes, including the co-adsorption of HSA and aBSA to the surface and 
various displacement reactions, including the Vroman effect [95]. A detailed analysis of the 
competing process is beyond the scope of this paper; here we present an empirical analysis 
that might form the basis for a simple interrogation algorithm for a point-of-care instrument 
based on the Liscar. The antibody immuno-kinetic response based on the Langmuir adsorption 
equation [86]. 
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Equation 2.2 
where  is the surface coverage (a fraction of the occupied binding sites, ϑ, to maximum 
binding sites, ϑm); [P] is the concentration of antibody in solution; and ka and kd are the 
adsorption and desorption rate constants, respectively; and t is time. Since the present data 
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show that on the experimental scale kd « ka[P] for antibody-antigen reactions, the equation 
may be simplified into: 
  tPkam ][exp1   
Equation 2.3 
where  refers to the experimental observable, namely change in scattering brightness and m 
corresponds to the maximum brightness change when complete coverage of the available 
active sites on the surface is achieved. Each recorded transient curve was fitted to this single 
exponential expression. ka is therefore the observed association constant derived from the 
data fit to Equation 2.3. 
 
Figure 2.5. Variation of bulk RI determined from the fibrinogen control spot responses to analyte 
samples containing 0-450 μM HSA (r
2
=0.98) 
The simple model contains the same assumptions as the Langmuir adsorption isotherm, 
notably the antibody interacting with its antigen on the surface but neglecting the interactions 
between antibodies at the surface or the interference from any other proteins fouling the 
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surface or the reduction in the rate of association as a result of diffusion through a viscous 
medium. Taking these into account the derived ka and m shall not be perceived as true kinetic 
constants for aBSA-BSA interaction but rather as effective/empirical factors describing the 
complex system of reactions in a most simple practical form. Moreover, a significant degree of 
correlation between ka and m may be removed by forming a single mka parameter [86] which 
is used to discuss the effects of nonspecific protein binding and presence of chaotrope on 
specific response due to aBSA-BSA interaction. The mka parameter is used to describe the 
data as it describes more accurately the processes occurring at the surfaces, namely bulk 
refractive index change, m, and antibody-antigen binding, ka. 
 
Figure 2.6. Dependence of mka on concentrations of HSA in the analyte; a) SensiQ, 30 nM aBSA; (b) 
SensiQ, 150 mM KSCN, 30 nM aBSA; (c) Liscar, 50 nM aBSA; (d) Liscar, 150 mM KSCN, 50 aBSA 
Using the mka analysis, calibration curves for the concentration may be derived for the SensiQ 
and Liscar platforms, Figure 2.6. The curves show a significant difference between the particle 
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and continuous gold surfaces and the effect of the chaotrope on both platforms. The limiting 
mka value for the continuous surface is 40% smaller than for the nanoparticle surface and 
with a smaller dynamic range for the assay. The effect of the chaotrope is more pronounced: 
on the SensiQ platform the value of mka is reduced by one third with the addition of the 150 
mM chaotrope which further reduced the dynamic range of the assay to 25% of the initial 
value and hence reducing the sensitivity. However, with the nanoparticle surface the dynamic 
range of the assay is only reduced to 60% of its original value. The variation in the performance 
of the Liscar platform in part depends on the variations during the printing process which 
dominates the error in the signal.  
 
Figure 2.7. aBSA-BSA assay with [HSA] = 450 µM and varying [aBSA]; (a) 20 nM, (b) 30 nM, (c) 40 nM, 
and (d) 50 nM 
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Figure 2.8. Immuno-kinetic aBSA-BSA assay in the presence of 150 mM KSCN, antibody 
concentrations; (a) 10 nM, (b) 20 nM, (c) 30 nM, (d) 40 nM, (e) 50 nM 
The data from the reference channel presented in Figure 2.5 can be used to correct for the 
effect of high HSA concentration on the observed aBSA-BSA association rates shown in Figure 
2.8. An empirical rational function efficiently describes the observed experimental dependence 
of mka parameter on bulk refractive index change associated with HSA concentration in the 
sample. The empirical functional form is defined as:  
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where a=0.0135, b=115 and c = -2.9  10-9 M are fitted parameters, c is a small offset 
parameter within the accuracy of the measurements. Consequently, with this correction the 
aBSA concentration may be derived with an accuracy of 10-15% for all samples containing HSA 
in 0-450 µM concentration range. The a, b and c parameters may be derived for a batch of 
slides produced and then used to calibrate each array slide, assuming consistent printing 
integrity.  
There is a clear difference in the performance of the two plasmon platforms which may in part 
be explained by the differences in the plasmon field penetration of the continuous and 
nanoparticle gold surfaces. The plasmon field penetrates typically 300 nm from the gold 
surface of which only approximately 10 nm is occupied by the antibody assay. The majority of 
the field plasmon field is sensitive to large changes in the bulk refractive index which in the 
presence of the large HSA concentration and the chaotrope is significant. In the two-channel 
SensiQ platform the specific binding contributions to the signal are derived from a subtraction 
of the large refractive index changes associated with HSA and the chaotrope. The subtraction 
produces the change associated with the binding, both specific and nonspecific to the surface, 
an effect occurring in less than 10% of the continuous surface plasmon field. This is based on 
the assumption that the assay layer is approximately 20 nm thick including all of the ligand 
molecules and proteins. However, the particle platform performs the same subtraction over a 
number of control spots on the array to observe the change assay in the volume which 
occupies nearer 50% of the plasmon field, where similar assumptions have been made about 
the thickness of the assay layer and a particle plasmon field penetration depth of 50 – 60 nm.  
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Figure 2.9. Variation of mka vs antibody concentration for the immuno-kinetic aBSA-BSA assays with 
different analyte buffer composition; (a) KSCN and HSA-free PBS buffer (r
2
 = 0.93); (b) PBS, 150 mM 
KSCN (r
2
 = 0.95); (c) PBS, 450μM HSA (r
2
 = 0.99); (d) PBS, 450 µM HSA, 150 mM KSCN (r
2
 = 0.72) 
Calibration curves may be constructed for the Liscar platforms from which variation of mka 
against aBSA concentration may be seen in Figure 2.9. There is a significant difference in 
sensitivity of the assay in PBS, 84 ± 3 RIU s-1 M-1, compared with the 23 ± 2 RIU s-1 M-1 for the 
assay at physiological HSA concentration. The detection limit and accuracy for the aBSA in PBS 
is 760 ± 160 pM (120 ± 25 ng ml-1) whereas in physiological HSA it is 2.5 ± 0.7 nM (380 ± 100 ng 
ml-1). The challenge for the measurement of antibodies in real serum samples with varying HSA 
concentrations is to provide a robust estimate of the effect of the HSA to enable to the 
concentration to be observed. 
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Figure 2.10. The effect of chaotrope on antibody binding from samples containing 50 nM aBSA and 
450 M HSA; (a) without chaotrope and (b) with 150 mM KSCN 
The effect of the chaotrope is also clear from the original trace in Figure 2.10 and the 
calibration curve in Figure 2.9 with a sensitivity and accuracy of 66 ± 3 RIU s-1 nM-1 in 150 mM 
KSCN and PBS. The kinetic trace in Figure 2.10 is slower in rate when the chaotrope is present 
and does not reach the same m during the course of the experiment. However, the quality of 
the exponential curve is better, resulting in an improved fit to the data. There is also a large 
increase in the refractive index of the sample with the added chaotrope and this causes a 
number of subtraction artefacts in the traces notably in the SPR surface but not as much in the 
particle plasmon surfaces. The chaotrope does however, improve the accuracy of the aBSA 
assay in the presence of 450 µM HSA ensuring the calibration is linear with a sensitivity of 2 × 
10-8 M-1 s-1 whereas the calibration for the aBSA with HSA without the chaotrope is not linear 
(seen from the r2 value for the line in Figure 2.9(d)). The detection limit for both assays is 2.5 ± 
0.7 nM (380 ± 100 ng ml-1) in PBS and 2.9 ± 0.5 nM (440 ± 80 ng ml-1) in the chaotrope 
augmented PBS.  
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The KSCN behaves as a chaotrope by surrounding the proteins in the solution with a small-
molecule, charged layer to each of the proteins in the solution causing a change in the protein-
protein interactions but not so as to denature them. There are both ionic and non-ionic 
chaotropes such as KSCN and urea respectively, as well as kosmotropes such as CO3
2- which 
affect the interactions between proteins and their solubility in solution [118]. The current 
mechanism of action [118] suggests polarisation of the salvation shell around large molecules 
such as proteins as well as hydrophobic, surface tension and direct binding mechanisms. 
 
Figure 2.11. Empirical correction of the immuno-kinetic assay for the variation of bulk [HSA] using 
Equation 2.4. □, experimental series A; , series B; ○, series C. r
2
 = 0.96. 
2.5 Conclusion 
We have demonstrated the albumin interference affect on the immuno-kinetic assay for aBSA 
in analytes with varying concentrations of HSA. The total RI can be used as a simple measure of 
the HSA concentration thus allowing an empirical correction to immuno-kinetic assay for aBSA 
under varying HSA conditions. While testing complex analytes with large HSA content, there is 
a clear particle plasmon detection advantage on the Liscar platform compared with the 
continuous gold surface and addition of the KSCN chaotrope somewhat improves the integrity 
and accuracy of the assay although there is a slight reduction in the detection limit. Since 
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albumin interference with assays in blood serum is well known and there are propriety 
reagents which have been added to serum solutions to improve the integrity of a number of 
assays [97; 119], a novel set of reagents with some of the advantageous characteristics of 
KSCN will need to be developed specifically for the immuno-kinetic assays based on continuous 
surface and particle-based SPR techniques. It is also apparent that a different analytical 
approach is needed to determine the competition between nonspecific and specific analytes. 
Although this investigation contained complex samples where antibodies and albumin were 
allowed to compete for reaction sites, a development of this would be to investigate the 
competition between these species when one is already present on the surface. This is 
therefore addressed in the following chapter. 
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Chapter 3 
Mathematical Model for Competitive Binding 
between Low and High Affinity Species  
on Biosensor Surfaces 
3.1 Introduction 
Nonspecific binding presents real problems to label-free, plasmon-based biosensors as shown 
in Chapter 2. Relative to the target analyte, the presence of abundant interfering components 
(with both high and low affinity for the sensor surface) affects the sensor’s ability to detect the 
target species, and creates uncertainties regarding the reaction mechanisms normally used to 
analyse the data. At present this is a weakness of label-free biosensors, with most investigators 
avoiding the problem altogether by performing experiments with clean, analyte-only solutions. 
This is a reasonable strategy for standard protein-protein interaction research, but it poses a 
significant challenge if label-free biosensors are to succeed as a diagnostic tool, screening for 
biomarkers from real samples at the point-of-care. Owing to the complexity of real biological 
samples, and therefore the uncertainty surrounding the reaction mechanisms involved, kinetic 
SPR data become difficult to interpret as the favoured 1:1 interaction model [12; 46; 47] is no 
longer the correct description of the true set of reactions. Surface chemistry advances [120] 
have, to some extent, reduced the amount of nonspecific protein interference on the sensor 
surface and therefore also improved the specific signal produced. Nevertheless, it is unlikely 
that any advances in surface chemistry, however good, will ever completely eliminate the 
effect of nonspecific proteins interfering with the interaction between the immobilised ligand 
and the target analyte.  
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The nonspecific binding problem is accentuated further if we consider the complexity of real 
biological samples, the medium within which diagnostic tests are performed. For example, 
human plasma contains 289 known proteins [121] spanning a concentration range of over 11 
orders of magnitude. In theory, affinity constants could be determined for all plasma protein-
protein interactions, and the results presented in an extremely large model, tailored for a 
particular target analyte. However this is well beyond the scope of this investigation, and the 
field of label-free protein interaction analysis as it stands. Such a model would not just be 
dependent on the number of proteins present, but also their concentrations and relative 
affinities, which will vary depending on the target assay species and the disease state of the 
patient – a potentially insurmountable problem. 
Many excellent SPR investigations [11; 12; 122] employing low-ligand surface coverage and 
low-analyte concentrations have yielded well-determined kinetic parameters for the 
interaction between proteins using the 1:1 interaction model, and thus the value of the 1:1 
model should not be under-estimated. Nevertheless, its applicability to real biological samples 
analysis is questionable, as there are a number of additional factors to consider which 
contradicts some of the assumptions of a 1:1 interaction model, Section 1.2.3. For the 1:1 
model to be employed with real biological samples, significant dilution of the sample is 
required to satisfy the non-interacting assumptions of the 1:1 interaction model. This has 
obvious detrimental effects for assay sensitivity and accuracy, and is therefore not appropriate 
for low-concentration analytes. Where investigations have used real biological samples, a 
number of techniques have been employed to obtain acceptable results. The simplest 
implementation to correct for any unwanted nonspecific binding is the introduction of control 
channels, present in almost all SPR-based studies to subtract the non-specific contributions 
from specific binding interactions. This involves functionalising one of the sensor surface 
channels with a protein that will not bind with the target analyte, and therefore it acts as a 
negative control for the interaction of interest.  
 
83 
Alterations to sensor surface chemistries have focussed around creating hydrophilic surfaces 
that limit interactions with any nonspecific proteins present in the sample. The most successful 
of these surface functionalisations have implemented poly-ethylene glycol (PEG) [123; 124] 
molecules of varying sizes and surface coverage. Furthermore, ‘blocking’ steps, whereby 
nonspecific proteins are bound to all sensor channels, followed by washing with regeneration 
buffers, have been introduced to binding protocols in order to stabilise the immobilised ligand 
[12] and cover any remaining immobilisation sites. Additionally, preconditioning of real 
biological samples has included delipidation [125], heat treatment [43], dilution [40; 41] and 
addition of chaotrope species [126; 127] prior to analysis. All these measures have been 
employed to investigate their effects on nonspecific binding in an attempt to minimise its 
effects.  
In addition to advances in surface chemistries and sample preparation, analysis of complex 
samples also needs to evolve to accommodate the ever-present sample complexity, especially 
the high abundance of nonspecific proteins relative to the target analyte. Association and 
dissociation rates must be considered for the individual components in the complex media, 
and competitive displacement of ‘low affinity’ proteins by ‘high affinity’ species should be 
measured. Several studies [12; 46; 128] have successfully presented global analysis of kinetic 
binding data whereby all the binding curves for different analyte concentrations are fitted with 
a single set of parameters. 
3.1.1 Aims and Objectives 
The investigation presented in this Chapter aims to address the simplicity of the 1:1 single 
analyte binding model by developing a model for the analysis of complex analyte mixtures 
which contain a ‘high affinity’ target analyte in low concentration, an antibody, and a high 
concentration of a ‘low affinity’ background protein, Human Serum Albumin (HSA). A first-
order kinetic model will be developed for a complex set of reactions by interrogating each 
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individual reaction subset that forms part of a system, and present the results in a global 
kinetic analysis model. Binding kinetics of the two competing analytes, with low and high 
affinity for the target ligand, will be studied separately, followed by a study where both 
analytes are allowed to compete for the surface ligand. This final set of conditions is therefore 
analogous to real blood where, for example, and antibody has to compete with a large 
background of nonspecific proteins (such as albumin) to locate and bind its respective antigen. 
The investigation will be conducted using the Liscar (Light Scattering Array Reader) instrument 
discussed in detail in Chapter 2, which relies on optical scattering by gold nanoparticles. The 
robust nature of the Liscar instrument allows samples of very high protein concentrations to 
be screened. The data is fitted globally to a 1:1 interaction model, and then the model is 
expanded to include additional reactions to account for the complexity of the assay sample, 
explicitly considering the competition between low and high affinity species. 
Model Nomenclature 
The molecules used to model the reaction are chosen for their respective masses and 
affinities. Anti-BSA (aBSA), the ‘high affinity’ analyte, is larger than the Human Serum Albumin 
(HSA), serving as the ‘low affinity’ analyte. As the low affinity molecule is also of lower mass 
than the high affinity molecule, the study has minimised the nonspecific Vroman effect [89; 90; 
91; 92], reducing the complexity of the model. Additionally, HSA does not interact with aBSA 
which serves to further simplify the model. 
3.2 The Binding Models 
A simple 1:1 model allows for the rate of adsorption to a surface to be proportional directly to 
the number of vacant sites on the surface, but its principal limiting assumption for protein 
binding studies is the lack of interaction between species as they bind to the sensor surface. A 
competitive binding model will allow for these co-operative binding interactions and additional 
reactions to occur at the sensor surface. This investigation identifies and analyses the 
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individual reactions that comprise a complex set of reactions forming a mechanism for the 
interaction of high affinity and low affinity species at a biosensor surface, Figure 3.1. 
Firstly, the well-known [125; 127] interaction between aBSA (analyte A) and BSA (the surface 
ligand, S) is studied, followed by the nonspecific interaction between HSA (analyte B) and BSA. 
The reaction sets will be combined to monitor the displacement of HSA from the surface by 
aBSA. The first two datasets are analysed separately and the parameters obtained used to 
model the data from an experiment where both analytes A and B are allowed to interact with 
S, Figure 3.1. Additional reactions will be added to the reaction mechanism model as required. 
 
Figure 3.1. Schematic diagram of the three reaction-sets studied: A = High affinity analyte. B = Low 
affinity analyte. S = Surface ligand, with high affinity for analyte A only. In each reaction-set the 
concentration of the analyte in solution is varied, detailed in Table 3.1. 
Figure 3.1 illustrates the three reactions that comprise this study. The high and low affinity 
analyte experiments are both performed with only the target analytes present in buffer, 
however the competitive binding experiment monitors the competition between A and B for S, 
with B already present on the surface before the introduction of the analyte solution which 
contains a low concentration of A against a large background concentration of B. A comparison 
with physiological conditions is possible, where antibodies (analyte A) in the blood in low 
concentration compete to bind with their respective antigens (the surface ligand, S) against a 
vast background of nonspecific protein concentrations such as albumin (analyte B). 
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3.3 Materials and Methods 
The method used to collect the data for this experiment has been described in detail in 
Chapter 2 and elsewhere [86; 125], and will be discussed again briefly here.  
The Liscar configuration is duplicated as per Sections 2.2.1 and 2.2.3, the only difference being 
the protein functionalization setup, Figure 3.2. A schematic diagram for the Liscar can be seen 
in Figure 2.3. A gold nanoparticle array is produced by chemical growing of small, ca. 3-4 nm, 
nanoparticles spotted onto a glass substrate in a 12×8 array format. The grown nanoparticles 
are in the shape of truncated polyhedra, approximately 130 nm in size [86]. The surface is then 
functionalised with a ligand according to the array key in Figure 3.2.  
 
Figure 3.2. Surface ligand functionalisation key. A 12×8 array of gold nanoparticle spots was 
functionalised with three different surface ligand proteins as indicated.  
A flow cell is fitted over the array to allow protein-protein interactions to be measured in real 
time by imaging the sensor array. The scattering properties of the nanoparticles depend on the 
local RI around the nanoparticle, which changes when proteins (RI = 1.36-1.55 RIU [22]) 
displace water (RIU = 1.33 [21]) in the immediate vicinity of the nanoparticles, which is 
detected by the photo camera and generates the signal. The scattered light intensity changes 
in time to provide real-time kinetic traces for individual array elements, which may be 
averaged together for a particular surface ligand channel. 
The surface is blocked using a solution of BSA in PBS (1 mg/ml), and the surface is cleaned 
using a regeneration buffer, 10 mM HCl. After obtaining a stable baseline with a particular 
BSA
Fibrinogen
HSA
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running buffer, the sample containing analyte is injected over the ligand-functionalised surface 
at a flow rate of 100 µl/min to ensure concentration-limited kinetics [125]. Table 3.1 contains a 
complete list of running buffers and analytes relating to each experiment set. In addition to the 
analyte channels, surface control array spots functionalised with fibrinogen were used to act as 
a negative control for the specific aBSA-BSA interaction, thermal variations in refractive index 
(RI) and light output intensity variations of the LED. The fibrinogen negative control was 
subtracted from BSA-channel traces in experiment sets 1 and 3 to produce a target ligand 
specific kinetic trace. The nonspecific nature of experiment set 2 meant such a subtraction was 
not possible, and therefore the unprocessed data was used. Furthermore, an additional HSA 
channel monitored the interaction between HSA and aBSA in experiment set 1 to report any 
interaction that may take place between the two species in solution in experiment set 3. 
Table 3.1. Detailed experimental conditions for the three experiment series  
Reaction Set 1: High Affinity Binding 2: Low Affinity Binding 3: Competitive Binding 
Surface Ligand BSA BSA Immobilised BSA covered in 
HSA from running buffer 
Running Buffer PBS PBS 100 µM HSA in PBS 
Injected 
Analyte 
aBSA (10 nM, 20 nM, 
40 nM) 
HSA (2 µM, 20 µM, 
50 µM, 100 µM) 
aBSA (10 nM, 20 nM, 40 nM) + 
100 µM HSA 
Association 
Time 
15 minutes 10 minutes 15 minutes 
Dissociation 
Time 
25 minutes 6 minutes 40 seconds 25 minutes 
Figure 3.4 Trace 
Colour 
Red Green Blue 
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The absolute response from each set of surface ligand spots was calibrated by measuring the 
change in response between PBS and double-concentrated PBS, which corresponds to a 
refractive index change (ΔRI) of 1.53×10-3 refractive index units (RIU). All data presented in this 
investigation are in Response Units (RU), which corresponds to 10-6 RIU. 
3.3.1 Chemicals 
Bovine serum albumin (BSA) (98%), human fibrinogen (60%, with 40% buffer salts; the protein 
content is >80% clottable FBR), and human serum albumin (HSA) (>96%) were obtained from 
Sigma-Aldrich; sheep polyclonal antibodies to BSA (aBSA, 23mg/ml, IgG fraction) were supplied 
by AbD Serotec UK; all solutions where prepared in 18 MΩ cm-1 deionised water and protein 
solutions were prepared in standard phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, and 1.5 mM, KH2PO4, pH 7.3) unless otherwise stated. 
3.3.2 Sensor Surface Preparation 
The array format sensors were functionalized with proteins by printing 1 mg/ml HSA, BSA, 
fibrinogen, and transferrin solutions in PBS directly over the nanoparticle containing array 
spots, according to the key in Figure 3.2. After a 2 hour incubation period the slides were 
washed with PBS and stored dry at 4oC before installation into the Liscar. 
3.3.3 Experiment List 
Three sets of reaction experiments were performed separately in order to interrogate 
individual parts of a complex set of reactions to determine rate constants. The experiments 
were: 
1: High affinity binding – this is the clean antibody-antigen binding experiment (high 
affinity reaction) using PBS as buffer, varying the concentrations of aBSA binding to 
BSA. As a control, the signal from the fibrinogen channel is subtracted. 
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2: Low affinity binding– the low affinity reaction, this experiment measures the binding 
of HSA at several different concentrations to the BSA surface from PBS buffer. 
3: Competitive binding – the competition reaction requires the surface ligand binding 
sites to be occupied with HSA before the high affinity binding reaction of interest can 
occur. Therefore PBS containing 100 µM HSA is used as the running buffer. The HSA 
from the running buffer is allowed to bind to the ligand first before the analyte 
solution, containing varying concentrations of aBSA in the same running buffer 
(100 µM HSA in PBS) is introduced to the surface. Once again the signal from the 
fibrinogen channel acts as a negative control and is subtracted from the BSA channel. 
The reactions sets, with their respective running buffers, surface ligands, analytes and injection 
times are summarised in Table 3.1. 
3.4 Results 
Three sets of protein-protein binding reactions were performed using the Liscar platform, 
employing the experimental setup detailed in Table 3.1.  
Firstly, to confirm that there was no interaction between HSA and aBSA in solution during 
experiment set 3, unprocessed data from the HSA control channel in experiment set 1 can be 
seen in Figure 3.3 compared with the unprocessed data from the BSA channel. It clearly shows 
the aBSA binding to the BSA channel, but shows no binding between HSA and aBSA. Therefore 
it can be assumed that the interaction between aBSA and HSA in experiment set 3 is negligible 
for the purposes of the model presented here.  
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Figure 3.3. Binding traces for 40nM aBSA injected over BSA-functionalised spots (black) and HSA-
functionalised spots (red). Switches between running buffer (PBS) and the analyte solution are also 
indicated. 
As seen in Figure 3.4, red, kinetic traces were obtained for aBSA-BSA binding reactions (high 
affinity binding, reaction set 1) at aBSA concentrations of 10 nM, 20 nM and 40 nM in PBS 
buffer. The low affinity binding experiment (reaction set 2) was performed by injecting HSA in 
PBS buffer at concentrations of 2 µM, 20 µM, 50 µM and 100 µM, as is seen in Figure 3.4, 
green. An initial large jump is seen in the signal, especially for the higher concentrations, owing 
to the ΔRI between the running buffer and the analyte solution. The sum of the ΔRI between 
the running buffer and analyte solution plus the HSA binding to the surface causes an 
increased total sensor response.  
Finally, the experiment for reaction set 3 was conducted to measure competitive binding 
between aBSA and HSA (high and low affinity analytes respectively), Figure 3.4, blue. The 
running buffer was changed to PBS + 100 µM HSA, and after the HSA was allowed to 
equilibrate on the sensor surface and the scattered light intensity had stabilised, analyte 
solutions containing aBSA at concentrations of 10 nM, 20 nM and 40 nM in PBS + 100 µM HSA 
were injected over the surface. A binding reaction can be seen for all three concentrations of 
aBSA. 
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Figure 3.4. Kinetic binding traces for three sets of reactions: High affinity binding, red (a = 10nM aBSA, 
b = 20nM aBSA, c = 40nM aBSA); Low affinity binding, green (a = 2µM HSA, b = 20µM HSA, c = 50µM 
HSA, d = 100µM HSA); and Competitive binding, blue (a = 10nM aBSA in 100µM HSA, b = 20nM aBSA 
in 100µM HSA, c = 40nM aBSA in 100µM HSA). The baseline for the competitive binding data is offset 
to represent the refractive index difference and equilibrium HSA surface coverage due to the high 
concentration of HSA present in the running buffer. Owing to the specific nature of aBSA binding to 
the BSA surface ligand, the high affinity binding and competitive binding traces were produced by 
subtraction of the signal from the negative control channel, fibrinogen. However the nonspecific 
nature of the low affinity binding reaction meant the raw data was used, as the signal was 
approximately equal over all channels. 
Each of the traces for the individual binding experiments produce sequentially increasing signal 
responses with increasing concentrations, as is expected. The high affinity reaction, Figure 3.4, 
red shows nearly no dissociation after switching back to the running buffer at 900 seconds, 
indicating a strong interaction between analyte and surface ligand. The low affinity reaction 
set, Figure 3.4, green, is comprised of a refractive index change (ΔRI) in the early part of the 
injection time, plus the binding of HSA to the sensor surface. The signal produced by the 
competitive binding reaction, Figure 3.4, blue, is therefore a sum of the ΔRI for 100 µM HSA 
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from pure PBS, plus the binding of HSA to the surface, plus the additional signal from the 
competitive binding reaction. 
A large wash-off is seen for the traces in the low affinity binding experiment, Figure 3.4, green. 
This is largely due to the change in bulk refractive index of the analyte and the running buffer, 
especially the initial drop. After the initial drop, it also shows a greater wash-off than either of 
the other two experiments, giving some indication towards the low affinity this molecule has 
for the surface ligand. 
It should be noted here that all traces shown in Figure 3.4 are averaged from three repeated 
binding traces at each concentration for a particular experiment set. 
3.5 Discussion 
The 1:1 interaction model for kinetic analysis of protein-protein interactions is used widely in 
the field as the first choice of model since it produces readily interpretable constants such as 
the association constant, ka, dissociation constant, kd and the affinity constant, ka/kd or KD, for 
nearly all simple binding experiments [46; 86; 122]. However the 1:1 model has immediate 
obvious limitations when the target analyte is part of a complex medium such as serum, 
plasma or urine. The 1:1 interaction assumptions that binding is limited to one monolayer only, 
all binding sites are equivalent, and binding to a particular site is independent of any 
occupancy of neighbouring sites [129] are difficult to satisfy within such a complex analyte 
solution. The high concentration of nonspecific proteins means the specific interaction 
between the target analyte and the surface ligand is unlikely to remain uninfluenced by 
species adjacent to binding sites. The nonspecific proteins are likely to interact with the 
surface as a whole (binding sites or free space) and therefore this will have an effect on the 
analyte’s ability to access the surface ligand, and in turn its ability to bind. 
Alternative models, so-called Parallel, Competitive and Two State models, have been 
compared with the 1:1 interaction model [130] with an improvement of a factor of 5 in the 
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goodness of fit. However, even this investigation only dealt with simple solutions, containing 
just the analyte in buffer. The study concluded that the experimental data were not conclusive 
and could be interpreted in several ways. In light of this, it is also stressed that the model 
presented in this study is constructed from the individual reaction sub-sets step-wise including 
additional reactions when it is clear the model does not fit the experimental data well.  
It is not possible to assign with statistical confidence the reactions to a particular analyte 
binding mechanism, but nevertheless this investigation aims to obtain meaningful parameters 
from three sets of reactions designed to give further insight into the possible binding and 
competition mechanisms present in real biological fluids. This is done by separating the 
individual components and monitoring their binding to the surface ligand, and then a 
competitive reaction is observed whereby the low affinity analyte obstructs the high affinity 
analyte for its binding reaction with the surface ligand. However, it is possible to assess the 
goodness of fit for a particular model, and thus to assess the chosen model based on its 
improvements from our starting point; the 1:1 interaction model in relation to complex media. 
3.5.1 High Affinity Binding (aBSA-BSA binding only) 
Initial analysis of the high affinity binding reaction used a 1:1 interaction model as 
characterised by the equations with rate constants k1 and k-1 in Figure 3.5. The experimental 
data were fitted using a nonlinear least-square regression method employing the ‘ode23’ 
differential equation solver in Matlab. The association and dissociation phases were treated 
separately with different starting conditions in the differential equation solver – ca. 20 seconds 
of data bridging the point where the association phase is stopped is not included in order to be 
certain that no overlap between fitting of the association and dissociation phase occurs with 
the data from the opposing phase. The global fit to the simple 1:1 model shows a poor fit to 
the data, with a χ2 value of 50.3. The χ2 value indicates a poor model for the experimental data, 
however it must be compared with alternative models in order to assess the worth of an 
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alternative model. Additionally, the χ2 value should be scrutinised with regard to increasing the 
number of parameters in the model for marginal improvement in χ2 at the expense of an 
overly complex reaction mechanism. Therefore the χ2 value should merely be considered a 
comparison metric for the models postulated herein, and is accompanied by the standard 
deviation of the residual which can also be compared between models.  
 
Figure 3.5. Schematic showing the reactions and mechanisms used in the model for the high affinity 
binding reaction set. The reactions in bold form the initial model, Figure 3.6, and the three extra 
reactions are added to refine it later, Figure 3.7.  
It should also be noted that the absolute χ2 value is not of particular use in this instance to 
determine the goodness of fit, as it can be seen from the residual plots in Figure 3.6 and Figure 
3.7 that there is still a systematic error in the model, evidenced by the linear rising trend in the 
residual. However χ2 is included for the purpose of evaluating the models employed within this 
study. The 1:1 model therefore needs further refinement, as the experimental data is not well 
defined by the 1:1 interaction model. It seems that the model consistently underestimates the 
initial association rate, but over estimates the maximum surface coverage (θmax) of the analyte, 
and deviates especially in the latter parts of the association phase, Figure 3.6. This gives some 
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indication towards the unsuitability of the 1:1 interaction model, in that it suggests that there 
is some interaction between molecules on the surface, which will have an effect on both the 
rate and θmax of the high affinity association reaction. Models have been altered before to 
allow the fitting of a heterogenous model in favour of the 1:1 [22]. 
 
Figure 3.6. High affinity binding reaction (aBSA, 
red, a = 10 nM, b = 20 nM, c = 40 nM) fit to a 1:1 
interaction model (grey), using the equations 
characterised by k1 and k-1. The residual between 
the fit and the raw data is shown in black. 
 
Figure 3.7. High affinity binding reaction (aBSA, 
red, a = 10 nM, b = 20 nM, c = 40 nM) fit using the 
model shown schematically in Figure 3.5, 
employing the reactions characterised by k1, k-1, 
k2, k-2 and k3 (grey). The residual between the 
fit and the raw data is shown in black. 
The first refinement of the model adds two further reactions to the reaction set: a co-
operative binding mechanism characterised by the rate constants k2 and k-2, and a further 
analyte-ligand complex stabilisation mechanism characterised by rate constant k3, Figure 3.5. 
The reactions characterised by k2 and k-2 allow for co-operative interactions between the 
analyte species on the surface, which will affect its binding to the surface, and therefore also 
its dissociation from it. This addresses the third assumption in the 1:1 model that species on 
adjacent binding sites do not interact with each other, which is highly unlikely in this scenario. 
The k3 reaction captures the concept of a stabilisation reaction at the surface which may be 
explained by the avidity of the antibody, whereby the aBSA analyte has two binding sites, 
allowing it to form a stronger bond to the surface as a single molecule. With the introduction 
of these reaction mechanisms, the global fit yielded an average χ2 value of 21.9, Figure 3.7, 
improving the fit by a factor of 2.3 from the initial 1:1 model. 
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The inclusion of the three extra reactions is empirical, and the mechanisms are postulated and 
not fully evidence-based from our experiments, however, it is needed to improve the 
goodness-of-fit to the data, and therefore the overall model. The justification for the inclusion 
of the extra mechanisms is explained below. The avidity of IgG, containing two Fab regions 
that can bind to the surface bound antigen, means that it can form a much more permanent 
bond to the surface, as can been seen experimentally by looking at the dissociation part of the 
binding trace in Figure 3.4, red. This provides justification for the addition of the reaction 
characterised by k3, where the high affinity species is bound pseudo-permanently, and is 
modelled with no dissociation constant. Another postulated reaction is that, if one high affinity 
species binds close to another one of these molecules, they will have some effect on each 
other. This is not present in the simple 1:1 model, however it is unlikely that this is the case in 
such a concentrated protein solution, and therefore the inclusion of this reaction may be 
justified. This reaction is therefore treated separately and characterised by the constants k2 
and k-2. 
The extended model for the high affinity binding reaction is a better description of the 
experimental data, as evidenced by the χ2 value above. Although it still overestimates the true 
θmax for the reaction, it provides a much better estimate of the initial rate of reaction. 
Additionally, the standard deviation of the residual (during the association phase only) for the 
1:1 interaction model is 13.4, compared with 8.6 in the alternative model. The extended model 
is only a reasonable description of the experimental data, and it suggests yet further complex 
mechanisms present at the surface, however expanding the model even more is unnecessary. 
Assessing the quality of fit of the model 
The model constructed herein attempts to present an undoubtedly highly complicated web of 
reaction mechanisms by a simple set of mechanisms, with specific focus on avoiding 
unnecessary over complication. The final model evolves from initial assumptions based on the 
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1:1 reaction model. Therefore any quantitative analysis of the goodness of fit only indicates 
the improvement of the model throughout its evolution. Thus, χ2 and the SD of the residual is 
only used to compare the initial (1:1 interaction) model and the final model based on an 
expanded set of reaction mechanisms. 
3.5.2 Low Affinity HSA-BSA Binding 
They key difference between the analytes A and B used in this experiment is their respective 
affinities for the surface ligand, S, evidenced later by the difference in their affinity constants, 
KD, Table 3.3. The concept of avidity allows for A to form a much stronger bond to S, and 
therefore it is referred to as the high affinity analyte, and B the low affinity analyte.  
 
Figure 3.8. Schematic showing the reactions used in the model for the low affinity binding part of the 
investigation. The reactions in bold form the initial model, and the two extra reactions are added later 
for further refinement, where it is suggested that HSA may bind to additional binding sites (compared 
with aBSA) on the surface. 
As with the high affinity binding reaction set, binding of HSA to the sensor surface, was initially 
fitted using a 1:1 interaction model as the starting point for the global fit using the reactions 
characterised by k4 and k-4, Figure 3.8. The global fit using a 1:1 interaction model yielded a χ
2 
value of 64.3, and as can also be seen visually in Figure 3.10, the 1:1 interaction model is a very 
poor description of the experimental data. Once again the θmax is underestimated, as is the 
initial rate of association.  
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Figure 3.9 Schematic showing the differential binding for the high affinity IgG (A) to the surface ligand 
site (S) only, whereas the low affinity HSA molecule (B) can bind to both the surface ligand sites (S) 
and any available free surface sites (SF). 
It is suggested that unlike aBSA, which is restricted to binding only to exposed BSA epitopes on 
the surface, HSA can also bind to free parts of the surface (SF) due to its nonspecific nature 
and, importantly, its large concentration in excess over the aBSA. The association reactions 
characterised by k4 and k5, (and their respective dissociation reactions, k-4 and k-5, Figure 3.8) 
indicate nonspecific adsorption of HSA onto two different types of binding sites on the surface. 
As there are large differences in analyte concentrations in this experiment, it is crucial to treat 
the species separately in the model, as shown in Figure 3.9. 
Justification for the binding of HSA to two different types of surface sites can be explained by 
considering the different maximum surface coverages (θmax) achieved by the nonspecific and 
specific analytes. The θmax achieved by the aBSA was 234 RU, compared with 195 RU for HSA 
(after subtraction of ΔRI contribution by bulk HSA from PBS), which yields a surface coverage 
ratio of 1.23. Considering that the mass ratio between aBSA (IgG) and HSA is 2.24 
(150kDa/67kDa), it suggests that there are fewer binding sites available for aBSA than for HSA. 
Comparison between the surface coverage ratio and the mass ratio shows that aBSA can bind 
only to 55% of the surface available for HSA (1.23/2.24). This is also intuitive, as the sites 
available for aBSA binding are only where the surface BSA ligand is present and its specific 
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epitopes are exposed. Conversely the nonspecific nature of HSA means that it can bind to 
other free surface sites as well as surface ligand sites. This is shown schematically in Figure 3.9. 
 
Figure 3.10. Low affinity binding reaction (HSA, 
green, a = 2µM, b = 20µM, c = 50µM, d = 100µM) 
fitted to a 1:1 interaction model (grey), using the 
equations characterised by k4 and k-4. The 
residual between the fit and the raw data is 
shown in black. 
 
Figure 3.11. Low affinity binding reaction (HSA, 
green, a = 2µM, b = 20µM, c = 50µM, d = 100µM) 
fitted to an alternative model (grey), using the 
equations characterised by k4, k-4, k5 and k-5 to 
take account of HSA binding to two different 
surfaces as shown in Figure 3.8 and Figure 3.9. 
The residual between the fit and the raw data is 
shown in black. 
As a result the model using the reactions characterised by k4, k-4, k5 and k-5 was fitted to the 
low affinity binding data, yielding a χ2 value of 5.48, Figure 3.11, improving on the 1:1 model by 
a factor of 11.7. Additionally, from the residuals traces in Figure 3.10 and Figure 3.11 it can 
clearly be seen that the introduction of the concept of different surface sites for HSA binding 
improves the fit considerably. For the association phase, the standard deviation of the residual 
was 12.1 for the 1:1 interaction model, cf. 4.0 for the alternative, free surface model, 
improving the fit by a factor of 3. Although the surface is blocked before any binding reactions 
are monitored, it would appear that nonspecific adsorption to the surface will take place 
regardless, and must therefore be considered in the model.  
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Table 3.2. χ
2
 values, mean residual and residual standard deviation (SD) for the different models 
applied to reaction sets 1 and 2. The average χ
2
 values for the global fir analysis is also calculated, 
taking into account the different association phase times between the low and high affinity analytes. 
High Affinity Binding 
Analyte Concentration 
(nM) 
χ2 values for 1:1 
Interaction fit 
χ2 values for fit using 
additional reactions 
10 14.3 13.0 
20 124 51.2 
40 11.8 1.51 
Average 50.3 21.9 
 
SD of Average 
Residual 
13.4 8.6 
Low Affinity Binding 
Analyte Concentration 
(µM) 
χ2 values for 1:1 
Interaction fit 
χ2 values for free surface 
reactions fit 
2 41.5 3.25 
20 83.4 7.76 
50 79.4 3.38 
100 52.9 7.51 
Average 64.3 5.48 
Average χ2 for Global 
Fit 
56.3 14.8 
 
SD of Residual 12.1 4.0 
3.5.3 Competitive Binding: HSA interference with aBSA-BSA binding 
One of the objectives of this experiment was to produce a mathematical model characterising 
the reaction mechanisms involved in a surface ligand-specific analyte binding from a complex 
solution containing 100 µM HSA, which acts as a representation of physiological conditions. 
Once the sensor surface was refreshed with a regeneration buffer following the low affinity 
binding reaction set, the running buffer was changed to PBS containing 100 µM HSA and the 
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signal was allowed to stabilise. Then analyte solutions containing varying concentrations of 
aBSA in the presence of 100 µM HSA were injected over the surface and the signal recorded, 
Figure 3.4 and Figure 3.12, blue. 
 
Figure 3.12. Kinetic traces for each set of reactions as seen in Figure 3.4: High affinity binding, red (a = 
10nM aBSA, b = 20nM aBSA, c = 40nM aBSA); Low affinity binding, green (a = 2µM HSA, b = 20µM 
HSA, c = 50µM HSA, d = 100µM HSA); and Competitive binding, blue (a = 10nM aBSA in 100µM HSA, b 
= 20nM aBSA in 100µM HSA, c = 40nM aBSA in 100µM HSA). Included is the simulated model for 
competitive binding using parameters from High and Low affinity analysis only (light blue). Finally, 
after the introduction of a ‘displacement’ reaction to the model, k6, a global fit for the data is achieved 
(grey). 
Initial modelling of the competitive binding reactions used only the reactions from the high 
(Figure 3.7) and low affinity (Figure 3.11) reaction sets. Using the rate constants k1, k-1, k2, k-2, 
k3, k4, k-4, k5, and k5 to model the data obtained from the competitive binding reaction set 
yielded the trace in Figure 3.12, light blue. Clearly, these reactions do not describe the 
experimental data, and therefore it could be concluded that using parameters derived from 
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high affinity and low affinity reactions in isolation are insufficient to model a competitive 
binding reaction between high and low affinity species.  
As a positive increasing kinetic trace is observed in all three competitive binding traces (Figure 
3.12, blue, a, b and c), it suggests the displacement of HSA by aBSA, as the positive change in 
signal is consistent with the difference in molecular mass (aBSA, 150 kDa > HSA, 67 kDa). 
Therefore it should also be noted that the signal change seen is not only aBSA binding to the 
surface, but rather the change in mass that comes with the displacement or replacement of 
the smaller molecule, HSA by the larger one, aBSA. The baseline for the competitive binding 
experiment is corrected for the bulk RI change and HSA binding to the sensor surface before 
the analyte is injected. This may be compared with Figure 3.4, green, d, where 100µM HSA was 
injected over a clean surface. It is therefore appropriate to include a further displacement 
reaction, as shown in Figure 3.13 and characterised by rate constant k6. 
 
Figure 3.13. Schematic showing the ‘competitive displacement’ reaction of the Low affinity analyte by 
the high affinity analyte. 
3.5.4 The Overall Global Fit – Competitive Binding Model 
The competitive binding model including all of the mechanisms discussed previously can then 
be fitted to the global data set and is shown in Figure 3.12, grey, based on all the reactions in 
Figure 3.5, Figure 3.8, and Figure 3.13. These have been combined in Figure 3.15 for 
completion. The differential equations for the model are shown in Figure 4.14 and were solved 
numerically, globally for the complete reaction mechanism. 
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The model accurately reproduces the complete experimental data set with a χ2 value of 1.16 
for the entire fit, and 2.43 for the association phase only. The standard deviation of the entire 
fit was 4.70, and 4.05 for the association phase only. 
 
Figure 3.14. Differential equations for each of the reactions used in the global fit model. 
 
Figure 3.15. Combined reaction schematic outlining the reactions modelled for each of the reaction 
sets. The finalised, over all fit, Figure 3.12, is based on all of these reactions combined, with 
differential equations outlined in Figure 3.14. 
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The model comprises a simple set of postulated reactions consistent with observed 
experimental data for high and low affinity species binding competitively at a biosensor 
surface. The model has evolved by considering individual and competitive reactions separately, 
starting with the 1:1 interaction model and expanding on it.  
Although there is no direct proof for the additional mechanisms in this model, there is some 
evidence of their existence in the literature. The reaction characterised by k2 and k-2 can be 
described by cooperative binding [131], and justification for the surface stabilisation reaction, 
k3, can be seen in Figure 3.12, red, c, where there is very limited wash-off when only PBS is 
reintroduced into the flow cell (after 900 seconds). Additionally, denaturation of proteins by 
the gold surface [132] may also explain the ‘stabilisation’ of molecule A onto the surface. The 
displacement reaction characterised by k6 can to some extent be explained by the Vroman 
effect [133], however the additional affinity the antibody has for its antigen will also be a 
factor. The quality and assumptions in the model may now be considered.  
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Rate Constant Comparisons 
The rate constants for the global kinetics model is presented below in Table 3.3. 
Table 3.3. Kinetic rate constants for all reactions in the global kinetic model for all three reaction sets. 
Where possible, affinity constants (KD) and the Gibbs free energy (ΔG) is also calculated. 
Reaction Set Reaction Rate Constant KD (mol) ΔG (kJ mol
-1
) 
1: High Affinity Binding k1 (mol
-1
 s
-1
) (1.255 ± 0.023)·10
5
 (6.51 ± 0.32)·10
-8
 40.73 ± 0.12 
k-1 (s
-1
) (8.17 ± 0.37)·10
-3
 
k2 (mol
-1
 s
-1
) (2.280 ± 0.045)·10
4 
(1.00 ± 0.12)·10
-9
 50.57 ± 0.31 
k-2 (s
-1
) (2.29 ± 0.28)·10
-5
 
k3 (s
-1
) (5.838 ± 0.091)·10
-3
   
2: Low Affinity Binding k4 (mol
-1
 s
-1
) (5.961 ± 0.053)·10
2
 (2.51 ± 0.22)·10
-6 
31.44 ± 0.23 
k-4 (s
-1
) (1.494 ± 0.013)·10
-3
 
k4’ (mol
-1
 s
-1
) (3.505 ± 0.033)·10
1
   
k-4’  Fixed at 0 (not 
defined)  
3: Competitive Binding k5 (mol
-1
 s
-1
) (6.41 ± 0.12)·10
4
   
k-5  Fixed at 0 (not 
defined) 
 
The mechanistic understanding following from the modelled set of reactions and rate 
constants focuses on comparisons between the low and high affinity reaction sets in order to 
determine the differences between them. Then a comparison is made between the high 
affinity and competitive binding experiment sets, as they both observe the binding of aBSA to 
BSA, albeit within a different environment. 
As expected, the association rate constants for the specific, high affinity analyte (k1 and k2) are 
higher than the association rate constants for the nonspecific, low affinity analyte (k4 and k5). 
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The low affinity dissociation constant, k-5 was set to zero as it correlated highly with the other 
low affinity dissociation constant, k-4. Therefore k-4 listed in Table 3.3 describes both 
dissociation processes of the low affinity analyte, and as the relative surface coverages of the 
reactions characterised by their respective association constants, k4 and k5, are in the ratio of 
55:45, the true value of the dissociation constant k-5 is of the same order, 10
-3 s-1. This can be 
compared with the dissociation constants of the high affinity reaction set, of order 10-3 and 105 
suggesting a stronger interaction between the high affinity analyte and the surface than the 
low affinity analyte.  
It is also interesting to observe the differences in KD, (hence ΔG) between the high affinity 
binding and the low affinity binding reaction sets. The binding energy is approximately 1.5 
times greater where the high affinity molecule is concerned, which is in line with expectations. 
Especially interesting in this comparison is the rates derived from k1 and k4 during the early 
part of the reaction, when the reaction characterised by k2 cannot play a large part in the 
overall description of the reaction Table 3.4. At the concentrations used in the experiment, the 
rate of HSA adsorption onto the surface is much faster than aBSA, especially when 100 µM HSA 
is used, as in the case of the Competitive binding experiment. This places extra importance on 
the reaction characterised by k6, as otherwise the sensor surface would be flooded by 
nonspecific proteins. This can be compared with physiological conditions, where the contrast 
in specific/nonspecific concentrations is even greater, as seen in Chapter 2.  
The last reaction, with rate constant k-6, illustrates the displacement of aBSA by HSA. This has 
been fixed at zero as the number could not be determined in the global fit. There could be a 
number of reasons for this, two suggested here. Firstly, the Vroman effect [89; 90; 91; 92] 
prohibits the reactions from taking place, as the mass of HSA is smaller than aBSA and it has a 
lower affinity for the BSA ligand. Secondly, from experimental observation we can see that in 
the competitive binding experiment, displacement of HSA by aBSA occurred in the presence of 
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a large concentration of HSA. This would suggest that the reverse reaction, HSA displacing 
aBSA is negligible at experimental conditions.  
The most important observation about the model is the value of the rate constant k6, which 
denotes HSA displacement by aBSA. More specifically, its magnitude in relation to k1 is 
interesting, as it is only a factor of two smaller than the direct binding of aBSA onto the ligand, 
denoted by k1. This suggests that, compared with no interference, when an antigen is 
surrounded by a large amount of albumin it takes approximately twice as long for a binding 
reaction to occur between the antibody and antigen. As already noted, the observed signal for 
the ‘displacement’ reaction is due to the change in mass between IgG and HSA, and not merely 
the arrival of IgG at the surface, which would yield a much greater signal. Also, as expected, we 
can see that the primary high affinity analyte association constant k1, is over 200 times greater 
than the primary low affinity analyte association constant, k4.  
Initial Binding Rates 
Further evidence for the existence of the displacement reaction characterised by k6 can be 
seen from the comparison between the initial rates of the high affinity and low affinity binding 
reactions, specifically for 40 nM aBSA and 100 µM HSA, Table 3.4. At these concentrations, the 
initial rate of binding to the surface is a factor of 11.8 faster for HSA than aBSA. Therefore the 
experimental data should be expected to reflect this.  
However, division of the kinetic trace for 40 nM aBSA in the high affinity binding reaction set, 
Figure 3.12, blue, (c), by the trace for 40 nM aBSA in the Competitive binding reaction set, 
Figure 3.12, red, (c), shows an initial ratio of ca. 8. This represents the upper limit of the ratio 
between the initial rates: firstly, as the signal from the Competitive binding is not all due to the 
arrival of the aBSA on the free surface ligands, HSA leaving the surface and aBSA taking its 
place results in signal proportional only to the aBSA-HSA mass difference rather than total 
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mass of aBSA. Secondly, only a fraction of the surface is freely available in the Competitive 
binding experiment. Therefore the observed faster-than-expected aBSA adsorption rate can be 
attributed to some other mechanism contributing to the model, here characterised by the 
exchange/replacement reaction with rate constant k6. 
Table 3.4. Comparison between association rates for the reactions characterised by k1 and k4, 
signifying specific and nonspecific adsorptions rates respectively at the given concentrations.  
[aBSA] (nM) [aBSA] × k1 initial rate 
(10
-3
 s
-1
) 
 [HSA] (µM) [HSA] × k4 initial rate 
(10
-3
 s
-1
) 
10 1.26
 
 2 1.19 
20 2.51  20 11.9 
40 5.02  50 29.8 
   100 59.6 
 
Correlation Matrix 
A correlation matrix was calculated for each of the parameters used in the global competitive 
binding model. There are two pairs of relatively correlated rate constants; k1 and k-1, and k1 
and k6. k1 and k6 are likely to be correlated because they describe similar processes – molecule 
A binding to S, even though the reaction described by k6 also involves the displacement of 
molecule B before A can bind to S. k1 and k-1 are likely to be correlated because they both 
contribute to the association phase for the high affinity binding reaction, however only k-1 is 
used to fit the dissociation reaction. 
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Table 3.5. Correlation matrix for all parameters used in the global analysis model. Correlated 
parameters are considered to be those > 0.8 and are indicated in red. 
Correlation Matrix for all rate constants used in overall global fit model. 
 k1 k-1 k2 k-2 k3 k4 k-4 k5 k6 
k1 1.00 0.84 -0.17 -0.62 -0.46 0.06 -0.15 0.01 0.83 
k-1 0.84 1.00 0.22 -0.71 -0.21 0.00 -0.21 0.03 0.65 
k2 -0.17 0.22 1.00 -0.18 0.13 0.01 -0.20 -0.08 -0.33 
k-2 -0.62 -0.71 -0.18 1.00 0.14 0.03 -0.42 -0.15 -0.46 
k3 -0.46 -0.21 0.13 0.14 1.00 -0.24 0.01 0.11 -0.71 
k4 0.06 0.00 0.01 0.03 -0.24 1.00 -0.04 -0.70 0.02 
k-4 -0.15 -0.21 -0.20 -0.42 0.01 -0.04 1.00 0.15 -0.06 
k5 0.01 0.03 -0.08 -0.15 0.11 -0.70 0.15 1.00 0.04 
k6 0.83 0.65 -0.33 -0.46 -0.71 0.02 -0.06 0.04 1.00 
 
3.6 Conclusions 
A 10-reaction competitive binding model is devised to describe the binding of a high affinity 
species against a large nonspecific low affinity species background. We have presented a 
global model for complex sample analysis employing individual high and low affinity reactions, 
and the displacement of the low affinity molecule by the high affinity molecule to simulate 
physiological conditions. Although the effect of albumin on antibody-antigen binding is 
notable, it is not major, which is expected and in line with biological considerations – for 
example if albumin had a notable effect on IgG binding to its respective antigen, the role of 
antibodies would be limited, especially given the high concentrations of albumin against 
individual IgG concentrations. Inclusion of additional postulated reaction sets has improved 
the model significantly. The correlation matrix shows only two out of a possible 18 correlation 
coefficients reaching ca 0.85, indicating that the model is not overcomplicated. 
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Our analysis shows that, even using complex samples, reliable and useful rate constants can 
still be extracted from kinetic analysis, and that the 1:1 interaction model should be expanded 
where complex samples are involved. This investigation shows the importance of a high 
affinity displacement reaction which has significance for all label free detection technologies 
screening complex samples. It provides a tool with which to analyse data from the Liscar where 
complex samples are analysed, and therefore has important implications for assay 
development on that platform. 
Transferring immunoassays onto the Liscar platform is now a possibility, the major advance 
being the ability to screen complex samples with no pre-treatment. Once assays are developed 
on well established platforms they can be transferred onto the Liscar. The potential high-
throughput capabilities of the Liscar instrument mean that we can interrogate an entire 
biological system by developing assays for the system constituents, thereby encouraging the 
introduction of multi-analyte biomarker panels. Such immunological systems could provide 
valuable information relating to patient recovery or overall state of health, which could prove 
valuable to clinicians. One such system-level profiling could be to interrogate the Complement 
cascade to profile the response of a patient to an immunological challenge rather than identify 
the challenge directly. The Liscar platform has the potential with the robust performance in 
the presence of high HSA levels to be a point-of-care device requiring limited sample 
preparation. 
 
 
 
 
.
 
111 
Chapter 4 
Development of Electrochemiluminescent  
Assays for Complement Activation Products  
C3d, TCC and Bb 
4.1 Introduction 
The localised surface plasmon resonance (L-SPR) technique employed in Chapters 2 and 3 is 
capable of multi-analyte detection from a single sample. Ensuring the technique is optimised 
and validated for a chosen set of assays, a snapshot of a particular biological system can be 
taken from a sample at any given time from a single sample. The relative absolute 
concentrations between analytes can produce a profile of system activity at a given time, 
which may provide useful host-based diagnostic information valuable to a clinician caring for a 
patient. One such biological system is the Complement (C) System, introduced in Chapter 1 
and outlined in Figure 4.1.  
The C System, as part of the innate mammalian immune system, plays a key role in the 
immune response against pathogens [134]. The C system can be triggered by carbohydrate-
recognising soluble factors, including mannose binding Lectin (MBL) and ficolins (Lectin 
pathway), microbial cell surfaces (Alternative pathway), or by antibodies bound to antigens in 
immune complexes (Classical pathway), Figure 4.1. Once triggered, the C system can trigger a 
number of responses including inflammation [57; 134; 135], chemoattraction of leukocytes 
[136], and lysis of pathogen membranes via the membrane attack complex (MAC) formed from 
the Terminal pathway [50; 57]. The C system is heavily self-regulated, with various 
mechanisms in place to ensure efficiency and prevent attack of host cells. Of particular interest 
is the fact that the C system is enzymatic, and does not require de novo production of system 
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components, as is required for CRP in the acute phase response. This means C can respond 
much faster when triggered, which has obvious advantages for monitoring patient recovery. 
 
Figure 4.1. Outlay of the C system, with specific focus on activators, major components, fragments, C3 
and C5 convertases, and the biological effects of the cascade. 
Monitoring the C system response to an immune system challenge, for example inflammatory 
tissue damage [137] as a result of a surgical insult, can provide important information relating 
to immune system response and subsequent recovery. In principle, intimate perioperative 
monitoring of the developing state of a particular person’s C system over the time course of 
recovery can provide a potential tool for presymptomatic diagnosis where pathogens 
activating C are involved. The idea being not to detect the pathogen itself but the response of 
the host’s immune system to the pathogen challenge to produce a targeted diagnosis. This 
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approach is therefore applicable for monitoring both the effect of the surgical insult and also 
any C activation or consumption that may result from post-surgical secondary infections.  
As mentioned, the C system has 4 distinct pathways [134], each with unique proteins that can 
act as a marker for activity in that particular pathway, Figure 4.2. The three triggering 
pathways may be activated separately, and therefore observation of activity in a particular 
pathway may be indicative of a trigger specific to that pathway, for example microbial cells 
triggering the Alternative pathway. The Terminal pathway can also be triggered independently 
by coagulation [138], so additional monitoring of this pathway is also crucial. It is with this aim 
and hypothesis that we have developed four assays to monitor the C system at key junctions, 
as they can be used to monitor complement activation at different points throughout the C 
system, which may lead to targeted diagnosis of disease based on relative pathway activity. 
4.1.1 Previous Complement Activation Studies 
Many C activation studies have been performed, where various combinations of fragments, C 
components and other activation products were used to establish C activation. A multi-analyte 
study was conducted which monitored levels and ratios of CRP, C3, C4, C9, TCC, C3a and C4d in 
pregnant women and in preeclampsia sufferers [139]. TCC and CRP was also used to monitor C 
activation following acute ischaemic stroke [140], and another study monitored the 
anaphylatoxins C3a and C5a, as well as C3, C4d and Factor B (fB) in emergency department 
patients with severe sepsis [141]. Two similar studies [142; 143] monitored C activation in 
cardiopulmonary bypass surgery, with both studies opting to monitor TCC, as it is an important 
and definite marker for overall C activation. However, the study by Hoedemaekers et al [143] 
also monitored the C3 convertase C3bBbP, and included the C3 and C4 fragments, C3bc and 
C4bc, as well as MBL and C1inh-C1rs. The other study, by Gu et al [142], monitored C3a, C4a, 
and the inflammatory marker Interleukin-6. Numerous investigations have shown C activation 
in Rheumatoid Arthritis (RA); one specifically monitored C3dg and TCC [144], and another 
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showed evidence for mediation of C activation by CRP [145]. A disease state firmly linked with 
C deficiencies is systemic lupus erythematosus (SLE) [146; 147], however C activation has also 
been monitored in patients with SLE using the anaphylatoxins C3a and C5a [148]. 
 
Figure 4.2. A schematic diagram showing the protein interactions of the three different C system 
pathways, leading to the formation of TCC. The selected assays are displayed in red. Ag-Ab denotes 
Antibody-Antigen complex 
Considerable work has also been performed on in vitro C activation [147; 149], especially using 
Zymosan and Heat Aggregated IgG (HAIGG) to initiate C activation. Sample storage 
optimisation protocols have been developed [150; 151] so as to halt further in vitro C 
activation, thereby effectively freezing the C cascade at the time of sample collection. Some 
studies have focused on single pathway activation by removing key proteins in other pathways 
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[152], therefore halting C activation via that route, and another constructed the Alternative 
pathway using six isolated proteins, activating the pathway with erythrocytes [153]. 
C activation could also be monitored using urine samples, which contain several C activation 
products including the anaphylatoxins C3a and C5a. The kidney filtration cut-off (~45 kDa 
[121]) is larger than several of these C activation products, and therefore they will be found in 
the urine shortly after activation. Another study that focused on C5a and C3a in relation to SLE 
was conducted by Manzi et al, [154], where the analytes were measured in urine rather than 
plasma. Proteinuric patients were also monitored for C activation products, including TCC by 
Morita et al [155]. 
4.1.2 Aims and Objectives 
This chapter explores the viability of developing immunoassays as biomarkers for Classical, 
Lectin, Alternative and Terminal pathway C activation. Specifically, electrochemiluminescence 
assays will be developed on the Meso Scale Discovery (MSD) platform for C3dg, TCC, Bb and 
C4d – all C activation markers. The development will also test the feasibility of using Activated 
Complement Serum (ACS) as a standard against which to measure C activation. Activation will 
be assessed in vitro using Zymosan and HAIGG as differential C activators, which will be a 
precursor for an in vivo C activation study in patients undergoing elective surgery in Chapter 6. 
4.1.3 Proposed Complement Activation Study 
This investigation aims to develop assays for C activation markers, with the explicit intention of 
combining the assays in a multiplex assay format later on, so that all the assays may be used 
together as a panel of biomarkers in a clinical trial to determine its use as a diagnostic test. 
The set of biomarkers assays should provide a snapshot of the C system at a given time, and 
therefore the development of the C system throughout activation can be monitored from 
several snapshots over a given time course. The objective is dependent on the relationship 
between C activation and secondary infection. Given that this approach monitors the host 
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response (the C system) rather than the infection itself, its diagnostic value depends heavily on 
the implicit assumption that C activation correlates causatively with infection. It is important to 
make this distinction, and to appreciate that the detection of C activation would not 
necessarily mean the onset of a serious infection, but rather that it has responded to some 
immunological challenge, and therefore the patient’s immune system has become alerted. 
Patients showing C activation could therefore be identified as ‘at risk’, and monitored more 
carefully for the event that the infection defeats the host’s immunological defence 
mechanisms. 
4.1.4 Differential Complement activation monitoring 
The first hurdle to overcome in providing an assessment of C activation is to select the assays 
for the components that will indicate separate C activation at different key pathways of the C 
system, thereby providing information on a patient’s C response profile, specifically the flux in 
each of the C pathways for that patient. The marker should ideally show a rapid response, and 
thus portray in ‘real time’ the developing state of the C system, and not suffer from the 
delayed reaction as with CRP. Finally and crucially, the protein should also be larger than the 
kidney filtration cut-off of ~45 kDa so that it remains present in the blood for a reasonable 
period of time and can therefore be detected in a blood sample.  
Ultimately, the analysis may lead to the development of a model for the C system whereby, for 
example, the flux through the different pathways could be determined for a variety of 
activations. A similar study has been conducted with some success by Liu et al, [156] whereby 
time profiles of four C proteins and CRP were monitored during different activations. This 
study could be expanded to include many more C proteins, and a similar time profile analysis 
could be conducted for each individual pathway to assess the interaction between C proteins 
during activation. This would be a significant contribution to the fundamental understanding of 
the C system and its potential application as a tool for targeted disease diagnosis. 
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Figure 4.3. Molar range of 34 C system proteins and the overall possible range for CRP in vivo. Data collected from throughout the literature* denotes the target 
analytes of this study. Data collected from various references: [139; 157; 158; 159; 160; 161; 162; 163; 164] 
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4.1.5 in vitro Complement Activation 
Many studies have been conducted to monitor Complement activation in vitro using Zymosan 
and HAIGG [147; 165; 166; 167; 168]. Kirschfink and Mollnes [166] point out that in vitro 
activation is useful for examining cross-species reactivity of an assay by activating the serum 
from a particular species using Zymosan, and comparing it with a non-activated control. 
Harboe et al used ‘Zymosan activated serum’ (the equivalent of ‘Activated Complement 
Serum’ in this study) as the standard for their TCC assay, which they defined as containing 
1000 AU TCC/ml. It is important to consider that in vitro activation is not subject to the 
clearance and regulatory controls that would be present in vivo, but from the perspective of C 
fragment assay development it is a helpful way to monitor the progression of C activation, 
especially for the production of C fragments and activation products.  
4.2 Target Activation Fragments  
From the previous work done on C activation, discussed in section 4.1.1, it is clear that there is 
a wide range of potential C activation markers to screen in order to determine the best 
pathway-distinct markers for individual pathway flux through the system. There are several 
factors that can affect the performance of a particular marker as an indicator of pathway flux, 
for example clearance rates, intermediate complex formation, and activation rates, and these 
will determine the outcome of any investigation where a particular marker is interrogated. 
Figure 4.3 shows the concentration range of C cascade proteins in serum and plasma, which 
gives an indication about the target sensitivity for assay development 
Biomarkers should be chosen and developed for clinical application and potential diagnostic 
use, and therefore should ideally be a good marker of activation in vivo. in vitro investigations 
can also be performed to validate the assays, yet the response from the target species will be 
different as activation fragments will not be cleared from the system. In light of the in vivo 
clearance of proteins, it is important to consider which fragments will be appropriate for a 
study to monitor in vivo C activation over a period of time. For such an investigation, plasma 
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samples are the only viable option as they can be taken at a specified time, and stabilised 
immediately with in EDTA. However, in vivo, due to the aforementioned clearance systems in 
place, it is possible to miss the increase in a particular protein concentration if activation and 
clearance occurs in between sampling points. For such a study timing will be as crucial as assay 
performance. However, if the window of opportunity for measuring increased analyte levels is 
indeed very small, the selected fragment may be unsuitable for in vivo C activation analysis.  
With this in mind, the anaphylatoxins C3a and C5a may be less appropriate for such a study, as 
they will be cleared quickly through the kidney due to their small size, and although it is 
possible to detect these markers in urine [154; 155], it would be require a different sample 
collection protocol design. This also means that the other smaller fragments, C4a, C2a and Ba 
would be unsuitable. To interrogate the entire system, larger fragmentation products, unique 
to a particular pathway should be chosen so that distinct C activation can be established, 
thereby identifying the type of activating impulse. 
We selected particular C target assays that would provide us with sufficient information to 
establish an overall C response. As is seen in Figure 4.2, C4d and Bb are fragments that are 
unique to the Alternative and Classical pathways respectively. C3d acts as an indicator for 
overall C activation, and TCC is the final component of the C system in the Lytic pathway. Thus, 
quantification of these four analytes over a given time course of patient samples will provide 
unique information about each pathway with regards to complement activation, and may lead 
to distinct diagnosis of disease, depending on the response obtained. Each target fragments 
chosen for this study is discussed individually below, with reference to their merits for 
selection. 
4.2.1 Bb Fragment 
The Alternative pathway protein Factor B, once bound to C3b, is enzymatically cleaved by 
Factor D to form the fragments Ba (33kDa) [169] and Bb (60kDa) [169], forming the unstable 
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C3 Alternative pathway convertase C3bBb, which can be further stabilised by 10-fold or more 
[170] by Properdin. The Alternative pathway can be triggered by various surface structures on 
foreign and apoptotic cells. This trigger not only supplements the spontaneous ‘tick over’ 
hydrolysis of C3 into its activation products C3a and C3b, but acts as a positive feedback 
amplification loop, significantly increasing C3 cleavage rate by formation of the active but 
unstable C3 convertase, C3bBb, as shown in Figure 4.4. Further binding of C3b to this 
convertase creates the C5 cleaving convertase, C3bBbC3b, leading to initiation of the Lytic 
pathway and eventual formation of TCC.  
 
Figure 4.4. Schematic outlay of the Alternative pathway amplification loop. They key to this 
magnification in C activation is the ability of the intermediate end product, C3bBb to further activate 
the starting product, C3, causing it to fragment into C3a and C3b, the latter being the precursor for yet 
more C3 convertase formation. Additional intensification is provided by Properdin, which stabilises 
the C3 convertase, allowing it to activate even more C3 molecules. 
As mentioned before, the Alternative pathway has been shown to be activated in a variety of 
diseases, including gram-positive and gram-negative bacterial infections [59; 171], viruses 
[172; 173], parasites [174; 175], cardiac bypass surgery [176]; and various dermatologic [177], 
renal [178] and hematologic diseases [179; 180]. Factor B and its fragments are unique to the 
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Alternative pathway, and therefore measuring activation of the Alternative pathway could be 
achieved by measuring Ba or Bb. A study by Wenish et al. [181] observed nearly a factor of 
three difference between C activated patients and healthy subjects. Commercial neoepitope 
antibodies exist for Bb, but not for Ba, and the molecular weight of Ba is below that of the 
kidney filtration cut-off (~45kDa) [121], which means it has a relatively short residence time in 
plasma. This suggests that Bb is the sensible option for monitoring the Alternative pathway. 
Bb is therefore the best option to monitor Alternative pathway activation as it satisfies many 
of the practical requirements for a differential pathway activation marker; such as a molecular 
weight greater than the kidney filtration cut-off, available antibodies and assays for the 
fragment, and most importantly exclusivity to the Alternative pathway. It has a relatively low 
concentration in plasma (~20 µg/ml [139; 157]), and therefore it is important that the assay 
type chosen is sufficiently sensitive to detect the low concentrations of Bb. There have been 
many previous Alternative pathway activation studies that have used Bb as the target 
fragment [165; 182; 183; 184], both in vivo and in vitro, and it is the dominating choice of 
fragment for Alternative pathway activation in C literature. For these reasons, Bb will be used 
to monitor Alternative pathway C activation. 
4.2.2 C3d Fragment 
Evaluation of C3 fragmentation gives a good indication of general C activation as C3 is a key 
central component of the C system and is consumed by either of two C3 convertases, Figure 
4.1. C3 can therefore be cleaved by activation of any of the upper cascade pathways, which is 
the first step in the production of our activation target. In the fragmentation process, C3dg is 
produced from a series of cleavages, as shown in Figure 4.5, that starts with cleavage of C3 
(either by convertase or tick-over hydrolysis) into C3b (177kDa) [185] and C3a. C3b then 
associates with Factor B, which allows fD to cause enzymatic cleavage of Ba from the fB part of 
the C3bB complex, leaving C3bBb. C3bBb is a short lived [185] C3 convertase (t1/2 = 90 seconds) 
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[186] that can be stabilised further by Properdin to form C3bBbP [158] to further stimulate the 
production of C3b, increasing C activation. C3bBb can then be dissociated into C3b and Bb by 
Factor H (which also acts as a cofactor to Factor I (fI) to degrade C3b into the inactive iC3b 
[187]) and finally C3dg (40kDa) [185] upon the cleavage of C3c [144; 185; 188], as shown 
schematically in Figure 4.5. In vitro, C3dg can be split into C3d and C3g [144; 189]. 
 
Figure 4.5 Detailed mechanism of C3dg formation from C3. 
It should be noted here that as the antibody used to capture our target C3 activation products 
is specific to a neoepitope on C3d (and therefore detects all C3d-containing fragments, but not 
C3 itself [190]) the collection of C3 fragments assessed in this study (C3b/iC3b/C3dg) will be 
referred to collectively as ‘C3d’. C3bBb could be detected but this is unlikely given its short 
serum half-life in vivo [185].  
C3b, iC3b and C3dg have long been favourite markers of activation in the C community, [144; 
190; 191; 192; 193] as C3 is such a central part of the C cascade. Commercial antibodies and 
assays exist for these fragments, and C3b and iC3b both have masses above (both 176 kDa 
[194]) the kidney filtration cut-off and are therefore present in circulation. Although the mass 
of C3dg is just below the kidney filtration cut-off, it still has a ‘very long half-life’ [195] which 
makes it a suitable target for this investigation. Therefore these fragments, collectively called 
‘C3d’ will be the C3 fragmentation markers used in this proposed study.  
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4.2.3 C4d Fragment 
An assay to determine the concentration of C4d in plasma will allow the observation of C 
activation via the Lectin and Classical pathways, Figure 4.2, as it is a fragment unique to this 
part of the cascade. The formation of C4d acts as a quasi-control on the C4bC2b C3 convertase 
formation as C4b is cleaved by Factor I and membrane co-factor protein (CD46) [196] into C4d 
– a catalytically inactive fragment [197]. Previous assessment of C activation by C4d 
measurement has included brain tissue of Alzheimer patients [198], and extensive assessment 
of organ allografts [197], particularly antibody-mediated rejection in human cardiac allografts 
[199], and capillary deposition of C4d in renal allografts [200]. The study by Wenish et al. [181] 
reported a concentration of C4d in C activated patients more than twice as big as the levels in 
healthy patients. Its molecular mass of 49 kDa [201] is also above the kidney filtration cut-off, 
which means it will remain in the blood supply for longer. 
However, it must be said that comparatively there have been far fewer studies monitoring C 
activation using C4d than of any of the other markers discussed. This may be indicative of the 
difficulty associated with developing an assay for C4d. However, as it is unique to the Classical 
and Lectin side of the C cascade, it is crucial that an attempt be made to quantify the fragment 
for in vivo C activation analysis.  
4.2.4 The Terminal Complement Complex (TCC)  
TCC, also known as SC5b-9, is the final component in the complement system. The Lytic 
pathway concludes with the formation of TCC, either on the surface as the membrane attack 
complex (MAC) or in serum as SC5b-9, explained below. 
Upon enzymatic cleavage by either the Classical or Alternative pathway C5 convertases 
(C4bC2bC3b or C3bBbC3b respectively), C5 splits into the anaphylatoxin C5a and C5b, the 
latter continuing the cascade as the basis for TCC formation. When C5b binds to C6 and C7, the 
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complex becomes inserted into the membrane and further associates with both C8 and several 
molecules of C9, forming the lytic pore. The nomenclature for this complex is therefore C5b-9. 
When activation occurs in the fluid phase, S protein binds to the complex rendering it nonlytic, 
and is referred to as SC5b-9, or TCC [61; 202]. Elevated levels of fluid phase TCC have been 
detected in patients with evidence of pathologic C activation, notably in cases of severe 
malaria [181] where plasma concentration of 1125.7 ± 496.9 µg/L TCC was observed, but also 
in kidney disease [203; 204; 205], inflammatory neurological disease [206; 207; 208], trauma 
and sepsis [209; 210; 211]. Therefore, serum TCC, SC5b-9, is the ideal target to measure C 
activation in the Lytic pathway and activity of the C5 convertases: its concentration is expected 
to rise with ongoing C activation in vitro. However, in the patient the surface-serum effects 
may be significant, making trends harder to observe especially given its low concentration in 
serum (~60 ng/ml), as shown in Figure 4.3. This requires the assay method employed to be 
sufficiently sensitive to detect such low concentrations of the TCC in order to establish its 
activation profile in vivo. 
Nevertheless, TCC has also been an extensively assayed activation marker in the past, and 
several commercial assays exist for it. Especially encouraging is the existence of a neoepitope 
antibody, clone aE11, which is specific to TCC-bound C9. Furthermore, the fact that TCC is 
made up of several C proteins means that a range of sandwich antibodies could be trialled for 
use in the TCC assay. It also has a half-life of 50-60 minutes [212; 213], and is relatively stable 
in vitro. Additionally, an increase of a factor of 6 was observed for C activated patients 
compared with a healthy population [181]. 
4.2.5 Fragment-Specific Antibody Assays – Neoepitopes 
The detection of C activation products is made possible by raising antibodies specifically to 
neoepitopes that are hidden in the native, un-fragmented component but become exposed on 
the surface of fragments formed during activation, Figure 4.6. This allows for the direct capture 
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of the activation fragment without interference from the respective parent C components. The 
development of specific monoclonal antibodies to the neoepitopes has generated new 
immunoassays to measure C activation specifically within the pathways of the cascade. These 
assays are a step forward from the older generation of C activation tests which concentrated 
on various separation and precipitation techniques [166]. 
 
Figure 4.6. Schematic outlining the principle and origin of neoepitopes used to detect complement 
fragments. 
A number of neopitope antibodies have been reported for the target fragments. Neoepitope 
detection principles have been reviewed recently by Mollnes et al, who describe the TCC 
neoepitope antibody [214], clone aE11. Three antibodies that each have an epitope on C9 are 
compared between EDTA-plasma and Zymosan activated serum. The first, polyclonal anti-C9 
shows fast protein liquid chromatography (FPLC) fractions in both EDTA-plasma and Zymosan 
serum, for both TCC and C9, suggesting general specificity to both native C9 and TCC-bound 
C9. This would be expected from a polyclonal antibody batch. The second antibody, clone M1, 
presents C9 fractions in both EDTA-plasma and Zymosan serum, suggesting that this clone is 
specific to an epitope on native C9 only. The final antibody, clone aE11 shows a very small 
fraction for TCC in EDTA-plasma, and a large fraction for TCC in Zymosan activated serum, 
suggesting that clone aE11 is specific to the neoepitope on C9, exposed only when C9 is bound 
to TCC. 
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C activation products are generated rapidly in vitro [149], so it is essential to ensure that 
samples are collected and stored properly to avoid in vitro activation and therefore further 
generation of neoepitope containing fragments. Activation can be stopped by addition of 
Ethylenediaminetetraacetic acid (EDTA) at a final concentration of at least 10mM, after which 
the sample should be stored at -70ºC [166]. EDTA acts as a chelating agent that strongly binds 
Ca2+ and Mg2+, both co-factors for complement activation. 
 
Figure 4.7. FPLC fractions of C components in normal EDTA plasma and C activated serum using 
Zymosan. C9 and TCC are detected using three different antibodies, displaying clearly the difference in 
epitope specificity: polyclonal anti-C9 reacting with a number of C9 epitopes, most activation 
independent; mAb M1 reacting with a native-restricted epitope exposed only on the native C9 
component, and mAb aE11, reacting with a neoepitope created on C9 when bound into the C5b-9 
complex (TCC). This is a key experiment to ensure the location of the epitope. 
Epitope Access/Presentation 
An important factor to consider when designing surface-mounted capture antibody assays is 
the position of the target epitopes on the analyte. If the detection antibody epitope is very 
close to the neoepitope used for capture, or if the binding of the neoepitope antibody to the 
fragment means that the epitope for the detection antibody is hidden, it is unlikely that the 
assay will perform well. Ideally the detection antibody should be specific to an epitope that 
C9 TCC
TCC
C9
C9
C9
EDTA-plasma Zymosan serum
Anti-C9
(polyclonal)
mAb M1
(native C9)
mAb aE11
(C9 neoepitope)
FPLC-fractions
 
127 
becomes presented when the neoepitope antibody binds to the fragment, shown 
schematically in Figure 4.8. 
 
Figure 4.8 Schematic for a neoepitope fragment assay, detailing the neoepitope antibody specific to 
the neoepitope on the fragment, which can then be detected by a fluorescent antibody specific to an 
epitope elsewhere on the antibody. 
4.3 Assay Method  
Two different classes of electrochemiluminescence (ECL) assays are tested, one being a 
classical sandwich assay, the other employing a secondary species specific reporter antibody. 
Activated Complement Serum (ACS) is used as the calibration standard (supplied by Dr. Claire 
Harris, Cardiff, and stored at -80°C) in all ECL assays, and has itself been calibrated for TCC and 
Bb. 
4.3.1 Electrochemiluminescence Assays 
Thullier et al have performed ECL and ELISA comparison studies for ricin B chain and 
Clostridium botulinum type B neurotoxin [30; 31], using the same capture and detection 
antibodies for both targets. One of the studies [30] reported an 8 fold increase in sensitivity in 
the ECL format over the ELISA. Further, owing to the cost of the commercial ELISA kits for the C 
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fragment assays discussed above and the reported advantage in sensitivity via the ECL 
technique, this investigation aims to develop ECL assays for TCC, Bb, C3d and C4d.  
The ECL platform used in this investigation is the Meso Scale Discovery (MSD) ECL instrument 
[30; 31]. The platform employs carbon electrodes in a 96-well plate format and, crucially, has 
the ability to perform multiplex assays, where each well can be functionalised with up to 10 
carbon electrodes – each a different assay. Upon electrochemical excitation, the MSD 
instrument employs a CCD camera to detect light at 620nm, thereby eliminating problems with 
quenching. Additionally, assays with very low detection limits (≤10-13M) [27] have been 
developed which is important from the perspective of this study, as the concentration of TCC 
in plasma is low (<10-10 M), Figure 4.3. 
We have chosen to develop ECL assays over ELISA or immunoturbidimetric assays because of 
the ability to multiplex the assays once developed. The performance of the assay in the clinical 
setting however needs to be assessed in a large scale clinical trial before it can be used as a 
diagnostic tool. The multiplexing capability of the MSD ECL instrument has significant 
economic implications for such a trial, which is a crucial advantage of this type of assay over 
ELISA or immunoturbidimetric assays. 
4.4 Methods: Complement Activation Assay Development - TCC, Bb, C3d and C4d 
4.4.1 Protocol for in vitro serum Complement Activation 
This protocol has been adapted by combining protocols used previously by Bergseth et al [167] 
and Harboe et al [168], and tailoring it to suit a time course type study. Each of the referenced 
protocols focused on one end point, and therefore EDTA was added once to stop the cascade. 
Therefore our protocol was adapted so that the time course could be stopped for individual 
aliquots while the activation in the master batch could continue. The protocol in this study also 
had lower concentrations of the activating agents, as the focus of the time course study was to 
obtain several time points during the activation. Given that the protocol by Bergseth et al 
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produced near-complete activation of TCC after 1 hour, it was decided to lower the 
concentration of the Zymosan and HAIGG to slow down the activation. Also, in an attempt to 
show differential C activation, the activators were isolated, and two series of activations were 
performed, one with Zymosan, the other with HAIGG.  
A stock of pooled human serum (Biochemed) was divided in two and temperature stabilised at 
37ºC: to one half Zymosan (Sigma-Aldrich) was added to give a final concentration of 
0.1 mg/ml; and to the second half HAIGG was added to make a final concentration of 
0.1 mg/ml. Both activators were added to their respective stocks of serum simultaneously, at 
t = 0. 1 mL aliquots were taken 5 minutes prior to the addition of Zymosan and HAIGG as an 
initial value, and at several time points over a 24h period; in total at 0, 0.5, 1, 2, 4, 6, 10, 16 and 
24 hours. Each sample was added to a concentrated solution of EDTA (Fluka) in PBS (Sigma-
Aldrich) to make a final concentration of 10mM. The samples were centrifuged for 30 minutes 
in a Microfuge (Thermo Espresso Centrifuge) at 14400 RCF, after which two 300µL aliquots 
were taken from the top of the vial, leaving a Zymosan pellet. These aliquots were frozen 
immediately using liquid nitrogen and kept at -80ºC until the assays were performed. Due to 
the frequency of the sampling points and the time taken by the centrifuge step, at least two 
centrifuges are required initially to accommodate the incoming aliquots. 
4.4.2 Polyclonal Secondary Antibody Assays 
A neoepitope capture antibody against the target assay fragment is immobilised overnight at 
4ºC onto the MSD high-bind plate surface (30µl, 1µg/ml in PBS). The surface is then blocked at 
room temperature for 1h using Blocker A (MSD) in PBS-T (PBS with 0.05% Tween-20), after 
which 25µl of the sample and assay standard, ACS (prepared in 10mM EDTA, 1% Blocker A PBS-
T solution) is added to the surface for 2h at room temperature to bind any fragment present in 
the sample to the immobilised neoepitope capture antibody. The plate is then washed 3 times 
with 150 µl PBS-T, after which 25 µl of the polyclonal antisera (1/5000-1/1500 dilution.) is 
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added to the wells and left to incubate for 1h at room temperature. The plate is washed again 
as before, after which 25µl of the SULFO-TAG labelled secondary anti-species antibody is 
added to the well, and again incubated for 1h at room temperature. The plate is then washed 
a final time before 150µl of 1 × MSD Read Buffer is added to the wells before reading the plate 
using the MSD instrument. The assay structure is shown schematically in Figure 4.9. 
  
Figure 4.9. Schematic of Polyclonal Secondary Antibody Assay 
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Figure 4.10. Schematic of SULFO-TAG labelled Monoclonal Antibody Assay 
4.4.3 SULFO-TAG® labelled monoclonal antibody assays 
A neoepitope antibody against the assay fragment is immobilised overnight at 4ºC onto the 
MSD high-bind plate surface (30 µl, 1µg/ml in PBS). The surface is then blocked at room 
temperature for 1h using MSD Blocker A in PBS-T (PBS with 0.05% Tween-20), after which 25 µl 
of the sample and assay standard, ACS (prepared in 10mM EDTA, 1% Blocker A PBS-T solution) 
is added to the surface for 2h at room temperature to bind any fragment present in the 
sample to the immobilised neoepitope antibody. The plate is then washed 3 times with 150 µl 
PBS-T, after which 25 µl of the SULFO-Tag labelled detection antibody (1/500 dilution) is added 
to the wells for 1h at room temperature. The plate is then washed a final time before 150 µl of 
1× MSD Read Buffer is added to the wells before reading the plate using the MSD instrument. 
The outlay of this assay can be seen in Figure 4.10, and is based on a classical ELISA assay, 
developed with the help of Dr. Yvonne Clements (MSD). 
The respective capture and detection antibodies for each assay are detailed below in Table 4.1, 
as well as the reported sensitivities and accuracies. 
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Table 4.1. Summary of all the monoclonal detection antibody electrochemiluminescence assays developed in this study. 
Analyte Capture Antibody Detection Antibody 
(Labelled) 
Detection Limit Dynamic Range 
(orders of 
magnitude) 
Intra-assay, 
Inter-assay 
Error 
ACS 
Calibration Value 
C3d Anti C3d neo 
(Quidel), 
1 µg/ml 
Anti-C3b clone C3/30  
(Dr. Claire Harris, Cardiff) 
0.864 ACS Units >3 8.8% 
3.6% 
C3bc in ACS ~1800 
AU/ml [167] 
Bb Anti Bb neo  
(Quidel), 
2 µg/ml 
Anti-fB 
clone JC1  
(Dr. Claire Harris, Cardiff) 
995 ACS Units  
(54.7 ng/ml) 
~1½ 13.7% 
3.9% 
55 ± 6 µg/ml. 
TCC TCC mAb, clone 
aE11  
(Hycult Biotech), 
1 µg/ml 
aC8  
(Dr. Claire Harris, Cardiff) 
1.11 ACS Units  
(2.32 ng/ml) 
~3 18.2% 
5.7% 
2.10 ± 0.04 mg/ml 
C4d Anti C4d neo  
(Quidel), 
up to 4 µg/ml 
Anti C4-1 (Dr. Diana Wouters), 
C4 mAb (Quidel) 
N/A <1 N/A ~18 µg/ml [167] 
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4.4.4 Labelling Detection Antibodies with MSD SULFO-TAG NHS Ester 
The antibody labelling protocol is supplied by MSD, and is repeated here for completion. A 1-2 
mg/ml solution of the antibody to be labelled is prepared in preservative-free PBS, pH 7.9. 
After equilibrating the antibody solution to room temperature, the MSD SULFO-TAG NHS ester 
(Figure 4.11) is reconstituted in water and immediately added to the antibody. The reaction 
vessel is incubated in the dark for 2 hours at room temperature, after which the free, unbound 
tag is removed from the reaction mixture by centrifuging three times at 1000 g for three 
minutes using a ZEBA Spin Desalting Column with a 40 kDa MW cut off at 4ºC. Once the 
unbound ester is removed, an optimal dilution of the antibody may be found for the respective 
assay. 
 
Figure 4.11. MSD SULFO-TAG® - Ruthenium (II) bi-pyridine, N-hydroxysuccinimide. 
4.4.5 Assay Optimisation, Calibration and Controls 
Two varieties of 96-well plates are available from MSD – standard bind and high bind (product 
numbers L11XA-6 and L11XB-6 respectively). Both were tested, yet the difference in assay 
performance between the plates was negligible. Therefore, the high bind plates were selected 
owing to the practical advantages: the high bind plates are hydrophilic as opposed to 
hydrophobic, and consequently initial filling of the well plate is easier; and incubation time for 
the capture antibody is also shorter. Concentrations of capture and detection antibodies were 
optimised by testing a variety of capture antibody and detection antibody concentrations, then 
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selecting the combination that yielded the greatest dynamic range. Consideration was also 
given to different dilution buffers at this stage.  
Assay calibration vs ACS 
All assays were calibrated using a stock solution of fully activated C serum (ACS) (prepared by 
Dr. Lana Hakobyan, Cardiff following the protocol set out by Mollnes et al [167]) that was 
quantified for TCC and Bb, and controls were performed for each test to determine assay 
degradation during the time it took to pipette all samples into the well plate. Every experiment 
included an ACS calibration channel employing 5-fold dilutions to obtain an ACS calibration 
curve, Figure 4.13, against which all assays were measured, with pure ACS being assigned a 
value of 106, and therefore values are reported relative to this. 
ACS acts as a good calibrant against which to measure C activation as it contains high levels of 
activations products. If an absolute concentration can be determined for a particular activation 
product present in ACS, then subsequent measurement of an unknown concentration of 
analyte can be assigned an absolute concentration by comparison against the ACS calibration 
curve. ACS can be made cheaply, and in large quantities, so it is particularly well suited to large 
scale, multi centre studies. It can be made centrally, stabilised with EDTA, frozen and 
distributed to all the study participants. 
4.5 Results 
The results from this investigation comprise the rejection of the secondary antibody assay 
format, positive results from the tagged monoclonal assay, calibration values for TCC and Bb in 
ACS, and data from in vitro serum activation for all three assays, TCC, Bb and C3d. 
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4.5.1 Secondary Antibody Assays 
Secondary antibody assays can be a useful format if monoclonal antibodies are not available to 
use as detection antibodies. Thus, a species specific antibody (pre-labelled by MSD) can be 
used to detect polyclonal antibodies specific to the analyte. 
 However, further development of secondary antibody assays was stopped owing to 
unacceptably high nonspecific background signal obtained from the whole antisera used in the 
assay, producing approx. 104 MSD counts. This high background level is most likely due to a 
high number of antibodies in the whole antisera having an affinity for the blocking solution 
used, Blocker A (MSD). Therefore, the labelled species specific antibody can bind to all these 
antibodies, as well as the specific antibody for the target analyte, as they are specific against all 
antibodies from a given species. This will then generate the large background signal from 
which any further increase in signal will be due to an increase in concentration of the analyte. 
However, as the upper limit for the MSD instrument is approx. 106 counts, the maximum 
obtainable dynamic range for this assay could only be two orders of magnitude, yet this was 
not attained as seen in Figure 4.12. This graph shows a typical secondary antibody assay, with 
a very high background signal and poor dynamic range – over one order of magnitude for TCC, 
but less than one for C4d.  
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Figure 4.12. Typical ACS calibration curves for TCC (black) and C4d (blue) as secondary antibody 
assays. The high background (10
4
 MSD Counts) and small dynamic range can be seen clearly. All data 
points are constructed from duplicate measurements. 
This was therefore an insensitive assay, and any subsequent work to quantify the fragments in 
a given sample would be subject to substantial error. As a result any further work on this class 
of assay was halted. Nonspecific binding, its associated problems and possible solutions have 
been discussed in Chapter 2. Fortunately, the use of monoclonal antibodies in a traditional 
sandwich assay all but removed any background signal seen in the secondary antibody assay, 
as is shown below. 
4.5.2 Tagged monoclonal assay development – TCC, Bb and C3d 
All monoclonal assays had much lower background signals, approx. 102 counts, obtained by 
employing the protocol in Section 4.4.3. An anti-C8 antibody (supplied by Dr. Claire Harris, 
Cardiff) was used as a detection antibody for TCC, which consistently yielded a dynamic range 
of 3 orders of magnitude (Figure 4.13, black) and an assay sensitivity of 1.11 ACS Units (2.3 
ng/ml). The anti Bb antibody, clone JC1 (supplied by Dr. Claire Harris) was used as a detection 
antibody in the Bb assay, and generally yielded a dynamic range of nearly 2 orders of 
magnitude (Figure 4.13, red) and a sensitivity of 995 ACS Units (54.7 ng/ml). The detection 
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antibody used in the C3d assay was the clone C3/30 (supplied by Dr. Claire Harris), which is 
specific to an epitope on C3b, from which C3d stems. This assay consistently yielded a dynamic 
range of nearly 3 orders of magnitude (Figure 4.13, green) and had a sensitivity of 0.864 ACS 
Units.  
 
Figure 4.13. Typical ACS calibration curves for TCC (black), Bb, (red) and C3d (green). All data points 
are constructed from duplicate measurements. 
All standard curves were fitted to the following expression by the MSD proprietary software, 
Equation 4.1, 
      
     
  (   ⁄ )
   
Equation 4.1 
where b1 and b2 defines the maximum and minimum of the curve respectively, b3 the 
midpoint and b4 the slope. Given there are 4 parameters in the curve it is important to have at 
least 4 points to fit within the dynamic range of the curve. All standard curves for all 
experiments fulfilled this requirement. 
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We were unable to develop an ECL assay for C4d. The antibody combinations used yielded a 
dynamic range of less than one order of magnitude with little or no linearity. With such a poor 
dynamic range it was decided to reject C4d from the current activation analysis.  
 
Figure 4.14. Typical upper (green) and lower (red) detection limits for all assays. Note C4d has a 
dynamic range of less than 1 order of magnitude. 
4.5.3 Activated Complement Serum (ACS) Calibration– TCC and Bb Calibration 
Both calibration experiments followed the same protocol as the tagged monoclonal antibody 
assays, Section 4.4.3, but for the dilution buffer. 
ACS was calibrated for TCC, Figure 4.15, using purified TCC protein supplied by Dr. Claire Harris 
at Cardiff School of Medicine, Figure 4.15, black. Human plasma was used as the diluent 
throughout this experiment to maximise dilution invariance, but as a result the background 
signal associated with the assay also increased to ~103 MSD Counts, compared with <102 when 
using the standard PBS-T based buffer as in Figure 4.13. Serial dilutions of ACS were assayed 
against the purified TCC, after which a concentration was obtained for the ACS sample. This 
was then multiplied by the dilutions factor to obtain the data in Figure 4.15, blue. The 
consistent vertical correlation indicates a very conformity between all samples as to the 
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concentration of ACS. The concentration of TCC in the ACS calibration standard was 
determined as 2.10 ± 0.04 mg/mL. 
 
Figure 4.15. Calibration of ACS (blue) using purified TCC protein (black). 
Similar ACS calibration experiments were performed for Bb, Figure 4.16, using a purified 
protein standard from Comptech, USA, Figure 4.16, black. The dilution buffer used in this 
experiment was human plasma, diluted 10 fold in PBS. Using pure plasma as the dilution buffer 
swamped the signal with high background noise, and using PBS only provided varying numbers 
depending on the level of ACS dilution. As for the ACS TCC calibration the separate dilutions of 
ACS assayed for Bb yielded consistent results, evidenced by the vertical line of blue circles in 
Figure 4.16. This experiment reported a Bb level in ACS of 55 ± 6 µg/mL. 
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Figure 4.16. Calibration of ACS (blue) using recombinant Bb protein (black). 
4.5.4 in vitro C activation assessment using Zymosan and HAIGG 
The serum C activation, as detailed in section 4.4, was assayed for TCC, Bb and C3d over the 
measured time course. For TCC separate C activations were observed between Zymosan and 
HAIGG, as shown in Figure 4.17, whereas there was little difference between the Zymosan and 
HAIGG activations of both Bb, Figure 4.18, and C3d, Figure 4.19, and as a result the average of 
both responses was taken.  
Comparison with the protocol and results from Bergseth et al [167], who observed near 
complete TCC formation after one hour using 10 mg/ml Zymosan and 1 mg/ml HAIGG, shows a 
slower rate of formation of TCC, continuing to rise up exponentially to 24, Figure 4.17. No 
activation is seen when HAIGG is used as an activator, the level of activation being within the 
error. 
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Figure 4.17. Zymosan (black) and HAIGG (blue) activation of TCC in human serum over a 24 hour 
period. Two repeats of both activations were performed, and the data shown is the mean ± standard 
deviation. 
 
Figure 4.18. Activation of Bb in human serum over a 24 hour period. Two repeats of both activations 
were performed, and the data shown is the mean ± standard deviation. Zymosan and HAIGG 
activations yielded similar responses over time, so an average is shown of the data from both 
activations. 
The variation of Bb with activation from both Zymosan and HAIGG is shown in Figure 4.18, with 
data from two activation experiments per activator presented. The concentration variation of 
the Bb fragment shows a complex behaviour up to 4 hours into the time course, after which it 
shows a steady decrease until 24 hours. 
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Figure 4.19. Activation of C3d in human serum over a 24 hour period. Two repeats of both activations 
were performed, and the data shown is the mean ± standard deviation. Zymosan and HAIGG 
activations yielded similar responses over time, so an average is shown of the data from both 
activations. 
The activation time course profile for C3d concentration shows a complex behaviour over the 
first 4 hours, followed by a steady, monotonic, increase until 24 hours. Two replicated 
activation experiments were performed to generate the data.  
Worth noting is the variation in the error bars – some points on the Bb and C3d time course 
seem well defined whereas others display a large error, which are likely to be due to 
experimental error -specifically the aliquot collection and activation halting part of the 
protocol. 
The Zymosan and HAIGG activated serum was also tested for C3 and C4 for comparison using 
an automated immunoturbidimetric assay performed in the clinical chemistry laboratory at the 
RD&E Hospital. Samples were collected at the activation time points, frozen or transported to 
the laboratory using dry ice. Interestingly, with an associated error of 7.1% there was no 
change in the concentrations of both C3 and C4 at the level of accuracy of the assay.  
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Figure 4.20. Levels of C3 and C4 were also measured over 16 hours of the activation. With an assay 
error of ±7% (2 SD), the levels of both proteins remain essentially constant. 
4.6 Discussion 
Many commercial assays exist for the assessment of C activation, such as the Hycult C5a, C3a 
and TCC ELISA kits. There are also Quidel Microvue EIA kits available for several fragments 
including Bb, C4d and TCC (SC5b-9). These kits are expensive and, crucially, cannot be 
multiplexed. Here we describe an ECL assay for the quantification of three C fragments, C3d, 
TCC and Bb. This technique has a unique advantage in that once developed, the assays can be 
‘multiplexed’ whereby up to 10 assays can be performed in a single plate well. A comparison 
study for multiplex immunoassay platforms was performed by Fu et al [34] where it was 
determined that the MULTI-ARRAY assays supplied by MSD were the most suitable for 
biomarker analysis. Multiplexed assays will be a cheaper [35] alternative to screen for C 
activation in blood samples, which will enable large scale C activation monitoring trials to 
proceed. 
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Assay Performance and in vitro Activation 
The TCC assay performed the best of the three assays, yielding a calibration curve with an 
excellent dynamic range (consistently greater than 3 orders of magnitude). The intra-assay 
accuracy was 18.2%, the inter-assay precision 5.7%, and the detection limit 1.11 ACS Units 
(2.32 ng/ml), Table 4.1. The intra assay accuracy gives an indication of the degradation of the 
antibody during the plate loading time for the analyte incubation, as this is the most time 
consuming part of the protocol. The inter assay precision shows the agreement between 
duplicate sample wells. Differential activation of TCC was shown, Figure 4.17, during in vitro 
activation using Zymosan and HAIGG, the former activation yielding an activation profile that 
reached a maximum of approximately 80% of the level present in ACS. For comparison, a 
recent experiment was conducted by Bergseth et al. [167] to establish ACS as an international 
complement standard. In their experiments the serum was activated with both HAIGG and 
Zymosan in tandem – the Zymosan having a concentration 100 times larger than that in our 
experiments and HAIGG 10 times greater. Their activation showed a rapid increase in TCC 
concentrations, reaching a maximum at 1h, then a slight decline at 4h which was stable until 
the final point at 24h. To observe the kinetic response, a lower 0.1 mg/ml concentration of 
Zymosan was used to obtain a profile of the production of TCC over a period of 24 hours with a 
greater sampling rate in the first 4 hours. The difference between the times to maximum TCC 
production between the two experiments suggests the kinetics of the TCC formation can be 
studied as a function of Zymosan concentration. That is an investigation that is outside the 
scope of this thesis, however the preliminary results show that this is possible, especially with 
comparison to the data presented by Bergseth and Mollnes [167]. 
The assay for Bb performed less well, with a dynamic range of typically one and a half orders of 
magnitude. The intra-assay accuracy was 13.7%, and inter-assay precision 3.9%, and detection 
limit 995 ACS Units (54.7 ng/ml), Table 4.1. The Zymosan and HAIGG activation showed little 
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differential activation for Bb, and the ‘activation’ actually showed a decrease in the Bb 
concentration in the serum by approximately 40% over the course of 24 hours. Regarding the 
comparison with Bergseth et al. [167], after an initial increase to approximately 90 µg/ml at 4 
hours, the Bb fragment level also decreased to approximately 55 µg/ml at 24 hours, in 
agreement with our calibration measurement. It is unfortunate that this is the case, as ideally 
such a standard will have high concentrations of all activation markers, however further study 
into the rates of production and consumption during activation of a wide range of C proteins 
will provide a unique insight into the C system, especially in terms of pathway speeds and flux 
markers. Another comparative study by Opperman et al [165] monitored Bb production during 
Zymosan activation of C, and observed a response similar to TCC in this study. It is therefore 
suggested that the production profile for Bb is not fully understood, and therefore further 
study of its production as a function of Zymosan concentration is needed. Bb must remain the 
fragment of choice for Alternative pathway activation monitoring, as its mass allows it to 
remain in circulation, and it is the only unique marker for the Alternative pathway for which 
there are neoepitope antibodies commercially available. 
The C3d assay performed well, consistently yielding a calibration curve of almost three orders 
of magnitude. The intra-assay accuracy was 8.8%, and inter-assay precision 3.6%, and 
sensitivity 0.864 ACS Units. Again, comparison with Bergseth et al. [167] is consistent, albeit 
with much lower concentrations of the activating substance. C3d steadily increases after 4h 
and 24h, however this time course study illustrates why closer examination is important, as a 
brief dip in C3d concentration is seen between 4 and 10 hours. As an isolated case this might 
not provide very enlightening insight into C system dynamics, however coupled with time 
course analysis of other C system proteins it can provide a telling insight into the relation 
between these proteins in this complex network.  
in vitro C Activation: Protein Cascade Interactions 
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Differential activation was observed for TCC in the Zymosan activated serum, but not in the 
HAIGG activation. Zymosan, a glycan derived from yeast cell walls [215], activates the C system 
via the Alternative and Lectin pathways, whereas HAIGG initiates the Classical pathway [147]. 
This suggests the TCC (a lower C cascade activation marker, indicative of general C activation 
to completion) was formed from initiation of the Alternative or Lectin pathways, but not via 
the Classical pathway. The lack of activation via the Classical pathway suggests that the 
concentration of HAIGG was not high enough to warrant activation, or that the flux via that 
pathway is considerably slower than the Lectin or, more likely, the Alternative pathway. The 
alternative pathway has enormous potential for amplification via its amplification loop, and 
therefore once initiated can lead to rapid formation of C3 and C5 convertases, leading to the 
production of TCC. 
More similar activation profiles were observed between the two activating experiments for 
C3d and Bb. This can be expected for C3d (a fragment common to all three activating 
pathways), but not Bb, especially given the differential production of TCC, most probably via 
the Alternative pathway. Experiments with varying concentrations of activators can be 
conducted to establish more firmly the role of Bb in the activating process, especially in 
relation to the formation of TCC, as Bb forms part of the C3 and C5 convertases, two quantities 
that the rate of TCC production is likely to be highly correlated with. 
Epitope Presentation in the Assay 
The difference in assay performance can be attributed to a number of factors, the most 
important of which is the choice of antibodies, and more specifically epitope access for those 
antibodies on the target analyte, explained schematically in Figure 4.21. Consider the well-
performing TCC and C3d assays. In this case it is likely that the neoepitope capture antibody 
immobilises the fragment in such a way that the epitope for the detection antibody is well 
presented, unhindered by the binding between the neoepitope and the capture antibody. 
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Therefore the detection antibody can access and bind the analyte easily, allowing for a greater 
detection range. The situation may be slightly different for TCC, which is a very large molecule 
(1000 kDa) made up of several components, each of which can have antibodies raised against 
them. Therefore epitopes for capture and detection antibodies are unlikely to be physically 
adjacent. Comparing with the poorer performing Bb assay, it is possible that once immobilised, 
the Bb fragment does not present its respective detection antibody epitope as well as C3d and 
TCC, and therefore fewer detection antibodies can bind to the assay to generate the signal. 
Therefore Bb would suffer from a smaller detection range, as evidenced by the data. 
Unfortunately the location of the epitopes for each of the commercial antibodies is not 
available, and the location and proximity of the two epitopes cannot be determined easily. 
These two scenarios are displayed schematically in Figure 4.21. 
 
Figure 4.21. Schematic diagram showing the possible different detection antibody epitope layouts for 
the TCC and C3d assays (a), and the Bb assay (b). 
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ACS was quantified for TCC and Bb using different dilution buffers for each calibration 
experiment. Calibration and stability of the ACS standard is critical to its adoption as an 
international standard for C activation studies. It was not possible to calibrate the ACS for the 
C3d assay because of the unknown mixture of individual fragments in the C3d group of 
analytes. As the ACS contained three fragments (C3b, iC3b and C3dg) that contained a C3d 
neoepitope it was not possible to determine their relative concentrations in ACS, and 
therefore an appropriate standard against which to calibrate ACS for C3d could not be made. 
As it was not possible to calibrate for C3d, consequently a value of 106 ACS Units was assigned 
to pure ACS, and all other values for all three assays were reported against this. If the levels of 
the fragments can be verified as stable in ACS when stored over a long period of time, ACS can 
become a useful international standard in C activation research, which is discussed below. 
A representation of the C3d assay is made in Figure 4.22, illustrating why it cannot be 
calibrated. It shows the three analytes that make up the C3d group of fragments being 
captured onto the surface, followed by the selective binding of the C3-30 antibody to only C3b 
and iC3b. Therefore, as the proportion of C3b to iC3b in ACS cannot be distinguished using the 
antibodies available, calibration of the C3d fragment group in ACS is not possible. 
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Figure 4.22. Illustration of antibody selectivity in C3d assay. Although the capture antibody can 
immobilise all three fragments, only two (iC3b and C3b) can be detected and reported by the 
detection antibody. 
 
Comparison with C3 and C4 
The constant level of C3 and C4 within the assay error during in vitro activation was not 
expected, especially considering the rise in C3d. The anticorrelation with C3d is consistent with 
data previously reported by Mollnes et al [144], but it is also potentially due to the specificity 
of the antibody used in the C3 assay. The antibody used is unlikely to be specific to C3 only, as 
the commonly used methods to detect C3 and C4 also detect their major soluble fragments, 
C3c and C4c [147], and therefore the signal is likely to be the sum of native C3 plus some C3 
fragments. It would therefore follow that the level would stay constant, as the fragment 
concentration would increase with the decreasing native C3 concentration, yielding a constant 
level of protein that is specific to the antibody. 
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Recently, an attempt was made by Bergseth et al. [167] to develop and establish an 
international standard against which to measure C activation, namely ACS, used as the 
calibration standard in this study. An assessment of its merit as such a standard is made here. 
In the same study the stability of ACS is shown as a function of a number of freeze/thaw cycles, 
Figure 4.24 and in time, Figure 4.23, – the only analyte to degrade being the C3 convertase 
C3bBbP. This is encouraging if you consider the practical implications for a clinical trial, or a 
multi-centre, standardised C activation investigation. The ACS can be made in bulk, aliquoted, 
frozen and transported with little impact on the stability of the components within the ACS.  
Once the assays for C3d, Bb and TCC were developed, ACS was used as the standard for all 
activation experiments and the values obtained were reported in ACS units, with pure ACS 
being 106 ACS Units for each assay.  
 
 
 
Figure 4.23. Reproduced with permission from conference poster by Bergseth et al [167] – Stability of 
C activation products over a period of 28 days when stored at 4°C. The only product to show notable 
degradation was the C3 convertase C3bBbP. The markers were assayed by ELISA, and the data are 
presented as the mean ± standard deviation. (n=6). 
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Figure 4.24. Reproduced with permission from conference poster by Bergseth et al [167] – 
Freeze/thaw cycles did not significantly degrade C activation products. The markers were assayed by 
ELISA, and the data are presented as the mean ± standard deviation. (n=6). 
 
Figure 4.25. Graph showing an average standard curve for TCC using ACS for 10 experiments over a 
period of ~ 6 months. The errors shown are 95% confidence intervals (n=10). 
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Figure 4.26. Graph showing an average standard curve for C3d using ACS for 10 experiments over a 
period of ~ 6 months. The errors shown are 95% confidence intervals (n=10). 
Ten ACS calibration curves were measured over a period of 6 months, and the variability for 
each assay was determined using a 95% confidence limit as a percentage of the mean (Figure 
4.25, TCC = 22.9%. Figure 4.26, C3d = 20.2% and Figure 4.27, Bb = 17.9%). The average value 
for the overall reproducibility of ACS was then determined to be 20.3% using data from all 
three assays. Coupled with the data from Bergseth et al. [167], as seen in Figure 4.23 and 
Figure 4.24, we can assume that the bulk of this variability is due to experimental inconsistency 
rather than degradation of ACS at -80°C, which was used with only one freeze/thaw cycle. 
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Figure 4.27. Graph showing an average standard curve for Bb using ACS for 10 experiments over a 
period of ~ 6 months. The errors shown are 95% confidence intervals (n=10). 
It should be noted that the relative values of the fragments in this experiment compared with 
the stock solution of ACS was in the same general range (<90% for TCC, 35%-550% for Bb, and 
<60% for C3d), which gives an indication towards the possible variability associated with 
activating serum for C from different batches of serum. However, it should also be considered 
that the protocols differ greatly with regard to the concentrations of the activating substances, 
and therefore a strict formal comparison is not appropriate. 
4.7 Conclusion 
In this study, ECL assays were developed for C activation products C3d, TCC and Bb, which 
were subsequently assessed on a simple serum C activation experiment. The assays were 
optimised, discarding the use of the secondary antibody assay technique, and selecting 
monoclonal antibodies that yielded the greatest dynamic range for each assay. The 
combination of antibodies selected for the sandwich assay is key to ensure proper epitope 
presentation in the assay. The monoclonal antibody assay has a further advantage over the 
secondary antibody assay in that it takes one and a half hours less to complete. It is possible to 
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measure in vitro activation kinetics of the C cascade fragments, and in preliminary analysis C3d 
and TCC behaved as expected.  
The standard for all experiments, ACS, was itself calibrated to quantify TCC and Bb, but 
unfortunately calibration for C3d was not possible. Given the stability of fragment components 
within ACS when it is stored over a long period of time, ACS can be used for further C 
activation studies as the standard against which activation is measured. We have developed 
two well performing electrochemiluminescence assays for C3d and TCC, an upper and lower 
cascade marker respectively. The assay for Bb performed less well, and we were unable to 
develop an assay for C4d that was deemed acceptable. The dynamic range of < 1 order of 
magnitude was not considered enough to proceed with further experiments using the assay. 
These monoclonal neoepitope antibody based ECL assays can be extended to other 
complement components and fragments, and once a particular set is optimised, a multiplex 
assay can be developed for multi-component (up to ten) screening from a single sample in a 
single plate well. 
The assays for TCC, C3d and Bb can now be employed in an in vivo complement activation 
study. As with the in vitro activation experiment, a well established trigger of C activity is 
needed, such as surgical trauma [216]. This will allow a well defined initial time point from 
which the kinetic progression of the C fragments can be monitored. The effect of C activity 
regulation is an unknown parameter, is likely to affect the observed response in vivo cf. in 
vitro. Any subsequent immunological challenge activating the C system may also be observed 
by monitoring C activation postoperatively. 
 
155 
Chapter 5 
The Complement System as a Surgical Procedure 
Outcome Predictor and Measure of Trauma 
5.1 Introduction 
Perioperative monitoring of hospital patients undergoing surgery, both clinically and 
biochemically, is an important facet of a given patient’s road to recovery. Currently a range of 
clinical factors and biochemical tests can be used to monitor and adjust a patient’s treatment, 
however a simple predictive test for the early onset of secondary complications could have 
significant effects on patient outcome, morbidity and mortality rates, length of stay and long-
term survival.  
Regular observations of temperature, blood pressure, full blood count and serum electrolytes 
are used together with C-Reactive Protein (CRP) as a routine set of tests and observations to 
monitor patients, especially post-operatively [63]. Post-operative complication rates following 
major abdominal surgery are reported to be as high as 27% [217] with potential for significant 
patient morbidity and mortality and the existing biomarkers, such as CRP, appear to be poor 
indicators of infection or complications especially in acute treatment scenarios [176].  
Patients undergoing surgery are at their most vulnerable, and are especially prone to an 
immunological challenge via viral or bacterial infections, for example. If untreated, these 
infections can lead to the onset of sepsis or systemic inflammatory response syndrome (SIRS). 
In the UK, sepsis costs the NHS approximately £2.3 billion and is responsible for the deaths of 
36,000 to 64,000 people every year [218]. Most notably, patients with severe sepsis use 46% 
of all intensive care unit bed days [218]. Therefore it is of significant interest to lower the rate 
of secondary infections, especially sepsis, which can be achieved by the concept of ‘enhanced 
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recovery’. Recently, a large cohort study in Canada demonstrated that despite similar rates of 
complications, different organisations had marked variations in their ‘in-hospital mortality 
rates’. The distinction came from the ‘time to rescue’ – the speed of recognition and 
management of complications [219]. Therefore, if a complication can be recognised early, 
before any signs of physical symptoms, the time to rescue could be reduced, thereby achieving 
lower mortality rates. 
In order to recognise patients who are at risk of imminent complications, a biochemical marker 
is needed to monitor the patient’s immune system to look for signs of activation upon 
immuno-compromise. An attempt has been made to predict shock and organ failure in septic 
surgical patients using so-called SMART (Systemic Mediator Associated Response Test) 
analysis, but unfortunately this relies on monitoring a number of factors including 
‘demographics, physiologic parameters, standard laboratory tests, and circulating markers of 
inflammation’ [220]. Combining such a large number of factors has difficult practical 
implications for the time-pressed clinicians. The biomarker should be an intimate reflector of a 
patient’s developing immunological state, and should be present systemically so that the assay 
can be performed on a routine blood sample.  
The solution may be found with the Complement (C) system. The hypothesis is that under 
‘normal’ conditions, the C system is ‘idle’, with stable levels of C components. Once the host is 
immunologically compromised, the C system becomes activated, evidenced by elevated C 
activation markers. In the context of a patient recovering from surgery, there will be an initial 
trauma associated with the procedure (reflected by C protein levels), however careful 
monitoring of the C system post operatively will identify when patients show C activity, and 
therefore a possible pathogenic invasion, for example. As this is the natural defence response, 
the patient’s immune system may be able to deal effectively with the compromise itself, 
however these patients could be identified as ‘at risk’ and therefore be more carefully 
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monitored so that the ‘time to rescue’ (and therefore mortality rates) may be improved. There 
will undoubtedly be localised C activation at the site of the surgical trauma associated with 
inflammation, but monitoring the patient for systemic C activation is of particular interest as it 
is at this point that the host is responding to a general compromise, separate from the 
localised response due to surgery.  
Our hypothesis states that consumption of the C proteins C3 and C4 is a general measure of 
surgical trauma for a typical broad cohort of major abdominal surgery and will provide 
significantly faster response than CRP. Further, the return of C3 and C4 pre-operative levels 
monitored over a serial time course can act as a personalised biomarker of recovery and 
secondary consumption events could indicate the potential onset of complications. 
A number of classifications are used to assess the fitness of a patient for a particular procedure 
[221; 222; 223] and considerable technical advancement has occurred in the performance of 
surgical procedures, but recovery monitoring remains limited to clinical observations and a 
limited set of blood biomarkers dominated by C-reactive protein (CRP). The acute phase 
response triggered by, amongst others, production of the cytokines IL-6 and IL-1 and 
corticosteroids is monitored systemically and post-operatively by the production of CRP [63; 
224]. CRP is a useful marker of the switch change in protein synthesis in the liver associated 
with the acute phase and can rise from typical healthy levels of (median) 0.8 mg/L in blood 
donors to up to 500 mg/L [63] during acute inflammatory events. After its production it is 
cleared with a constant plasma half-life of 19 hours under all health conditions [63]. There are 
an increasing number of studies however, pointing to limitations and diagnostic accuracy of 
CRP [225; 226]. 
CRP production is monitored by a cheap, reliable assay in the laboratory routinely with fairly 
low sensitivity typically 3 mg/L and it does not show a response during the 10 hours 
immediately post operatively. Thereafter its concentration continues to rise reaching a 
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maximum between 24 and 48 hours, after which the level falls as long as there is no further 
production stimulus, ie. inflammation resulting from infection. CRP is also a complex 
pentameric protein that requires considerable biosynthetic effort to produce. 
The C cascade, however, is maintained homeostatically with sufficient levels of C3 and C4 to 
launch a C counter attack against a potential immunological challenge, with many control and 
regulatory proteins such as Factor H (fH) and Decay Accelerating Factor (DAF) present to 
ensure efficiency and rapid activation. These proteins form an enzymatic cascade which may 
be triggered by a number of challenges forming the innate immune response for an individual. 
This is a marked contrast with the de novo synthesis CRP in response to inflammation. Once 
the C cascade has responded the proteins will return to their normal concentrations, ready to 
be activated once more. The resetting to normal C component levels can therefore be 
monitored and considered as the return to health of a patient postoperatively.  
The response of the cascade may then be considered a sensor system for all possible 
challenges including surgical trauma and secondary complications and infections, to name but 
a few. The enzyme-kinetic response is rapid resulting in the consumption of C3 and C4 proteins 
following the formation of the two key C3 convertases, C4b2b from the Lectin and Classical 
pathways and C3bBbP from the Alternative pathway, Figure 5.1. C3 consumption is then 
related to the number of the membrane-bound and serum C3-convertases resulting from 
surgical trauma, producing a rapid change of the serum C3 concentrations in minutes. This has 
the potential to provide information on the extent of trauma and the onset of recovery of the 
patient in the hours immediately post-operatively before CRP has responded. Further, the C3 
and C4 levels will be reset during recovery to levels controlled by the patient’s homeostasis 
indicating a healthy innate immune system – a personalised measure of recovery. 
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Figure 5.1. The Complement cascade showing the Classical, Lectin, Alternative pathways, the origin of 
C3 and C4 consumption, and Terminal Pathway. The C3 and C5 convertases are indicated with a bar 
above the text.  
In order to evaluate the C system as a predictive test for secondary complication development 
and to monitor patient recovery post-operatively, a clinical trial was conducted at the Royal 
Devon and Exeter (RD&E) Hospital. 45 patients undergoing elective abdominal surgery were 
recruited and blood samples were taken from them during a time course before, during and 
after their operations. These samples were assayed for a range of C fragments (TCC, Bb and 
C3d), Chapter 6, and components (C3, C4) in order to gain an overview of overall C system 
activity in each patient. In addition the samples were assayed for CRP and IgG, and general 
routine tests ordered by the clinicians were added to the data set. This chapter aims to 
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interrogate the C system during the perioperative period as a diagnostic tool, and employs a 
number of parameters from a range of assays in order to do so. 
5.2 CPOP Trial Protocol  
The CPOP (Using Complement as a Procedural Outcome Predictor) trial was conducted at the 
RD&E Hospital, Devon between November 2010 and February 2011. 45 patients undergoing 
elective abdominal and pelvic surgery were recruited based on the following exclusion criteria: 
unable or unwilling to provide informed consent, pregnant women, patients under the age of 
18, diabetics, patients with inflammatory bowel disorders, immuno-suppressed patients, or 
patients who underwent immuno-suppression or steroid treatment in the 12 months 
preceding their operation. The recruited patients were then monitored for C activation over a 
time course of typically 48-60 hours. The trial proposal received ethical approval from the 
LREC, South West Committee A, UK, REC, with reference number 10/H0107/66a. 
Blood samples were taken from patients over a time course outlined in Table 5.1, with each 
sample coming from a fresh skin prick, or after 2mL blood had been discarded if a catheter was 
in place. Blood samples at each time point were split into clot samples and EDTA-stabilised 
plasma samples, the latter being split into 5 aliquots and frozen at -80ºC. The clot samples 
were used to perform C3, C4, CRP and IgG assays, and the EDTA samples were used to test for 
the C fragments – TCC, Bb and C3d – the focus of Chapter 6. It has been reported that further 
in vitro activation of C can occur, and therefore fragment analysis is performed in EDTA plasma 
so as to minimise C component degradation [191; 227; 228], effectively freezing the C cascade 
at the time of taking blood. 
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Table 5.1. Trial time course and samples 
Time Point Time of Test Trial Test Trial Assays Indicative Day 
Timings 
1 
t = -1 hour 
Pre-admission clinic 
CONSENT 
ROUTINE C3, C4, IgG, CRP t =-1 day 
2 
t = 0 
Pre-operatively 
Under anaesthesia 
Trial Sample 
NO.1 
C3, C4, IgG, CRP 9:30 hours 
3 
t =1 hour 
Under anaesthesia Trial Sample 
NO.2  
C3, C4, IgG, CRP 10:30 hours 
4 
t = 2 - 4 hours 
immediately post 
surgery  
ROUTINE C3, C4, IgG, CRP 13:30hours  
5 
t = 8 hours 
 Trial Sample 
NO. 3 
C3, C4, IgG, CRP 17:30 hours 
6 
t = 12 hours 
 Trial sample 
NO. 4 
C3, C4, IgG, CRP 21:30 hours 
7 
t = 24 hours 
 ROUTINE C3, C4, IgG, CRP 09:30 hours 
8 
t = 36 hours 
 ROUTINE C3, C4, IgG, CRP 21:30 hours 
9 
t = 48 hours 
 
Some Patients 
Discharged 
Complications 
Develop 
ROUTINE C3, C4, IgG, CRP  
 t = x1 ROUTINE CRP  
 t = x2 ROUTINE CRP  
10 Discharge    
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C components C3 and C4 are studied to monitor differential C consumption postoperatively. 
CRP is measured routinely and is currently a broad spectrum marker for the acute phase 
response and its subsequent development. The analysis of the C components will be compared 
with CRP to determine whether there may be any clinical advantages in using C3 and C4 to 
monitor patient recovery. Total IgG is also included in the study and acts as a control for any 
dilution that may occur during perioperative fluid administration. 
Complement Component and Biomarker Assays 
Assays for C3, C4, CRP and IgG were performed locally in the Clinical Chemistry Laboratory and 
Immunology laboratories. All assays were performed by Cobas® Immonoturbidimetric assays 
on Roche/Hitachi analysis platforms with the following accuracy and detection limits shown in 
brackets (percentage accuracy, detection limit): C3 (4.0%, 0.04 g/L), C4 (7.1%, 0.015 g/L), CRP 
(4.1%,0.3 mg/L) and IgG (3.7%,0.3 g/L). The general immunoturbidimetric technique has been 
described before, (Section 1.1.3) but briefly, antibodies against the target analyte are 
immobilised on latex beads that aggregate in the presence of the analyte as a result of 
antibody-antigen binding. The aggregation increases the turbidity of the solution in line with 
the analyte concentration, which can then be derived from measuring light absorption at a 
specified wavelength. 
This is in contrast with the sandwich ECL C activation assays developed in Chapter 4, (and used 
in Chapter 6), where the capture antibody is immobilised. The immunoturbidimetric assays 
employed in this chapter are widely used, well established diagnostic assays, and therefore 
provide results with very good accuracies and precision. Just as in the ECL assays, a calibrant is 
used along with control samples to ensure quality control. The immunoturbidimetric assay 
relies on aggregation of antibody-immobilised latex particles, whereas the ECL assay employs 
an immobilised antibody raised against the target analyte, which can then be identified by 
binding to a second, labelled antibody that emits light upon electrochemical excitation. 
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To supplement the C analysis, complications were recorded where applicable using the 
Clavien-Dindo classification system, outlined below in section 5.3 [229]. 
5.3 General Trial Results 
A total of 45 out of 52 approached patients were recruited into the trial, giving an 85% 
recruitment rate, and a further 96% retention (to time course completion) rate. 25 males and 
20 females were recruited, with an average age of 64 years (inter quartile range 53-72 years). 
Blood samples were collected in 96% of the planned schedule, and the assay success rate for 
each sample was 92% for C3 assays, 92% for C4 assays and 91% for IgG assays. A total of 
11,481 data points were collected from the 45 patient cohort. The average operation time was 
154 minutes (inter-quartile range 105-205 minutes) and the average length of stay was 200 
hours (inter-quartile range 94-199 hours). Eight operations were performed laparoscopically, 
the rest were open surgery in a cohort typical of an abdominal surgery list, included for 
completion in Table 5.2  
Ten patients suffered complications (22%), of which two died, three developed sepsis (one of 
whom died) and 5 were re-admitted. The complications were reported in the patients’ clinical 
notes along with their assigned Clavien Grades I – V [229]: Grade I, any deviation from the 
normal postoperative course without the need for pharmacological treatment; Grade II, 
requiring pharmacological treatment with drugs (blood transfusions and total parenteral 
nutrition are also included); Grade III, requiring surgical, endoscopic or radiological 
intervention; Grade IIIa, intervention not under general anaesthesia; Grade IIIb, intervention 
under general anaesthesia; Grade IV, life-threatening complication (including central nervous 
system complications) requiring intensive care management; Grade IVa, single organ 
dysfunction; Grade IVb, multiple organ dysfunction and Grave V, death. In this trial, the patient 
complications according to their respective Clavien grades were Grade I = 4, Grade II = 9, Grade 
IIIa = 1, Grade IIIb = 1, Grade IV = 1 and Grade V = 2. The results are summarised in Table 5.3  
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Table 5.2. List of surgical procedures carried out in the CPOP Clinical Trial supplied by Dr. Ian Daniel. 
Major Pelvic Surgery Stoma Colonic Surgery 
Laparoscopic sigmoid 
colectomy 
Laparoscopic total colectomy 
and ileostomy 
Elective laparoscopic right 
hemicolectomy 
Laparoscopic sigmoid 
colectomy 
Laparoscopic anterior 
resection 
Laparoscopic hemicolectomy 
and bilateral salpineo-
oophrectomy 
Extended right 
hemicolectomy 
Subtotal colectomy and 
ileostomy 
Extended right hemi-
colectomy and anastomosis 
of ileum to colon 
Sigmoid colectomy and 
colostomy 
Open right hemicolectomy 
Re-sighting of ileostomy 
Closure ileostomy 
Defunctioning colostomy 
Transverse colectomy 
Parastomal hernia repair 
Anterior resection 
Completion protetecomy, 
adhesionolysism, ileional J 
pouch defunctionaing loop 
ilesotomy 
Abdominoperineal excision of 
rectum and end colostomy 
Laparotomy, Protectomy, 
excision of anus 
Male Pelvic Clearance 
Anterior Resection 
Low Anterior Resection 
Proctectomy 
Anterior Resection 
Panproctocolectomy, 
Anastomosis of ileum to anus 
Reversal Hartmann’s 
Anterior Resection +/- 
ileostomy 
Right total nephrectomy 
Laparoscopic 
nephrouretectomy 
Left open 
nephrourecterectomy 
Left laparoscopic nephro-
ureterectomy 
Partial nephrectomy 
Radical retropubic 
prostatectomy 
Radical Prostatectomy 
Radical prostatectomy 
Elective total right 
nephrectomy 
Radical retropubic 
prostatectomy 
Radical prostatectomy 
Radical retropubic 
prostatectomy 
Radical prostatectomy 
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It is appropriate here to give due attention to the small number of patients involved in this trial 
and its implications for statistical analysis. Given that a broad objective of the trial is to 
monitor C activation during post surgical complications, especially sepsis, any statistical data is 
hampered by the low number of complication outcomes (ten in this case, of which only three 
developed sepsis). It is therefore imperative that any conclusions drawn from this study be 
taken with caution, and considered only in light of the merits for conducting a larger trial to 
thoroughly test the conclusions drawn here. It is therefore important that the analysis herein 
remains largely descriptive and comparative, placing only limited emphasis on statistical 
analysis where it is used. This is especially important in light of the surgical procedures carried 
out. The scale of surgical trauma is broad, ranging from small laparoscopic procedures to large 
open surgery procedures. The trauma and subsequent recovery of each procedure differs, and 
this only adds to statistical uncertainty. However given this range of surgical procedures, it 
provides opportunity for extra observations regarding future trial design, as the type of surgery 
carried out should be considered. 
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Table 5.3. Trial demographics and biomarkers distributions 
Property November 2010 – February 2011 
Number of Patients 45  Patients Approached 52 Recruitment Rate 85% 
Retention Rate 96% 
Males 25  Females 20 
Number of Deaths 
CPOP0015, CPOP0028 
2  Death Rate 4% 
Number of Re-admissions 
CPOP0002, CPOP0010, 
CPOP0024, CPOP0048, 
CPOP0050 
5  Re-admission Rate 11 % 
Number of Sepsis Cases 
CPOP002, CPOP0015, 
CPOP0049 
3  Sepsis Rate 7 % 
Complications Rate 22 %  Clavien Grade I = 4 
Clavien Grade II = 9 
Clavien Grade IIIa = 1 
Clavien Grade IIIb =1 
Clavien Grade IV = 1 
Clavien Grade V = 2 
 
 Mean (SD)   Mean (SD) 
Age of Participants (years) 64 (16)   Length of Stay (hours) 200 (195) 
Surgery Duration (minutes) 154 (49)  Max CRP (mg/L) 134 (85) 
Initial C3 (g /L) 1.42 (0.25)  C3 Maximum Depletion 
(%) 
45% (15%) 
Initial C4 (g/L) 0.27 (0.06)  C4 Maximum Depletion 
(%) 
35% (13%) 
Initial IgG (mg/L) 9.2 (2.4)    
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Trial Overview Results 
The CPOP clinical trial recruited 45 patients out of 52 patients approached at a recruitment 
rate of 85%. Two patients withdrew their consent for participation during the sampling time 
course, yielding a retention rate of 96%. The complications rate also compares well with the 
reported rate of 27% [217]. These are three important parameters to consider if a similar large 
scale trial is to be conducted, especially to manage resources and expectations. The initial C3 
concentration in the cohort of patients fits within the reference range of 1-1.5 g/L [162], Figure 
5.2A, whereas the initial C4 value observed in the trial is 0.26 ± 0.06 g/L, approximately half 
the reference value of ~0.6 g/L [162], Figure 5.2B. An important initial observation is the 
readmission rate of 11%. By monitoring a patient’s postoperative recovery using the C system, 
it is anticipated that a predictive test can be developed as supporting evidence for discharging 
a patient, with the aim of reducing the number of readmitted patients.  
 
Figure 5.2. Distribution of C3 (A, bin = 0.2) and C4 (B, bin = 0.05) concentrations on admission across 
the patient cohort. 
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5.4 Results and Discussion 
5.4.1 Time Course Data Analysis: Nomograms 
The time course analysis of the data was descriptive given the small number of patients 
involved in the trial. All data points in the time course for each of C3, C4 and IgG were 
normalized by dividing by the C3, C4 and IgG values on admission, C30, C40, and IgG0. CRP data 
were presented in the conventional units. Individual patient recoveries were plotted over the 
serial time course from admission to discharge. The evolution of the normalized analyte 
concentrations ‘nC3’, ‘nC4’ and ‘nIgG’ were plotted against the collection time precisely with 
the errors stated above. A linear interpolation was used between the data points to provide 
data points at consistent intervals between induction and discharge. The data at each 
interpolated point was then averaged over all 45 patients to produce the average recovery 
profile or ‘nomogram’, plotted as the mean of all values, Figure 5.3. The standard deviation 
(SD) was calculated from the sample at each time point from which the 95 % confidence limit 
was calculated (1.96 x SD x (n)-1/2 where n=45). The resulting nomogram is therefore the 
perioperative average population response for each assay. Individual patient recoveries can be 
compared with the derived nomogram for nC3, nC4 and nIgG, Figure 5.4. 
Furthermore, a stratification of nomograms for surgical procedure subclasses was created, 
Section 5.4.2. Nomograms were constructed for the group of patients that experienced 
complications, and the response was compared with patients who recovered without 
complication. 
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Figure 5.3 Consumption biomarker 'nomograms' for C3 (black, with dashed grey confidence intervals), 
C4 (red, with dashed pink confidence intervals) and total IgG (blue, with dashed light blue confidence 
intervals). 
 
Figure 5.4. Normalised C3 consumption nomogram averaged over the 45 patient cohort; nC3, black; 
95% confident limit, grey dashed; CPOP001 patient recovery pathway, green: Age: 63, Male, Radical 
Retropubic Prostatectomy, Duration of Operation 90 minutes and Length of Stay: 75 hours; and 
CPOP028 patient recovery pathway, red: Age 75, Male, Transverse colectomy, duration of operation 
100 minutes and died at 192 hours. 
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Nomogram Observations 
Observations are made about the time course nomogram profiles for all assays throughout the 
patient cohort. Both C3 and C4 nomogram profiles display similar behaviour, reaching a 
minimum and starting recovery within the first 10 hours after the knife-to-skin (KTS) time. C3 
and C4 levels recover towards their pre admission values, whereas IgG remains diluted at the 
level to which it dropped immediately post operatively. The CRP assay does not show a 
response until approximately 10-12 hours, after which it increases considerably in a sigmoidal 
fashion before either decreasing reaching a plateau by 60 hours, see individual CRP profiles in 
Appendix 1. The contrast between C3 and C4 recovery and CRP production is stark, which may 
have important implications for recovery monitoring immediately post operatively. Some 
individual C3 and C4 time course profiles also show secondary consumption between 36 and 
60 hours, indicating a potential secondary consumption event which may itself be indicative of 
some C activity. 
Nomogram Discussion 
The C cascade is an enzymatic pathway that leads to the rapid cleavage of a number of 
proteins starting at the two lead proteins for the Alternative and Classical/Lectin pathways, C3 
and C4. The trigger is a rapid biochemical process with degradation of C3 and C4 occurring in 
minutes. This is in contrast to the delay in triggering the acute phase response in the liver and 
the de novo synthesis of the complex pentraxin CRP. Thus monitoring the consumption of C3 
and C4 is a possible alternative measure of the activation of the C cascade observed for all 
patients in the prospective cohort of abdominal surgery. Conventional C activation focuses on 
the detection of activation fragments such as C3dg, C4d, Bb, C3a and C5a, however here we 
investigate whether the consumption of the parent components (C3, C4, Factor B) could also 
be used to determine C activity. Conventional C activation monitoring for the same patient 
cohort is performed in Chapter 6. 
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The nC3 and nC4 nomograms show an initial change in concentration by ~20% consistent with 
the fluid regimen given on anaesthetic induction. A similar comparative drop is seen in the 
concentrations of IgG, which remains permanently diluted during the 60 hours of the trial time 
course. There are two explanations for the observed dilution: the circulating volume is 
increased by ~20% or the mass circulation volume is maintained and there is a mass loss which 
is not replaced. Blood loss during the procedure is reported at ~300 mL, or a ~6% decrease. IgG 
levels show no recovery during the stay in hospital. Similar observations have been made 
previously and are attributed to insensible losses and haemodilution [230; 231]. The IgG 
observations indicate there is a permanent mass loss from the circulating volume during the 
surgical procedure with the circulating volume returning to near-normal on closure. Addition 
of saline to the closed circulating system volume results in kidney-lead homeostasis in 20 
minutes to maintain the volume: the IgG appears to be lost to the patient for the duration of 
the trial time course. 
One of the roles of the C cascade is to remove dead and ischemic tissue and as such should 
respond to the degree of surgical trauma. In this cohort study and representative selection of 
45 procedures was undertaken with C consumption beyond dilution occurring in all but 5 
cases. Intuitively, laparoscopic procedures would be expected to produce less surgical trauma 
compared with open procedures, although this will still depend critically on the comorbidities 
of the patients concerned. The C response to damaged tissue would predict, theoretically, that 
the surface area of the damaged tissue in the wound is responsible for C3 and C4 consumption 
with a larger surface area supporting a greater surface concentration of stable C3 convertases 
which causes further consumption of C3. Hence there is an expected correlation between the 
surface area of damaged tissue in the wound, surgical trauma, and C3 consumption. Within 10 
hours from KTS the C3 levels are providing information on the degree of consumption and the 
C-compromised status of the patient. 
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The kinetic response of the cascade is fast showing a rapid decline in C3 and C4 concentrations 
within hours. Further, the minimum in C3 and C4 concentrations represents the balance in the 
rate of C consumption and the rate of de novo synthesis, predominantly in the liver [232; 233]. 
C3 and C4 start to return to admission levels much faster than the production of CRP in 
response to the surgical insult. The 10-hour window during which CRP synthesis is not 
observed with the conventional assays provided, C consumption and production provides 
information on the trauma from the procedure and the onset of recovery. The self-
normalisation of C3 and C4 to the levels present in the patient on admission is important and 
these levels are set by the patient’s homeostasis at a level that defines a patient-specific 
readiness of the innate immune system – a phenotype or personalised recovery metric. The 
normalisation allows the recovery of the entire cohort to be compared indicating the degree of 
C consumption and the time it takes to return to near pre-admission levels. 
The C3 and C4 nomograms suggest the idea of a normal recovery, consisting of an average 
expected level of consumption as a result of the surgical trauma and an average rate of 
recovery associated with the production of C3. Surgical procedures that are minimally invasive 
should allow the patient to recovery faster than average and those with extensive trauma 
would expect to be slower based on the 10 hour minimum observation. The rate of return to 
normal depends on the health of the liver and the rate of synthesis with the slope of the 
increasing trend suggesting the return of the innate immune system to levels at which it 
should be able to mount a successful response to a challenge. 
5.4.2 Complement Recovery Profiles: Stratified Nomograms 
The comparison between nomograms of patients with normal recoveries and patients who 
suffered complications or were readmitted shows a clear difference, most notably in the rates 
at which C3 and C4 is produced after the initial trauma of surgery, Figure 5.5, Figure 5.7 and 
Figure 5.6, Figure 5.8, respectively. Unfortunately, given the low number of patients in the 
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study, and the discrepancy in time points for those patients (caused by varying induction 
times, surgical times and varying times of sample collection) there is a large error associated 
with perioperative C3 and C4 responses. This makes it difficult to distinguish patients with 
normal recoveries from patients with complications at this stage. Nevertheless as there is, on 
average, a definite difference in C3 and C4 recovery rates post operatively between normal 
recovery patients and patients with complications, it is relevant to consider the necessary 
implications of this result. In the scope of developing this study for a larger trial, analysis like 
this will be improved greatly by increased patient numbers. 
 
Figure 5.5 Two comparative C3 consumption nomograms for patients with normal recoveries (black, 
with grey 95% confidence intervals) and patients who suffered complications (blue, with light blue 
95% confidence intervals, n=10). 
Patients who develop complications appear to suffer a greater initial surgical trauma, 
evidenced by a greater early drop in concentration, followed by a slower recovery towards the 
analyte level on admission. In order to quantify this rate, the recovery section (after the initial 
analyte level drop) for both normal and complicated recovery patient groups was isolated and 
fitted to a 1-exponential model, and the rates of production compared. For C3, Figure 5.7, the 
initial rate at which the protein was produced in patients with normal recoveries was 2.46 
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times faster than in patients who suffered complications. For C4, Figure 5.8, the difference was 
a factor of 1.73, also faster in patients with uncomplicated recoveries.  
 
Figure 5.6 Two comparative C4 consumption nomograms for patients with normal recoveries (black, 
with grey 95% confidence intervals) and patients who suffered complications (blue, with light blue 
95% confidence intervals, n=10). 
A number of conclusions can be suggested here. Firstly, given the slower rate of C3 and C4 
production (primarily synthesised in the liver [162]) in patients who developed complications, 
it may be suggested that this group of patients suffer from a slower homeostatic system, and 
therefore respond to immunological challenges slower than their normal recovery 
counterparts. The patients who recovered without complications may have faced similar 
immunological challenges, but their ability to combat the challenge was greater because of 
faster C3 and C4 production (and likely other proteins as well) and therefore they did not 
develop complications. The faster rate of synthesis may also give an indication of the state of 
the patient’s liver (and possibly their wider health) as this is the primary synthesis site for C3 
[162]. Secondly, the greater fall in C3 and C4 concentrations for patients who suffered 
complications, Figure 5.5 and Figure 5.6, suggests the trauma of surgery was worse for these 
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patients, which may also infer a likelyhood of developing secondary infections, as the trauma 
to the host was greater.  
 
Figure 5.7 C3 replenishment profiles (taken from the tail end of the C3 consumption nomograms, after 
the initial fall in concentration) for patients with normal recoveries (black) and patients who suffered 
complications (blue). The respective 1-exponential fits can be seen in grey and light blue. 
 
Figure 5.8 C4 replenishment profiles (taken from the tail end of the C4 consumption nomograms, after 
the initial fall in concentration) for patients with normal recoveries (black) and patients who suffered 
complications (blue). The respective 1-exponential fits can be seen in grey and light blue. 
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For comparison, very little difference can be seen in the comparative nomograms for IgG. Both 
sets of normal recovery patients and patients who suffered complications display very similar 
IgG response profiles, with both levels falling to nearly the same level, and remaining low for 
the duration of ~60 hours as is seen in Figure 5.9. 
 
Figure 5.9 Two comparative IgG consumption nomograms for patients with normal recoveries (black, 
with grey 95% confidence intervals) and patients who suffered complications (blue, with light blue 
95% confidence intervals). 
The notion of a ‘personalised recovery’ may allow us to scrutinise this result appropriately. 
That is, every patient will have their own individual benchmark rate of healthy recovery, and 
therefore any actual post surgery recovery of an individual may be compared, especially the 
relative rates. The immediate practical limitations of this theory are obvious. If this can be a 
useful metric to measure an individual’s recovery, an initial recovery profile should be 
obtained for each patient, against which their actual surgical recovery can be compared, which 
is unrealistic in the extreme. Therefore ideally, a biomarker (for example creatinine, which 
indicates healthy liver function) is needed that may give some indication as to what a 
particular patient’s healthy recovery rate should be. This could then be compared with the 
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actual rate of C3 and C4 recovery post-operatively to determine whether a patient is likely to 
suffer complications. 
Alternatively, it is suggested that an individual in vitro C activation profile may allow the 
investigator to assess the patient’s C system response preoperatively, which may then be 
compared with postoperative recovery rate of C components C3 and C4. This personalised 
immunological screening may provide an insight into the biochemical ability of a patient to 
recover postoperatively or combat an immunological challenge, and therefore patients may be 
identified as high or low risk before admission. 
Another hypothesis is that a patient’s length of stay may be predicted from a patient’s C 
recovery profile, possibly within 24 hours. It is shown that, on average, C3 and C4 levels 
recover to ~85% 60 hours postoperatively, and therefore a desired arbitrary percentage may 
be assigned by clinicians which can act as a biochemical marker that can support a clinician’s 
decision to discharge a patient from hospital. With regard to length of stay, given that a 1-
exponential growth model is assigned to C3 and C4 recovery, as few as three time points may 
be needed over a period of 12 hours post surgery to extrapolate the recovery profile and 
therefore predict when the level will recover to the desired percentage. Intuitively, such an 
arbitrary recovery measure may be linked with length of stay, and could form the basis of a 
hypothesis test for linking C3 and C4 recovery with fit-to-discharge criteria, which is currently a 
subjective decision for the on duty clinician.  
5.4.3 Complement Component Consumption 
The extent of C consumption across the cohort is shown in Figure 5.10 for the early-time 
minima in nC3 and nC4. Some patients show changes in C smaller than the indicated 20% 
dilution level and received only one unit of fluid on induction. All but 5 patients showed C 
consumption greater than the plasma dilution with similar nC3 and nC4 consumption minima, 
although there is some differential consumption between these two analytes. 
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Figure 5.10. Normalised C3 (blue) and C4 (red) consumption minima for all patients in the cohort: the 
dotted line shows a 1L haemodilution level. 20% dilution level indicated. 
Complement Consumption as a Measure of Surgical Trauma 
Mr. Ian Daniels, the surgical consultant who performed many of the procedures as part of the 
CPOP trial, has classified all procedures into six subsections on the basis of ascending 
procedure severity, Table 5.4, determined qualitatively. C3 consumption (nC3 minimum) is 
plotted against each procedure subclass for all patients, Figure 5.11. A correlation is observed 
between increasing C3 consumption and procedure severity, R = 0.922. 
 
Figure 5.11. Stratified C3 consumption based on procedure severity based on a set of procedural 
classes outlined by Mr. Ian Daniels. 
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Table 5.4. Surgical procedure classification according to severity by Mr. Ian Daniels. 
Class Procedure 
1 Sighting of ileostomy 
Closure ileostomy 
Defunctioning colostomy 
Transverse colectomy 
Parastomal hernia repair 
2 Laparoscopic sigmoid colectomy 
Laparoscopic total colectomy and ileostomy 
Elective laparoscoping right hemicolectomy 
Laparoscopic sigmoid colectomy 
Laparoscopic anterior resection 
Laparoscopic hemicolectomy and bilateral salpineo-oophrectomy 
3 Extended righ hemicolectomy 
Subtotal colectomy and ileostomy 
Extended right hemi-colectomy and anastomosis of ileum to colon 
Sigmoid colectomy and colostomy 
Open right hemicolectomy 
4 Anterior resection 
Completion protetecomy, adhesionolysism, ileional J pouch defunctionaing loop ilesotomy 
Abdominoperineal excision of rectum and end colostomy 
Laparotomy, protectomy, excision of anus 
Male Pelvic Clearance 
Anterior Resection 
Low Anterior Resection 
Proctectomy 
Anterior Resection 
Panproctocolectomy, anastomosis of ileum to anus 
Reversal Hartmann’s 
Anterior Resection +/- ileostomy 
5 Nephrectomy 
Laparoscopic nephrouretectomy 
Left open nephrourecterectomy 
Left laparoscopic nephro-ureterectomy 
Radical retropubic prostatectomy 
Radical Prostatectomy 
Radical prostatectomy 
Partial nephrectomy 
Elective total right nephrectomy 
Radical retropubic prostatectomy 
Radical prostatectomy 
Radical retropubic prostatectomy 
Radical prostatectomy 
6 Radical lystectomy, radical hysterectomy, left salpingo-oophrectomy 
Radical cystoprostatectomy ileal conduit formation and lymph node clearance 
Radical cyctectomy, ileal conduit, total abdominal hysterectomy, Bilateral salpingooophrectomy 
Abdominoplasty and epigastric hernia repair 
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The extent of C consumption could be therefore be indicative of the trauma suffered during 
surgery, and act as supporting evidence for the post surgical evaluation of the procedure. Once 
an average consumption value is established for a given procedure, an individual patient’s C 
consumption may be compared to assess the biochemical effect on the patient by the 
operation. C consumption between different types of surgery, such as laparoscopic vs. open 
could be compared, and therefore further surgical advances that cause less trauma to patients 
can be proven to do so. Continued collaboration with clinicians is in place to properly evaluate 
the merits of C consumption as a measure of surgical trauma. Potential stratification of 
patients based on C consumption to identify risk patients is hypothesised, and may lead to 
more efficient management of complications by reducing the time to rescue, as these 
identified patients may be monitored more carefully. 
5.4.4 Secondary Complement Consumption 
The idea of secondary consumption of C3 and C4 is of interest when monitoring the host’s 
response to infection following surgery. The initial fall in C3 and C4 concentration is probably 
entirely due to fluid administration under anaesthesia, however once concentrations have 
been replenished, any subsequent drop in concentrations may indicate cleavage of C3 and C4 
and therefore C activation for some reason. It is this event, which can happen well before CRP 
has completed its response to the surgery-induced inflammation, which could indicate an 
immunological compromise of the host. Additionally, any sign of C fragment activation markers 
increasing in concentration before the end of the CRP response to surgery could indicate 
similar immune response action. The reason for such an apparent immune response may be 
unclear, however it should be enough to indicate that the host is under attack, which has 
important implications for post-operative patient care. Patients who show this response could 
be identified as ‘at risk’ and therefore monitored more carefully by clinicians and nurses. 
Secondary consumption was observed for a number of patients, and will be considered using 
individual case studies in conjunction with C activation in Chapter 6.  
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5.4.5 CRP vs C3 and C4 Consumption Nomograms 
When compared with CRP production post surgical trauma, monitoring C3 and C4 gives a 
significant time advantage as it responds approximately 12-24 hours before CRP levels start to 
rise. Furthermore, this initial rise in CRP is in response to the initial surgery, and it is not until 
~48 post surgery that the trauma-induced CRP response plateaus. CRP therefore has very little 
predictive clinical value in the immediate postoperative period, compared with C here and 
previously with Interleukin-6 [234; 235]. This is due to the initial rise in CRP being merely the 
‘background’ signal related to the inflammation as a result of surgery, and due to its slow 
response, it will only be indicative of an infection well after the host is compromised. The time 
gap between C and CRP response is assessed using individual patient case studies in Chapter 6. 
5.5 Conclusions 
Complement activation during surgery has been observed previously associated with the effect 
of extra-corporal bypass circulation [176; 208; 236]. We have demonstrated C component 
consumption with all surgical procedures in our cohort which should produce C activation 
products. In addition, we have observed secondary consumption events which points to the 
potential for Complement to be a better marker of recovery than the conventional CRP levels 
which has been shown to correlate poorly with outcome in acute treatment scenarios in 
particular [237; 238]. The rapid response of C in the early 10 hour period immediately post 
operatively provides information of the degree of surgical trauma and the onset of recovery. 
We have also established that C components C3 and C4 recover slower in patients who go on 
to develop complications post surgery. C component recovery monitoring could provide an 
individual patient-normalised metric of recovery as supporting evidence for a clinician to 
discharge a particular patient. Recovery could be measured against the self-normalised innate 
system indicating a time at which the innate system has returned to an arbitrary percentage of 
its healthy levels indicating the patient is fit to discharge. Early recognition and potential 
identification of ‘at risk’ patients could reduce significantly the time to rescue which has been 
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shown to be beneficial in the management of the recovery in patients reducing in-hospital 
mortality rates. Furthermore the potential for predicting length of stay from early C recovery 
profiles could provide a valuable tool for hospital resource management. 
The potential for the C system to be used as a health monitoring mechanism must also be 
considered in light of C activation products, which forms the second half of the CPOP 
investigation, Chapter 6. 
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Chapter 6 
Complement Activation as a Biomarker  
of Secondary Complications in the Recovery  
of Patients from Abdominal Surgery 
6.1 Introduction 
Electrochemiluminescence assays for three Complement (C) activation markers, TCC, Bb and 
C3d, have been developed, Chapter 4. These assays can be used to measure overall C 
activation (C3d), Alternative (Bb) and Terminal pathway (TCC) activation. C components C3 and 
C4 have been shown to be consumed in the hours immediately following surgery, Chapter 5, 
after which the protein levels are replenished quickly; secondary consumption events and 
slower rates of recovery have been observed in patients presenting clinical complications.  
The C activation assay development in Chapter 4 also measured in vitro activation of these 
three products over a given time period, and the same study has been proposed in vivo. in vivo 
and in vitro C activation profiles will clearly differ, as the homeostatic systems in place in vivo 
will alter the rates of activation marker production. For example, small activation products 
produced in vitro will remain in solution for much longer, as they are not be subject to 
filtration by the kidney as would be the case in vivo.  
In order to evaluate C activation products as biomarkers for secondary complications in 
patients recovering from surgery, a clinical trial was conducted at the Royal Devon and Exeter 
(RD&E) Hospital. 45 patients undergoing elective abdominal surgery were recruited and blood 
samples taken over a perioperative time course. These samples were assayed for three C 
activation products, TCC, Bb and C3d, in order to monitor C activation intra and 
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postoperatively. These samples were also assayed for C3, C4, CRP and IgG for a separate C 
consumption and CRP-comparison investigation, Chapter 5. This chapter aims assess the 
potential for C activation to be a biomarker of secondary infection by monitoring C activation 
levels in patients undergoing abdominal surgery, with the hypothesis that C will react rapidly 
to any secondary complications, and therefore any activation postoperatively may be 
indicative of an immune system challenge. If successful, the C system can be used as a 
companion diagnostic for infections, or as a supporting evidence tool for clinicians to 
determine the immunological state of a patient.  
6.1.1 Complement Consumtion vs Activation 
Complement activation markers should, in theory, provide a much better indication of C 
activation activity, possibly even pathway specific activation because the background levels of 
the fragments should be small normally and activation should show a large rise. There are 
several C components that are individual to each pathway, and the enzymatic cleavage of 
these components upon activation can create large concentrations of cleavage products, or 
fragments or activation markers, very quickly. There are two main advantages to using C 
fragments, rather than the parent components. Firstly, during normal health, when the C 
system is idle, the fragments should be in a much lower concentration than when activated. 
This could provide a sensitive test for C activation, as the contrast between idle and activated 
fragment concentrations in the blood should be high. Secondly, the nature of the 
fragmentation process means neoepitopes are created, which can be used to isolate and 
detect fragmentation products only. These neoepitopes become exposed only when 
fragmentation occurs, as they are hidden on the native, parent component. Therefore specific 
assays can be developed for fragmentation products only. 
 
185 
 
Figure 6.1. Simplified overview of the Complement system showing the three activating pathways, key 
C pathway components (black text), activation products (red boxes), C3 convertases (green boxes) and 
C5 convertases (blue boxes). 
Many studies have been performed using C activation fragments as markers. TCC in particular 
has been used as C activation marker, [140; 142; 143; 239], and also the anaphylatoxins C5a 
and C3a [142; 239; 240]. Two of these investigations have even focused on C activation during 
and after surgery, particularly in cardiopulmonary bypass surgery looking at the effect of 
surfaces in the extra-corporeal circulation [142; 143]. Younger et al. concentrated on C 
activation in patients with severe sepsis, focusing on C components C3 and Factor B (fB), as 
well as fragments C5a, C3a and C4d [240]. They concluded that patients with community 
acquired sepsis show extensive C activation, particularly in the Alternative pathway. This is 
encouraging, and suggests that monitoring C system activation is a sensible metric to observe 
the development of sepsis post operatively. C activation has also been measured previously in 
relation to several other diseases including age-related macular degeneration [241], ischemic 
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heart disease [157], inflammatory disorders [242] and rheumatoid arthritis [144]. Figure 6.1 
shows a simplified overview of the C system, indicating in red some of the most popular C 
activation products cited in the literature. 
6.1.2 Detection of Complement Activation Markers 
As briefly mentioned above, the exposure of neoepitopes on C fragments upon activation 
creates a good opportunity to detect, specifically, individual C activation products without 
interference from the whole parent component. This has already been discussed in detail in 
Chapter 4, but will be revisited here.  
 
Figure 6.2. Schematic showing the origin of neoepitopes from parent components and the principle 
for a fragment immunoassay based on its neoepitope. 
Antibodies can be raised against neoepitopes on C fragments, allowing the development of 
immunoassays against these fragments, Figure 6.2, whereby the neoepitope antibody captures 
the fragment and some other labelled reporter antibody is used to generate the signal.  
Practically, it is very important that the fragmentation be stopped upon sample collection, as 
further in vitro activation of the C system has been shown to rapidly generate more 
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fragmentation products [149]. Therefore, to avoid post-sampling in vitro activation, it is 
important to collect blood samples directly into tubes containing EDTA at a final concentration 
of at least 10mM [147]. It is possible to measure C activation products C5a and C3a in urine 
[154; 155]. Both these fragments are excellent activation markers, and especially good 
candidates to measure from the urine as their masses are below the kidney filtration cut-off 
(45 kDa) [121], meaning they will be removed from the bloodstream into urine shortly after 
their production. However, urine samples would be unsuitable in a study looking for systemic 
complement activation during a given time course. Activation products in urine would mean a 
build-up of the target fragment over a given period of time, limited by the frequency of 
urination. Therefore, instead of obtaining a snapshot of C activation at a given time point, 
urine samples would only supply information regarding C activation over a given period of 
time. The level of activation over a given period of time will be determined, however given the 
rapidity of the C system it will not be possible to determine a well defined time course of 
fluctuating C fragment concentrations during activation. 
6.1.3 Current Perioperative Patient Monitoring 
Current patient monitoring post surgery is dominated by a range of simple clinical observations 
including heart rate, blood pressure and temperature, and a small list of biochemical markers 
such as C-Reactive Protein (CRP), creatinine, haemoglobin, white blood cell count and platelets 
[243; 244]. CRP and its limitations has already been explored in Chapter 5, and its continued 
use to monitor post operative well-being allows much room for improvement with regard to 
patient recovery monitoring, especially the early detection of the onset of sepsis [245]. A 
biochemical marker that could predict, presymptomatically, the development of secondary 
infection such as sepsis would be a significant improvement in post-operative patient 
monitoring and care. Effectively, it would create an presymptomatic early warning system for 
medical staff if a patient is likely to develop an imminent secondary infection, allowing them to 
take the necessary steps to treat the condition. Currently, an Early Warning Score (EWS) 
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system exists [246; 247; 248], and is based on monitoring a number of parameters including 
temperature, heart rate and blood pressure, producing a score from 0, normal, to 7, critical, 
based on the parameter output values and is presented in a simple chart. The score does not 
take account of any biochemical information and only triggers an intervention from a senior 
clinician. An example EWS sheet for a patient who developed sepsis is shown in Figure 6.3. It is 
suggested that an alternative EWS may be created that considers a range of interconnected 
biomarkers, and reports the developing state of a biological system within a patient, thereby 
monitoring and reporting on an individual’s biochemistry.  
It has been shown that a reduced ‘time to rescue’ [219] has significant implications for reduced 
‘in-hospital’ mortality rates, so such an early warning system would be desirable within the 
medical community. Therefore a biochemical marker that can monitor the development of 
infection, or indeed the activation of the immune system in response to infection, will be a 
significant advance that will supply clinicians with a supporting tool to effectively monitor 
patients for either a healthy recovery or the development of complications. 
The use of such a biochemical marker could be particularly useful in the early detection of 
systemic inflammatory response syndrome (SIRS) – a systemic inflammatory state diagnosed 
from the observation of at least two signs of inflammation [249] – or sepsis, diagnosed as such 
if a case of SIRS is coupled with a highly suspected infection [249]. Sepsis is extremely costly to 
the NHS, amounting to over £2 billion per year [218], and additionally causing the deaths of 
approximately 50,000 people. 
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Figure 6.3. EWS sheet for a patient who developed postoperative sepsis. The EWS is indicated by the 
white box, and shows and rapid increase of their EWS from 0 to 7 towards the end. 
Early Warning Scores
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6.1.4 Mechanisms for Complement Activation from Secondary Infections 
The major advantage in using the C system as a tool with which to monitor the host’s immune 
response is that it can be activated differentially. That is, different pathways can be activated 
by different immuno-compromising agents [57; 147; 228]. The Classical pathway is 
predominantly activated by antibody-antigen complexes, whereas the Alternative and Lectin 
pathways are mainly activated by microbial cell surfaces and microbial surface sugars 
respectively, as detailed previously in Chapters 4 and 1. Additionally the Terminal pathway 
may be activated by coagulation [138]. Therefore the ability to monitor in vivo C activation 
products unique to each pathway will provide information about differential C activity in each 
pathway, and will therefore allow the clinician to diagnose the response based on the known 
activators for that particular pathway. Figure 4.1 shows a simplified diagram of the C system, 
with specific focus on general pathway activators, major component, fragments, convertases 
and biological effects. There is a vast collection of C activators, which have been listed 
previously, Chapters 4 and 1, and will not be revisited here. However, the key assumption is 
that the C system can be activated differentially, and therefore the ability to detect individual 
C pathway activation may enable a clinician to make a differential diagnosis and determine the 
type of immuno-compromise to which the host is making a response.  
If a patient develops an infection postoperatively, his or her C system will be activated to 
combat the compromise, causing C fragments to be produced quickly (within a matter of 
minutes) [250] and in large numbers. If this fragment production can be monitored, clinicians 
can be provided with more information regarding the recovery and well being of their patients 
post operatively.  
6.1.5 Differential Complement Pathway Activation Markers 
Previously, three assays have been developed for TCC, Bb and C3d with a view to monitoring 
differential C activation in vivo. Surgical trauma and potential consequent infection can be 
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used to activate the C system in vivo, and therefore a cohort trial involving elective surgery can 
be used as the platform with which to monitor C activation in vivo. The markers chosen to 
conduct this study have been chosen for their exclusivity to their respective pathways: Bb and 
TCC for the Alternative and Terminal pathways respectively and C3d to show overall C 
activation. All three chosen activation products and their respective merits are discussed in 
Chapter 4, but will be revisited here in the context of differential activation. 
The collection of fragments referred to as ‘C3d’: C3b, iC3b and C3dg are all overall C activation 
markers, as they are fragments of the central C component, C3, Figure 4.1. Large quantities of 
C3 activation products (C3b) can be made quickly via the amplification loop along with Bb, a 
fragment from the Alternative pathway. However both these fragments together form the C3 
convertase, C3bBb, which is the key contributor to the amplification loop in the Alternative 
pathway, especially if it is stabilised by Properdin. Therefore, with production and 
consumption processes in place for both markers, the success of these markers as biomarkers 
of activation may be dependent on the time at which blood samples are taken. It is not 
possible to know exactly when a peak in concentration is expected in either fragment before it 
is reduced by convertase formation. This is encapsulated in the concept of a C fragment 
‘avalanche’, whereby the rise and fall of a C fragment may be over very quickly, especially 
within the initial pathways. Therefore an equally interesting observation from an in vivo C 
activation study will be the determination of a good time course from which to measure 
temporal activation.  
Finally, TCC production indicates C activation to completion via initiation from any of the 
pathways, as it is the final activation product in the cascade to be produced. Therefore 
production of large amounts of TCC in patients post operatively could well indicate the 
development of bacterial or viral infections, the exact target it is designed to attack in the form 
of MAC. TCC may not be as vulnerable to the avalanche effect, as it is the final product to be 
 
192 
made in the C system, and is not subject to any additional clearance processes, other than 
normal homeostatic breakdown.  
A review of previous C activation studies can be found in Section 4.1.1. 
6.1.6 Aims and Objectives 
This investigation aims to assess the potential for C activation as a biomarker of the early onset 
of complications during recovery following major abdominal surgery. A clinical trial was 
conducted at the Royal Devon and Exeter (RD&E) Hospital, from which 45 patients undergoing 
elective abdominal surgery were recruited and blood samples were taken from them during a 
time course before, during and after their operations – protocol and demographics presented 
in Chapter 5. These samples were assayed for three Complement activation markers; Bb for 
Alternative pathway activation, C3d for overall C activation, and TCC for activation in the 
Terminal pathway. Electrochemiluminescence assays were used to test the samples for the 
activation products, as developed in Chapter 4. C activation was then compared between 
patients who recovered normally and patients who suffered complications in order to establish 
whether C activation has potential to be a presymptomatic biomarker of secondary infections. 
6.2 Methods 
The CPOP trial, introduced in Chapter 5, included 45 patients undergoing elective abdominal 
and pelvic surgery. The blood samples collected were split into clot and EDTA stabilised plasma 
samples, the former being used to carry out the C consumption and CRP comparison 
investigation in Chapter 5. The EDTA-stabilised samples were collected in order to assay for C 
fragments. It has been reported that further in vitro activation of C can occur, and therefore 
fragment analysis is performed in EDTA plasma so as to minimise C component degradation 
[191; 227; 228], effectively freezing the C cascade at the time of taking blood. Bergseth et al. 
[167] have recently shown the effectiveness of EDTA in stopping the C cascade. They also 
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showed that it can be improved further by addition of Futhan, however the standard hospital 
collection protocol in the hospital only employs EDTA. 
Samples were tested for C fragments TCC, Bb and C3d using the electrochemiluminescence 
assays developed in Chapter 4, using the protocol laid out in Section 4.4.3. Each assay is based 
on a classic immunoassay whereby a neoepitope antibody is used to capture the C fragment, 
Figure 6.2, and another antibody, labelled with SULFO-TAG (MSD), serves as the detection 
antibody that generates the signal. The antibody pairs, sensitivity, inter and intra-assay 
reproducibility for each assay is outlined in Table 6.1. Calibration values are also provided for 
each fragment in Activated Complement Serum (ACS), used as the standard for all assays 
throughout this investigation. Values are therefore reported in ACS Units, pure ACS itself being 
assigned 106 ACS Units for each fragment. ACS and has been quantified for Bb and TCC at 55 ± 
6 µg/ml and 2.10 ± 0.04 mg/ml respectively, and its stability and suitability for its use in this 
study was review in Section 4.6. 
Table 6.1. Summary of all assays employed to monitor C activation within the CPOP trial cohort. From 
Chapter 4. 
Analyte Capture 
Antibody 
Detection 
Antibody  
(Labelled) 
Sensitivity ± 
Accuracy 
Intra-assay,  
Inter-assay 
Error 
ACS  
Calibration 
Value 
C3d Anti C3d neo 
(Quidel) 
Anti-C3b clone 
C3/30 (Dr. Claire 
Harris, Cardiff) 
0.864 ACS 
Units 
8.8% 
3.6% 
C3bc in ACS ~ 
1800 AU/ml 
[167] 
Bb Anti Bb neo 
(Quidel) 
Anti-fB 
clone JC1 (Dr. 
Claire Harris, 
Cardiff) 
995 ACS Units 
(54.7 ng/ml) 
13.7% 
3.9% 
55 ± 6 
µg/ml. 
TCC TCC mAb, clone 
aE11 (Hycult 
Biotech) 
aC8 (Dr. Claire 
Harris, Cardiff) 
1.11 ACS Units 
(2.32 ng/ml) 
18.2% 
5.7% 
2.10 ± 0.04 
mg/ml 
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6.3 Results 
The time course profiles for each of the three assays did not follow a general pattern, as with 
the C3 and C4 time course profiles in Chapter 5. Therefore a ‘nomogram’ analysis was not 
suitable for this investigation, and the results therefore remain largely descriptive and 
comparative. The results from each assay will be considered in turn. All time courses are 
complete for the C3d assay, although 8 entire time course profiles are missing for the TCC 
assay, as the values obtained fell below the detection limit. Of the remaining time course 
values, 96% were within the detection limit and remain in the overall time course. 98% of Bb 
time course values are intact, with the exception of a few individual time points which fell 
below the detection limit of the assay. 
6.3.1 C3d Activation 
The majority of observations regarding the fragment analysis was dominated by ‘peak’ 
analysis, after it was observed that many time course profiles contained at least one spike in 
fragment concentration, usually only for one time point. This is consistent with the ‘cascade 
avalanche’ theory, whereby the formation and subsequent consumption of a particular 
fragment may happen very quickly. A peak is defined as a value that is two times greater than 
the average time course value for a particular patient. For all time courses, 33 out of 45 
patients displayed a peak during the time course, with 7 of the 33 having two points that 
classified as peaks. Seven out of the ten patients who developed complications show a peak in 
C3d. The average concentration of all C3d peaks was 8.1×104 ± 7.0×104 ACS Units, compared 
with the average concentration on admission of 2.0×104 ± 3.7×104 ACS Units. 
Further investigation of the C3d activation events showed that there was some stratification 
regarding the peaks in C3d concentrations. Some patients displayed early peaks, either during 
or very shortly after the surgical procedures, and others much later – after 12 or even beyond 
24 hours following the operation. Four patients showing typical early C3d peaks are shown in 
Figure 6.4 and similarly four typical time course profiles for late peaks are shown in Figure 6.5. 
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Three patients showed both early and late peaks. Four time course profiles with no C3d peaks 
are shown in Figure 6.6 (for comparison the time and concentration axes are consistent on all 
three graphs). 
 
Figure 6.4. Graph showing early C3d peaks for patients CPOP0010 (black), CPOP0015 (red), CPOP0020 
(green) and CPOP0035 (blue). 
Figure 6.4 shows C3d activation profiles for 4 patients, all displaying early concentration spikes. 
CPOP0015, CPOP0020 also show secondary activation peaks after 36 and 24 hours 
respectively. Very noticeable is the quickness with which the C3d concentrations return to 
their respective preadmission levels, which indicates rapid clearance post production. 
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Figure 6.5. Graph showing late C3d peaks for patients CPOP0019 (black), CPOP0021 (red), CPOP0022 
(green) and CPOP0042 (blue) 
Figure 6.5 shows C3d activation profiles for 4 patients who did not present an initial 
concentration spike, but did show a peak in C3d concentrations after 12 hours, the latest peak 
recorded ~30 hours post operatively. Once again C3d concentrations return to their 
preadmission values after a concentration spike, however the timescales associated with this 
return to normal in this case may not be representative of the true situation due to the lower 
sampling frequency compared with the activation profiles in Figure 6.4. 
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Figure 6.6. Graph showing no C3d peaks for patients CPOP0007 (black), CPOP0012 (red), CPOP0023 
(green) and CPOP0028 (blue) 
Figure 6.6 shows stable C3d levels for all patients, remaining constant throughout the time 
course of 60 hours, especially relative to the concentration peaks seen in Figure 6.4 and Figure 
6.5 (note y-scale). In this instance it may have been possible that the spike in C3d 
concentrations occurred in between sampling points, and therefore it is not seen. Another 
explanation may be that these patients simply did not show C activation, and may be 
considered to have an inactive C system, possibly due to the absence of some cascade 
components. 
All C3d peaks are collated and shown in Figure 6.7. It was expected that all patients would 
show C activation, however in this instance 73% of patients presented a peak in C3d. As seen 
from the rapid concentration spikes in Figure 6.4, it may be possible that the patients who did 
not present C3d peaks did so in between sampling points, and therefore the spike may not 
have been seen. 
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Figure 6.7. C3d concentration peaks for all 45 patients across the cohort. (Note ‘Patient Number’ does 
not correspond to the number of patients in the trial. It is the number assigned to patients as they 
were recruited) 
6.3.2 TCC activation 
TCC values for the majority of time course profiles remained relatively constant, with very few 
time course profiles displaying a significant rise or fall in analyte levels. The values were also 
low, often falling just above the detection limit for the assay. In total 9 patients displayed TCC 
peaks as in the C3d peak analysis, 20% of the cohort. The average relative ratio of the TCC 
concentration peaks to the values on admission was a factor of 9.1. Only one of these peaks 
correlated with a patient that developed a complication, CPOP0050. 
6.3.3 Bb Activation 
The concentration of Bb also remains fairly constant throughout the time courses for the 
majority of patients. For comparison only 10 patients (22%) display concentration peaks where 
values were greater than twice the average of the time course it is in. The same patient, 
CPOP0050 is the only one from those that developed complications that shows a peak in Bb. 
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6.4 Discussion 
C activation assays were performed for C3d, TCC, and Bb on plasma samples from a 45-patient 
time course study. These markers are well documented in the literature as being good markers 
of C activation, and therefore they were implemented here. Samples were collected as EDTA-
plasma, which has been well documented [57; 147; 149; 228] to stop the cascade and prevent 
any further in vitro formation of C activation products. 
From the conclusions drawn in Chapter 4, the TCC and C3d assays worked well, yielding a 
dynamic range of ~3 orders of magnitude. With a dynamic range of <2 orders of magnitude, 
the Bb assay did not perform as well. These assays were employed to measure C activation 
among a cohort of patients undergoing elective abdominal surgery. Observed changes in TCC 
and Bb concentrations throughout the measured time course were small within individual time 
course profiles, with the absence of any regular pattern in biomarker behaviour. However a 
large range of concentrations was observed for both analytes on admission throughout the 
patient cohort: TCC, 505 ± 1078 ng/ml cf. 0.06 ± 0.03 µg/ml [157] and Bb, 0.429 ± 1.45 µg/ml 
cf. 0.20 ± 0.04 µg/ml [157], Figure 6.8. Absolute concentrations of C3d could not be 
determined, explained in detail in Section 4.5.3. 
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Figure 6.8. Concentration distributions (in ACS Units) of all three activation markers assayed; A, C3d, 
one value not shown (2.37×10
5
), B, Bb, one value not shown (1.78×10
5
) and C, TCC, two values not 
shown (1.82×10
3
 and 2.27×10
3
). 
The concentration distribution profile of all three fragments is consistent with expected levels 
on admission. The C system should be idle in the majority of patients, however it is likely that 
some patients will exhibit an activated C system on admission, either due to the disease they 
are receiving surgery for, or another undiagnosed condition. Therefore a distribution that is 
shifted towards the lower concentration range is expected. 
The low concentrations of both Bb and TCC in the samples, especially the latter, made it 
difficult to measure the analytes accurately, as they presented a low signal below the 
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calibration curve. Initial assessment suggests the low concentration of both of these analytes 
in plasma therefore has negative implications for their use as a predictive biomarker for C 
activation. However it should be stressed that the potential for TCC to be a C activation marker 
should not be easily dismissed.  
TCC has a half-life in plasma of order 24 hours [251], and therefore systemic C activation 
leading to TCC formation may be detected by daily sampling. The time course designed for this 
clinical trial did not continue monitoring patients until they developed complications, which 
was days after the time course stopped in some cases. Once secondary infection develops 
postoperatively, a large increase in TCC levels will be observed, and may be detected 
systemically using daily routine blood samples. Therefore, in this case, the low native 
concentration of TCC in blood is in fact helpful, as any great increase in TCC levels will be 
indicative of systemic C activity. The surgical trauma almost certainly produced high amounts 
of TCC local to the surgical area, however no patients developed a systemic condition which 
would warrant the increase of TCC concentrations from their initial low levels after only 60 
hours of monitoring. In a private communication with Prof. Tom Mollnes about the TCC 
activation data, it was suggested that noticeable increases in systemic TCC concentrations 
would not be seen unless the trauma of surgery was extremely large, for example major open 
heart surgery. This view is supported in several previous cardiopulmonary studies [252; 253; 
254] and possibly explains why such little activation of TCC was observed here. 
The C3d assay worked well as a C activation marker. Activation was observed in 33 out of 45 
patients (73%), meaning that in the remaining 12 patients there was either no C activation, or 
the activation avalanche was missed with the time points of the samples taken. 7 out of 8 C3d 
time course profiles for laparoscopic procedures showed a peak in C3d, indicating that more 
minor procedures also cause C activation. The average C3d value on admission for all patients 
was 2.0×104 ACS Units, and the value of the observed peaks was more than a factor of 4 
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greater at 8.5×104 ACS Units. If C3d had been used as a predictor for complications in this 
study using the peak metric, it would have truly predicted 7/10 complications. However, it 
would also have identified a further 26 who did not develop complications – a high false 
positive rate. 
Consideration should be given to the position of C3d and TCC within the C cascade. C3d is an 
upper cascade activation marker, whereas TCC is a lower cascade activation marker indicating 
C activation to completion. Therefore the lack of TCC activation may be indicative of the lack of 
activation conversion between C3d and TCC. In other words, a low fraction of patients 
converted upper cascade activation to complete C activation. All 9 of the TCC profiles that 
displayed a peak also showed a peak in C3d, as expected, however that means only 9 of the 33 
C3d patients who showed C3d activation presented activation to completion by TCC formation. 
This suggests C3 fragmentation is required to cause TCC formation, as expected, however 
upper cascade activation does not necessarily lead to TCC formation, and therefore complete C 
activation. The long half-life of TCC [251] further indicates that the lack of TCC formation 
suggests lack of activation to completion rather than clearance in between sampling points. 
Sample Collection Protocol 
The collection of samples as EDTA-containing plasma is well advocated throughout the 
literature [147; 149; 166]. This investigation employed the same protocol, collecting blood 
samples directly into EDTA-containing tubes, and then centrifuging the blood samples to 
obtain EDTA-plasma. The absence of any unexpected concentration rises in any of the patient 
time course samples indicates that the collection protocol was suitable, and supporting 
evidence for EDTA-stabilisation of fragment concentrations can be seen in the study by 
Bergseth et al. [167]. Their study also demonstrates that the addition of Futhan increases 
fragment stability even further, however this is impractical for sample collection in a hospital 
ward, as the standard collection tubes contain EDTA only.  
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6.4.1 Complement Fragment Clearance 
As mentioned before, many of the patient time course profiles did not present a peak in a 
certain analyte’s level (11 time course profiles failed to show a peak in any of the fragment 
concentrations). There are two possible explanations for this. Firstly, given the short time span 
in which many of the peaks were observed, it is possible that for these patients the 
concentrations spike simply went undetected. That is, the concentration spikes possibly 
occurred in between blood sample time points, and therefore the event goes unnoticed. The 
second explanation could be that these patients have an idle, unresponsive C system, which 
may be indicative of a weak immune system. Again, the small number of patients involved in 
the trial means this inferred C inactivity cannot be proven, but it is an important consideration, 
especially if the trial is to be expanded to address further questions such as this. 
Complement deficiencies must also be considered briefly, for if there are components of the 
cascade with low concentrations or missing completely, then the cascade function would be 
compromised. Many deficiencies in C components have been reported and have been linked 
with clinical disorders or accentuated susceptibility to infections [255; 256]. However such 
deficiencies are extremely rare, and therefore consideration of C deficiencies in a trial of this 
size should be limited.  
6.4.2 Using the Complement System Clinically – CPOP Care 
As the CPOP clinical trial yielded two parallel investigations, the C consumption (Chapter 5) and 
the C activation studies (Chapter 6), they will both be discussed here to address the question 
of whether monitoring the C system perioperatively has positive implications for patient 
recovery care. In addition to time course profile data for CRP, IgG, C3, C4, TCC, C3d and Bb, all 
other results from routine tests ordered were recorded and collated into a database, Appendix 
1. This included a host of tests and observations that form part of regular patient monitoring 
perioperatively. 
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Monitoring Recovery 
The starting point is that all patients will have an individual C activity measure, comprising 
initial component levels and C activation potential. The basis for the ‘CPOP care’ hypothesis is 
that all homeostatically controlled variables (in this case C component and fragment 
concentrations) must return to their preoperative values following complete recovery. 
Therefore the rate and status of recovery may be measured by monitoring a variety of 
measures, including immuno-components. 
Currently the clinical standard for recovery monitoring is comprised of a list of clinician 
observations and checkpoints, with a limited role of biochemical markers mainly limited to 
creatinine and CRP. As we saw in Chapter 5, CRP is slow to respond to an immunological 
challenge, and therefore a more responsive marker would be preferred. The immediate 
postoperative synthesis of C3 and C4 could therefore provide a better indication of a patient’s 
recovery status. It is not suggested that this should be a marker to replace the current status 
quo of patient monitoring, however it could be an additional test to supply the clinician with 
supporting evidence if they decide to discharge or keep a patient in hospital, for example. 
Not only may it be a good addition for patient care, the initial rate of biochemical recovery, as 
measured by C3 and C4 levels returning to their preoperative levels, for example, may be of 
use in predicting a patient’s length of stay postoperatively. Therefore stratification of patient 
recovery can also be attempted, whereby patients can be classified according to their initial 
rates of recovery postoperatively. This has significant implications for hospital ward 
management by optimising the use of the available resources. Early identification of patients 
who are at risk of developing infections will also help in this regard, as resources can be 
channelled more effectively.  
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Developing a Testable Hypothesis for further Investigation into CPOP Care. 
There have been several unexpected results gained from the CPOP trial. Firstly, the consistent 
initial C3, C4 and IgG dilution was a surprise, however the additional C consumption was 
expected. The continued depletion of IgG levels was also not foreseen. The apparent C system 
inactivity in some patients, as evidenced by the lack of fragment peaks, also warrants further 
questioning, however it may be explained simply by a low frequency of sampling points, as 
activation could have occurred and been missed by the sampling regimen. The TCC assay 
performed very well, and although few patients presented with TCC peaks, the assay should be 
included in an expended study. TCC would be especially useful to monitor the levels of 
systemic TCC in patients with SIRS or sepsis by employing an extended time course, as TCC 
production would be expected from a severe systemic immunological challenge, as mentioned 
in the private communication with Prof. Tom Mollnes. 
Crucially, to confirm or refute any of the hypotheses made in this study, any future trial will 
have to sample a far greater number of patients, all ideally undergoing a limited subset of 
procedures. Although the surgical procedures in this study are relatively comparable, further 
consistency with regard to the surgical procedures will remove some uncertainties, especially 
with regard to C consumption and subsequent recovery of the components. For example 
comparison between laparoscopic and open surgical procedures can introduce questions with 
regard to the degree of severity of the procedure, and therefore comparison between C 
consumption levels may not be valid. Although it was useful in this study to observe the 
difference between the two procedures, any future trial should employ a greater surgical 
procedure consistency in order to focus on stratified recovery profiles only. Although unknown 
variables such as co-morbidities cannot be controlled, experiment design can, and therefore 
known variables should be standardised as much as possible. A higher number of patients is 
required to obtain a meaningful number of patients who develop secondary infections so they 
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can be compared with the patients who recover normally. Comparing with the current size of 
the trial, to obtain data for 45 patients who develop complications would require a cohort of 
approximately 205 patients in a similar study with a similar complications rate. Ideally the 
number should be as high as possible to make the data obtained statistically significant. 
6.4.3 Case Studies 
Given the low number of participants in the prospective cohort, there is only a small group of 
patients who developed complications. It is appropriate to consider individual case studies, 
and compare their clinical data against surgery outcomes in light of all three fragments 
together, especially compared with their C3 and C4 time course profiles – a full C analysis. 
Where appropriate, comparison should also be made with the CRP response. 
CPOP0015 – Secondary Complement Consumption, Figure 6.9 
Figure 6.9 shows selected the clinical time course data for patient CPOP0015. Initial 
consumption of both C3 and C4 can be seen up to 12 hours, after which a partial recovery 
synthesis of both proteins is followed by a secondary consumption event from 38 hours, Figure 
6.9A. Fragment data, Figure 6.9B shows an early spike in C3b concentrations followed by a 
rapid return to admission levels within 12 hours. After 36 hours a slower, smaller activation is 
observed up to 72 hours. The concentration of both other fragments, Bb and TCC, remain 
largely constant throughout the duration of the time course. Figure 6.9C shows the time 
course profiles for CRP and IgG, the latter displaying a large initial dilution, followed by a slight 
recovery up to 38 hours, after which another large drop in concentration is seen. CRP 
concentration rises as expected from an elevated initial value of 27 mg/L, but crucially, is then 
falls after 36 hours, indicating a decline of the acute phase response and therefore a return to 
normal health. The patient’s basic observations of heart rate and temperate can be seen in 
Figure 6.9D, which forms a vital part of postoperative patient monitoring, and is two of the 
parameters monitored for the EWS. Note that the time scale for both these observations 
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continues well beyond the timescale for the other markers, up to approximately 170 hours. 
Heart rate shows a sharp initial rise associated with surgery, but then continues to display an 
elevated level for most of the continued time course. Temperature is normal for the majority 
of the time course, however the rise to ~38°C at 144 hours satisfies the temperature criteria 
for the definition of SIRS or sepsis [249]. 
 
Figure 6.9. Clinical time course data for patient CPOP0015. A, concentrations of C3 (black) and C4 
(blue). B, activation fragment time course profile for C3d (black), Bb (blue) and TCC (red). C, time 
course profiles for CRP (black) and Total IgG (blue). D, standard observations, temperature (black) and 
heart rate (blue). 
Patient CPOP0015 was a 73 year old male who also received an anterior resection after being 
diagnosed with colorectal cancer. The patient’s CRP level on admission was 27mg/L. 
Comparison between the C components C3 and C4, and CRP shows that C3 and C4 has 
responded to the initial trauma of surgery just as CRP begins its response, which does not 
conclude until 38 hours. After this time the concentration of all three analytes fall, indicating 
opposite outcomes. As mentioned, a reduction in CRP concentration suggests the recession of 
the acute phase response to the initial surgical trauma, and therefore suggests the patient is 
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returning to normal health. Conversely, C consumption may suggest complement activation, 
especially if coupled with the fragment C3d, which begins to rise after 36 hours. This patient 
went on to develop sepsis 6 days after surgery, consistent with the temperature rise to 38°C at 
144 hours, and ultimately died a further 8 days later following additional complications. 
Therefore, for patient CPOP0015, C recovery and the secondary consumption event suggests 
that this patient had not returned to preadmission levels of health 72 hours postoperatively, 
and warranted heightened attention from medical staff. CRP concentrations continued to 
decline for three consecutive (third not shown) time points after 36 hours, which is not 
indicative of the imminent onset of sepsis that was to come. Crucially, the information 
provided by C recovery is observed considerably earlier than any of the other parameters 
available. 
CPOP0003 – Complement Activation 
Figure 6.10 shows the analyte concentration and basic observations time course data for 
patient CPOP0003. The patient experienced a large initial consumption of C3 and C4 levels, 
after which the levels replenished quickly, followed by some secondary consumption of both 
proteins from 8-12 hours, after which C recovery continued, Figure 6.10A. In terms of 
activation markers, CPOP0003 is exemplary with regard to what was expected from the C 
cascade activation markers. C3d and Bb, present earlier in the cascade than TCC, peak first – 
around 6 hours post induction, Figure 6.10B. Although TCC is seen to increase between 9 and 
12 hours, it is not until 28 hours that a peak is seen in TCC, suggesting a lag period of 22h from 
initial C activation stimulus to cascade completion. This patient presented with elevated CRP 
levels on admission, which then continued to rise for 50 hours postoperatively, Figure 6.10C, 
and their IgG response profile was similar to C3 and C4, which is inconsistent with the rest of 
the patient cohort in this study. The patient’s standard observations (temperature. heart rate) 
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were normal, with the exception of a slightly raised heart rate towards the end of her stay in 
hospital, Figure 6.10D. 
 
Figure 6.10. Clinical time course data for patient CPOP0003. A, concentrations of C3 (black) and C4 
(blue). B, activation fragment time course profile for C3d (black), Bb (blue) and TCC (red). C, time 
course profiles for CRP (black) and Total IgG (blue). D, standard observations, temperature (black) and 
heart rate (blue). 
Patient CPOP0003 was an 87 year old female who received an anterior resection after being 
diagnosed with colorectal cancer. The procedure severity was classified as Class 4 of 6 by Mr. 
Ian Daniels, the surgical consultant on the CPOP trial. Given the severity of this procedure 
classification by Mr. Daniels, it is expected that the physiological fingerprint evidenced by C3 
and C4 consumption would be large. Indeed, a very large initial drop in C3 and C4 levels is 
observed, however the concentrations of these proteins are replenished rapidly, suggesting a 
fast recovery. The activation markers Bb and TCC reflect the consumption in C3 and C4, 
suggesting C activation as a result of surgical trauma in this instance, in particular Alternative 
and Lytic pathway activation. This patient suffered no complications and was discharged 8 days 
after surgery, a decision consistent with the C recovery of this patient. 
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CPOP0001 – Differential C3 and C4 recovery and comparison with IgG 
Figure 6.11 shows the time course variations for C3, C4, IgG and CRP for patient CPOP0001. In 
the first ten hours the C3 and C4 levels decrease with an initial dilution consistent with the 
anaesthetic fluid regimen resulting in ~20% decrease in the circulating concentration of C3 and 
C4, Figure 6.11A. The C3 and C4 show a minimum after 2 hours from induction, where t=0. C3 
and C4 synthesis starts immediately so that within the 60 hours of the trial time course their 
concentrations have returned towards the levels on admission, however C3 recovery at 50 
hours is substantially lower than C4. The expected rise in CRP associated with the surgical 
incision trigger of the acute phase response is shown in Figure 6.11C. The de novo synthesis of 
C3, C4 and CRP may be contrasted with concentrations of total IgG, Figure 6.11C, blue, which 
shows an initial decrease associated with the 1 L fluid administration on induction and remain 
at or below the post-induction levels for the 60 hours of the trial time course. The time point 
for IgG at 34 hours is likely to be an anomaly. The basic observations of temperature and heart 
rate, Figure 6.11D are normal, aside from the low temperature early on, possibly associated 
with measurement error, and the initial spike in heart rate that can be attributed to the 
surgical procedure.  
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Figure 6.11. Clinical time course data for patient CPOP0001. A, concentrations of C3 (black) and C4 
(blue). B, activation fragment time course profile for C3d (black), Bb (blue) and TCC (red). C, time 
course profiles for CRP (black) and Total IgG (blue). D, standard observations, temperature (black) and 
heart rate (blue). 
An interesting observation is the difference between C3 and C4 recovery, Figure 6.11A. 
Apparent C3 consumption without C4 consumption may imply C activation via the Alternative 
pathway, which does not require C4, indicating the type of challenge the host is responding to. 
However very little C activation is shown by the C activation fragments for this patient to 
confirm activation. Although this patient recovered normally and was discharged after three 
days, cases of differential C3/C4 consumption pose interesting questions about individual C 
activity, as on average, both proteins respond the same across a patient cohort, meaning that 
differential C3/C4 activation for an individual patient is unusual. The contrast between C 
components and IgG is more typical of the patient cohort (bar the anomaly), as seen by the 
nomogram analysis in Chapter 5. 
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CPOP0025 and CPOP0039 – CRP vs Complement Response 
The time course profiles of CRP, C3 and C4 are shown in Figure 6.12 for a laparoscopic 
procedure, Figure 6.12A, CPOP0039 and an open procedure Figure 6.12B, CPOP0025. In the 
less invasive laparoscopic procedure the patient shows a rapid return to near admission levels 
for C3 and C4 within 12 hours, whereas the CRP levels for this patient showed no significant 
change during this period. The concentration of CRP then increased to the comparatively low 
maximum of 28 mg/L before starting to decrease. The patient remained in hospital with near-
normal levels of C before being discharged after 100 hours. CRP is an extensively studied 
marker for inflammation, and its relatively low maximum concentration in this case is likely to 
be related to a low amount of inflammation during surgery which is expected from the 
laparoscopic procedure [257; 258; 259]. However, the maximum in CRP is not reached until 24 
hours, and a decrease is not seen until 34 hours, which indicates a reduction in inflammation. 
C component levels, on the other hand, are replenished in this case within 12 hours and 
provide a much earlier indication of the low trauma associated with this surgical procedure, as 
was the case with CPOP0003, Figure 6.10. Therefore C recovery profiles provide much faster 
information to the clinician with regard to patient recovery postoperatively. 
Figure 6.12B shows a patient with a more complex procedure, (radical cystectomy, radical 
hysterectomy and left-salpingo-oophrectomy, lasting 190 minutes) which presented with 
greater than 50% C consumption within 10 hours of the procedure, indicating severe surgical 
trauma. The patient showed a slow but consistent recovery in C3 and C4 levels over the first 72 
hours of their time course profile. The patient presented with a peak in CRP levels after 38 
hours although the patient still showed significant C consumption. The CRP peak >80mg/L 
suggests a greater acute phase response compared with CPOP0039, as would be expected 
from the greater surgical trauma and tissue damage, which is also consistent with the large C 
consumption shown which reached a minimum before 10 hours. Thus, even in the largest C 
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consumption within the cohort, C consumption can still provide clinicians with recovery 
information well before CRP has finished its initial response, the offset in this case being ~24 
hours. 
 
Figure 6.12. CRP and C3 time course profiles for two patients: A CPOP0039 Diagnosis colorectal cancer, 
Laparoscopic right hemicolectomy, Age 75, duration of surgery 115 minutes, length of stay 99 hours; B 
CPOP0025 Diagnosis of Bladder Cancer, radical cystectomy, radical hysterectomy and left-salpingo-
oophrectomy, Age 83, duration of surgery 190 minutes, length of stay 386 hours. Recovery risks based 
on C3 consumption are indicated. CPOP0039 showed secondary CRP production 128 hours 
6.5 Conclusions 
The results from the initial, 45-patients CPOP clinical trial are promising, yielding a number of 
unexpected outcomes which warrant further investigation. The preliminary results from the C 
activation assays did not respond as expected, with the exception of C3d which showed both 
rapid and late C activation. The low TCC concentrations obtained is consistent with values 
previously reported in the literature, as shown in Figure 4.3. 
Regarding the presymptomatic identification of patients who may be at risk by using C 
fragments, it is clear that a larger patient cohort is required to increase the numbers of 
patients suffering complications, and the surgical procedures can also be standardised. This 
will allow significant statistical analysis between patients who recover normally and patients 
who suffer complications. Furthermore, the usefulness of TCC as an indicator for SIRS or sepsis 
can be investigated by lengthening the time course over which blood samples are taken. Blood 
samples will need to be taken with relatively high frequency, as TCC can be generated quickly 
by the enzymatic cascade.  
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A study of possible C inactivity could also be designed, whereby blood samples are taken with 
a very high frequency early on in the time course, during and immediately following surgery. If 
some of the time course profiles in this study did indeed miss the C3d concentration spike, a 
study with a higher frequency of blood samples will stand a greater chance of detecting the 
peak. Such C inactivity may render an individual more vulnerable to an immunological attack, 
and therefore this inactivity may then be compared between patients who suffer 
complications and patients who follow a normal recovery.  
6.5.1 CPOP Care Conclusions 
C consumption and synthesis profiles of both C3 and C4 appear to be highly personalised 
markers of recovery, although a much larger patient cohort is required to test the hypothesis 
for statistical significance. There are a number of hypotheses which can be derived from the 
prospective cohort study. The degree of C3 consumption is correlated to an empirical 
classification of surgical trauma on the basis of severity – a successful trial here could prove C3 
consumption to be a biomarker of surgical trauma. C response profiles are also considerably 
faster than CRP in reporting information regarding the patient’s recovery postoperatively – C 
biomarkers may be better and more personalised measure of patient recovery. A combination 
of C metrics such as percentage consumption, postoperative synthesis rates and an arbitrary 
recovery percentage may be combined to assess their performance against the existing EWS 
system which may then be augmented by these markers to provide a biochemical element to 
the score. The C panel would then be a biomarker of infection or secondary complications. For 
all of these hypotheses however, a larger trial is required to assess significance and most 
importantly to establish clinical utility.  
The combination of clinical observations and new C biomarkers has potential to change the 
biochemical monitoring of patient recovery. Simple correlations between rising parameters 
such as temperature and blood pressure may need to be analysed in a larger algorithm to 
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provide a significantly better informed clinical decision. Trends and significance tests of a 
systemic view of an individual’s health appear very promising from the profile of C critically 
addressing a personalised recovery, perhaps leading to a more general stratification of 
outcomes against which healthcare resources can be marshalled. The multi-biomarker panel 
may provide pre-symptomatic diagnoses which will not be evident clinically and would require 
a change in the intervention strategy from clinicians if the full potential of CPOP care is to be 
achieved. 
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Chapter 7 
Conclusions and Future Work 
George Poste has written about the ‘fragmented research on disease’, and notes how although 
there are over 150,000 papers documenting thousands of different biomarkers for disease, 
only about 100 biomarkers are routinely used in the clinic [260]. He calls for the replacement 
of investigator-initiated research by a collaborative ‘big-science’ approach comprised of 
industry and multi-disciplinary scientific experts, including engineers, statisticians and experts 
in clinical trial design. From the point of view of the university researcher it is imperative to 
initiate collaboration, drawing together a range of expertise and consulting with scientific 
funding and governing bodies to bring potential biomarkers to the regulatory authorities such 
as NICE or the FDA for approval. 
The cohort study marks the beginning of a long pathway to the validation of the Complement 
(C) system as a biomarker panel to be implemented as a companion diagnostic or a recovery 
monitoring tool. Monitoring of C activation in relation to disease states is well studied and has 
been discussed, with many infections and inflammatory disorders shown to stimulate the C 
system. The differential manner in which the C system is activated has promising potential for 
stratifying patients who present with C activation into different disease states, which has 
significant implications from the point of view of targeted disease diagnosis and treatment. 
However, the current state of the field is that individual C components and fragments are 
monitored to establish activation, but it is suggested here that a panel of C system proteins are 
used to obtain a dynamic interaction profile between the components. This will provide a 
better understanding of C activation in relation to disease states, and may allow a more 
specific diagnosis of disease based on the C component interaction profile.  
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7.1 Thesis Conclusions 
Complement 
In this thesis, three working assays for C components TCC, Bb and C3d have been developed 
and employed to monitor C activation in a prospective cohort clinical trial for patients 
undergoing major abdominal surgery. Bb and TCC indicated low levels of C activation across 
the patient cohort, however a substantial rise in C3d concentrations indicated significant C 
activation in 73% of patients during the observed time course. Additionally, by monitoring 
levels of C3 and C4 it was demonstrated that consumption of the C system may be used to 
stratify surgical trauma and monitor subsequent recovery. Preliminary analysis was performed 
to establish hypotheses for testing stating that the initial rate of synthesis of C3 and C4 to pre-
admission levels may identify patients at risk of developing complications. A slower synthesis 
rate could mean the patient’s C system is compromised for longer, possibly leaving the host 
susceptible to a secondary immunological challenge. 
C consumption appears to be a promising biomarker for surgical trauma that provides a 
response that is faster than CRP or other clinical observations. Stratification of patients based 
on this metric in relation to recovery monitoring looks interesting and may lead towards to 
new ways to manage clinical resources. Crucially, the assays are already in place and approved 
for clinical use. Additionally, normalised C3 and C4 recovery profiles may be used to predict a 
patient’s length of stay, however an arbitrary percentage recovery threshold must first be 
established as an indicator of individual biochemical recovery. Interesting observations 
regarding secondary C consumption coupled with activation may lead to presymptomatic 
diagnosis of disease, which would allow the current Early Warning Score (EWS) system to be 
improved. Although surgical and drug advances for patient care have been large, postoperative 
patient monitoring has not enjoyed the same level of progression, and remains based around 
monitoring the vital signs of a patient. 
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The nature of conventional blood sample collection in hospitals means that detection of C 
system activity reflects the systemic health state of the patient, as activated C fragments 
present in plasma, for example, indicates systemic C activation. Therefore better and 
additional assays for C activation are needed to establish the full potential of the C system as a 
health monitoring tool.  
Label-free Assay Development 
In order to transfer established immunoassays, such as those developed to monitor C 
activation, onto label-free, kinetic binding measurement-type instruments such as the Liscar, 
the nonspecific interference effect of plasma proteins was investigated and demonstrated. In 
an effort to reduce nonspecific binding to the surface, addition of a chaotropic agent to the 
sample was also investigated. However, in an acknowledgement that nonspecific interference 
from real biological samples is unlikely to be completely removed, a mathematical model for 
data analysis was created based on a 10-reaction mechanism to account for specific binding, 
nonspecific binding and competitive binding between the analytes in solution. This can be used 
going forward, along with additional measures to improve label-free, kinetic binding signals in 
order to screen real biological samples for target analytes. 
Efficient sample handling is a key aspect for point-of-care diagnostic technologies. The Liscar 
nanoparticle platform has many suitable properties in this regard – a robust sensing chip and 
fluid management system (possibly containing a chaotrope buffer if needed) has the potential 
to be a point-of-care technology capable of detecting up to ca. 20 biomarkers from a single 
blood sample. The investigation in Chapter 2 indicates that whole serum or plasma samples 
can be used. The concept is supported by the mathematical model which suggests there is a 
fundamental advantage in detecting a high-affinity molecule to a sensor surface. Currently, 
antibody-analyte solutions are preferred, employing the corresponding antigen as the surface 
 
220 
ligand, however recent screening of antigen-target analytes has been demonstrated by Tom 
Read.  
7.2 Future Work 
Complement 
Going forward immediately, it is suggested that a detailed study of in vitro C activation is done 
to expand on the investigation carried out by Liu et al. [156]. Many different C components 
and fragments should be monitored with differing concentrations of Zymosan and Heat 
Aggregated IgG (HAIGG). The concentration dependence of the activation substance can then 
be determined, and the relative interactions of C system proteins studied mechanistically and 
mathematically. A high sampling rate during activation is important to observe fast, complex 
behaviour which is likely to be present. Preceding this investigation it would be useful to 
develop more C activation assays, ideally on the MSD electroluminescence platform so that the 
assays may be multiplexed and analysed in tandem. The activation markers should reflect the 
activity in each of the 4 C pathways so that differential activation may be observed. The range 
of activators could then be expanded to include gram-positive and gram-negative bacteria 
[141], for example. From a successful, complete in vitro activation analysis, the established 
assay set will be able to monitor the activation flux through all of the pathways which can then 
be tested in vivo. However, many unknown kinetic factors such as clearance rates and surface 
regulation alters the in vivo model drastically cf. in vitro. Additionally, the rapid kinetic 
response of the C cascade avalanche produces real practical problems for blood sampling time 
point selection. 
Therefore, once the activation process is fully understood in vitro, it is suggested that a similar 
study to the CPOP trial be conducted to include C fragment screening in urine samples. Urine is 
not liable to many of the clearance and regulation factors present in blood, which can 
contribute to the rapid rise and fall in C fragment concentrations. If urine output could be 
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collected at recorded time points and assayed for C activation markers, the fragment 
concentration present in the urine sample could be integrated over the time in between 
sampling points, thereby producing a C activation profile over a given time period. Another 
important point is that this provides insight into the patient’s immunological response over a 
given integrated time period, and not at a specific moment in time. This means the integrated 
signal is not subject to much of the fluctuations in C system protein concentrations. 
Additionally, C activation fragments such as C5a and C3a that have short half-lives in plasma 
can be detected easily in urine, which further increases the options for C activation monitoring 
fragments. Commercial ELISA assays exist for both C3a and C5a, and therefore this analysis 
would not be subject to a lengthy assay development stage along with its associated costs. 
In order to test the hypothesis of differential postoperative C3 and C4 synthesis rates to 
identify patients at risk of developing complications, it is suggested that individual 
preoperative C activation screening is performed. The suggested experiment requires patients 
undergoing surgery to donate blood before their operation. Their blood can be clotted, and 
the serum activated using relatively low concentrations of Zymosan. The rate of TCC 
production, for example, could therefore be used as an individual C cascade calibration metric, 
against which their immediate postoperative C3 and C4 synthesis rates can be compared. This 
may give some indication of a particular patient’s ‘immuno-capacity’; that is, the ability of the 
patient’s immune system to successfully combat an immunological challenge. The established 
immuno-capacity can be compared for differing demographics and age groups, supplying yet 
more information to surgeons preoperatively, allowing them to identify patients who may be 
at greater risk of surrendering to an immunological challenge. 
Some further investigation regarding percentage C3 and C4 recovery as a supporting evidence 
metric to discharge patients can also be performed. This investigation requires input from a 
wide variety of surgeons to establish the recovery level at which they would discharge a 
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patient. This can be achieved by a blind investigation, whereby patients are monitored as 
standard by clinicians, and are discharged subjectively according to the clinicians criteria. A 
blood sample on admission and discharge can be assayed for C3 and C4 and compared to 
establish the average C recovery across all patients at time of discharge. A well-considered trial 
design is needed, as the time of discharge can be subject to considerable variation associated 
with the time gap between late night and early morning, when patients are unlikely to be 
discharged regardless of health state. 
Alternatively, the study CPOP trial could be replicated in an animal model, which will have 
significant implications for the quality of results, as the experiment can be standardised, with 
known positive and negative controls put in place. Specific immunological challenges, and their 
effect on C activation can be studied. Individual pathways can be targeted using selected 
activators, which may confirm the best activation marker for a particular pathway for such an 
investigation. Assays for these activation markers could then be developed, combined, and 
multiplexed in order to create a single assay for overall C activation. From the data a 
multidimensional panel assay can be created, using the data in an algorithm to generate a C 
activation value. 
Transfer of Assays to Label-free nanoparticle Based Platform, Liscar. 
Once a panel of assays for C activation has been developed using well established, proven 
methodologies, the assays can be transferred to the Liscar platform. It has been shown that 
biomolecule detection from a complex sample is possible, and if an appropriate model is 
applied meaningful parameters can be obtained. The advantage is that potential high 
throughput screening capabilities of the Liscar instrument are enormous. Protein 
functionalised arrays can be produced to contain many ligands on a single chip against which a 
sample can be screened. In principle, this allows the detection of many different analytes from 
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a single sample, and therefore the ideology of a panel-assay from a single sample may be 
possible. 
Furthermore, the cost, size and speed of the Liscar instrument may allow its widespread 
implementation as a point-of-care diagnostic device. Returning to the point made by Poste 
[260], this end point can only be facilitated if a big science approach – clinician led, 
multidisciplinary collaboration – is employed early on to ensure the C system, if truly 
warranted, is to become the monitoring system for disease diagnosis and recovery monitoring. 
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